ÌåäÓíèâåð - MedUniver.com Ïîèñê ïî ñàéòó è åãî ðàçäåëû Âèäåî ïî ìåäèöèíå  
Ðåêîìåíäóåì:
Ïðîôèëàêòèêà çàáîëåâàíèé:
Ïðîôèëàêòèêà çàáîëåâàíèé
Áåçîïàñíûé äîì è êâàðòèðà
Âûáîð îäåæäû è îáóâè
Çàêàëèâàíèå îðãàíèçìà
Îáñëåäîâàíèå áîëüíîãî
Îñíîâû ïðîôèëàêòèêè
Ïîëåçíûé îòäûõ
Ïðàâèëüíîå ïèòàíèå
Ïðîôèëàêòèêà îæèðåíèÿ è ÑÄ 2 òèïà
Ïðîôèëàêòèêà ó äåòåé
Ëèõîðàäêà ó äåòåé è âçðîñëûõ
Ïðîÿâëåíèÿ áîëåçíè
Ñîâåòû íàðîäíîé ìåäèöèíû
×òî çíà÷àò àíàëèçû?
Áîëåçíè ðóê è ðåàáèëèòàöèÿ ïðè íèõ
Áîëåçíè òàíöîðîâ è èõ ðåàáèëèòàöèÿ
Ïðîôèëàêòèêà àëêîãîëèçìà
Ïðîôèëàêòèêà â óðîëîãèè
Ðàáîòà ïîäðîñòêîâ è îõðàíà èõ òðóäà
Ðåêîìåíäàöèè áîëüíûì
Ôîðóì
 

Àâòîðû òðóäîâ (ñòàòåé) èñïîëüçîâàííûå ïðè ïîäãîòîâêå ñòàòüè ïî èçáûòî÷íîìó âåñó è îæèðåíèþ ó äåòåé

 ñòàòüÿõ ïî ïðîôèëàêòèêå îæèðåíèÿ è ñàõàðíîãî äèàáåòà ó âçðîñëûõ è äåòåé èñïîëüçîâàíû ñëåäóþùèå îáùåïðèíÿòûå ñîêðàùåíèÿ:

  • ÀÃ — àðòåðèàëüíàÿ ãèïåðòåíçèÿ
  • ÀãÏÏ — àãóòèïîäîáíûé ïåïòèä
  • ÀÄ — àðòåðèàëüíîå äàâëåíèå
  • ÀÌÔ — àäåíîçèíìîíîôîñôàò
  • ÀÒÔ — àäåíîçèíòðèôîñôàò
  • ÂÈ× — âèðóñ èììóíîäåôèöèòà ÷åëîâåêà
  • ÂÎÇ — Âñåìèðíàÿ îðãàíèçàöèÿ çäðàâîîõðàíåíèÿ
  • ÃÈ — ãëèêåìè÷åñêèé èíäåêñ
  • ÃÈÏ — ãëþêîçîçàâèñèìûé èíñóëèíîòðîïíûé ïîëèïåïòèä
  • ÃÍ — ãëèêåìè÷åñêàÿ íàãðóçêà
  • ÃÏ — ãàñòðîïàðåç
  • ÃÏÏ — ãëþêàãîíîïîäîáíûé ïåïòèä
  • ÃÑÄ — ãåñòàöèîííûé ñàõàðíûé äèàáåò
  • ÄÈ — äîâåðèòåëüíûé èíòåðâàë
  • ÆÊÒ — æåëóäî÷íî-êèøå÷íûé òðàêò
  • ÈË — èíòåðëåéêèí
  • ÈÌÒ — èíäåêñ ìàññû òåëà
  • ÈÏÆÆ — èñêóññòâåííàÿ ïîäæåëóäî÷íàÿ æåëåçà
  • ÊÀÐÒ — êîêàèí-àìôåòàìèí-ðåãóëèðóåìûé òðàíñêðèïò
  • ËÏÂÏ — ëèïîïðîòåèíû âûñîêîé ïëîòíîñòè
  • ËÏÍÏ — ëèïîïðîòåèíû íèçêîé ïëîòíîñòè
  • ËÏÑ — ëèïîïîëèñàõàðèä
  • ÌÍÆÊ — ìîíîíåíàñûùåííûå æèðíûå êèñëîòû
  • ÌÑ — ìåòàáîëè÷åñêèé ñèíäðîì
  • ìÐÍÊ — ìàòðè÷íàÿ ðèáîíóêëåèíîâàÿ êèñëîòà
  • ÍÀÆÁÏ — íåàëêîãîëüíàÿ æèðîâàÿ áîëåçíü ïå÷åíè
  • ÍÀÑÃ — íåàëêîãîëüíûé ñòåàòîãåïàòèò
  • ÍÃÍ — íàðóøåííàÿ ãëèêåìèÿ íàòîùàê
  • ÍÒÃ — íàðóøåííàÿ òîëåðàíòíîñòü ê ãëþêîçå
  • ÎÃÒÒ — îðàëüíûé ãëþêîçîòîëåðàíòíûé òåñò
  • ÎÆÀÐ — îáõîäíîé æåëóäî÷íûé àíàñòîìîç ïî Ðó
  • ÎÊÌ — îêñèíòîìîäóëèí
  • ÎÐ — îòíîñèòåëüíûé ðèñê
  • ÎØ — îòíîøåíèå øàíñîâ
  • ÏÄ — ïðîëîíãèðîâàííîå äåéñòâèå
  • ÏÍÆÊ — ïîëèíåíàñûùåííûå æèðíûå êèñëîòû
  • ÏÎÌÊ — ïðîîïèîìåëàíîêîðòèí
  • ÏÐÆ — âåðòèêàëüíàÿ ïðîäîëüíàÿ ðåçåêöèÿ æåëóäêà
  • ÐÁÆ — ðåãóëèðóåìîå áàíäàæèðîâàíèå æåëóäêà
  • ÑÄ — ñàõàðíûé äèàáåò
  • ÑÄÑ — ñèíäðîì äèàáåòè÷åñêîé ñòîïû
  • ÑÆÊ — ñâîáîäíàÿ æèðíàÿ êèñëîòà
  • ÑÏÈÄ — ñèíäðîì ïðèîáðåòåííîãî èììóíîäåôèöèòà
  • ÔÍÎ — ôàêòîð íåêðîçà îïóõîëè
  • Ô×È — ôàêòîð ÷óâñòâèòåëüíîñòè ê èíñóëèíó (ISF)
  • ÕÖÊ — õîëåöèñòîêèíèí
  • ÖÍÑ — öåíòðàëüíàÿ íåðâíàÿ ñèñòåìà
  • ÝÍÊÏ — ýíòåðàëüíàÿ íåéðîíàëüíàÿ êëåòêà-ïðåäøåñòâåííèê
  • ADA — Àìåðèêàíñêàÿ äèàáåòè÷åñêàÿ àññîöèàöèÿ (The American Diabetes Association)
  • AGB — ðåãóëèðóåìîå áàíäàæèðîâàíèå æåëóäêà (adjustable gastric band)
  • Akt — ïðîòåèíêèíàçà Â
  • ATP III — Ïðîãðàììà ïî ëå÷åíèþ âçðîñëûõ ïàöèåíòîâ III (Adult Treatment Program III)
  • BCAA — àìèíîêèñëîòà ñ ðàçâåòâëåííûìè áîêîâûìè öåïÿìè (branched-chain amino acid)
  • BDNF — íåéðîòðîôè÷åñêèé ôàêòîð ãîëîâíîãî ìîçãà (brain-derived neurotrophic factor)
  • BPD — áèëèîïàíêðåàòè÷åñêîå øóíòèðîâàíèå (bilio-pancreatic diversion)
  • CGM — íåïðåðûâíûé ìîíèòîðèíã ãëþêîçû (continuous glucose monitoring)
  • DASH — àíòèãèïåðòåíçèâíûé ýôôåêò äèåòû (The Dietary Approaches to Stop Hypertension)
  • DPP — Ïðîãðàììà ïðîôèëàêòèêè ñàõàðíîãî äèàáåòà (Diabetes Prevention Program)
  • DS — äâåíàäöàòèïåðñòíàÿ êèøêà (duodenal switch)
  • FDA — Óïðàâëåíèå ïî êîíòðîëþ êà÷åñòâà ïèùåâûõ ïðîäóêòîâ è ëåêàðñòâåííûõ ñðåäñòâ (Food and Drug Administration)
  • GPR — ðåöåïòîð, ñîïðÿæåííûé ñ G-áåëêîì (G-protein-coupled receptor)
  • GWAS — ïîëíîãåíîìíûé ïîèñê àññîöèàöèé (genome-wide association study)
  • HbA1c — ãëèêîçèëèðîâàííûé ãåìîãëîáèí
  • HL — âûñîêîå ñîäåðæàíèå æèðà, íèçêîå ñîäåðæàíèå ñàõàðîçû (high fat, low sucrose)
  • HR — îòíîøåíèå ðèñêîâ (hazard ratio)
  • IDPP — Èíäèéñêàÿ ïðîãðàììà ïðîôèëàêòèêè ñàõàðíîãî äèàáåòà (The Indian Diabetes Prevention Program)
  • IMCL — ñîäåðæàíèå âíóòðèìèîöåëëþëÿðíûõ ëèïèäîâ (intramyocellular lipid content)
  • IRS — ñóáñòðàò èíñóëèíîâîãî ðåöåïòîðà (insulin receptor substrate)
  • mTOR — ìèøåíü ðàïàìèöèíà â êëåòêàõ ìëåêîïèòàþùèõ (mammalian target for rapamycin)
  • NPY — íåéðîïåïòèä Y (neuropeptide Y)
  • NSD — íåò ñóùåñòâåííîé ðàçíèöû (no significant difference)
  • PPAR — ðåöåïòîð, àêòèâèðóåìûé ïåðîêñèñîìíûì ïðîëèôåðàòîðîì (peroxisome proliferator-activated receptor)
  • PYY — ïåïòèä YY (peptide YY)
  • SG — ïðîäîëüíàÿ ðåçåêöèÿ æåëóäêà (sleeve gastrectomy)
  • SMBG — ñàìîêîíòðîëü óðîâíÿ ãëþêîçû â êðîâè (self-monitoring of blood glucose)
  • VSG — ïðîäîëüíàÿ (âåðòèêàëüíàÿ) ðåçåêöèÿ æåëóäêà (vertical sleeve gastrectomy)

 õîäå ïîäãîòîâêè ñòàòüè ïî ïðîôèëàêòèêå îæèðåíèÿ è ñàõàðíîãî äèàáåòà ó âçðîñëûõ è äåòåé äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:

  1. Association AD. Standards of medical care in diabetes-2017: Summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–5. doi:10.2337/dc17-S003.
  2. Jaiswal M, Divers J, Dabelea D, Isom S, Bell RA, Martin CL, et al. Prevalence of and risk factors for diabetic peripheral neuropathy in youth with type 1 and type 2 diabetes: SEARCH for diabetes in youth study. Diabetes Care. 2017;40(9):1226–32.
  3. Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, et al. Prevalence of diabetes in U.S. youth in 2009: The SEARCH for diabetes in youth study. Diabetes Care. 2014;37(2):402–8.
  4. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell. 2012;148(5):852–71.
  5. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191.
  6. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, et al. Prediabetes in obese youth: A syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet. 2003;362(9388):951–7.
  7. Unger RH. Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144(12):5159–65.
  8. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32 Suppl 3:14–23.
  9. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulinresistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350(7):664–71.
  10. D’Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33(8):1817–22.
  11. Van Name M, Santoro N. Type 2 diabetes mellitus in pediatrics: A new challenge. World J Pediatr. 2013;9(4):293–9.
  12. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.
  13. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311–26.
  14. Frohnert BI, Rewers MJ. Metabolomics in childhood diabetes. Pediatr Diabetes. 2016;17(1):3–14.
  15. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723–36.
  16. Yoon MS. The emerging role of branched-chain amino acids in insulin resistance and metabolism. Nutrients. 2016;8(7):405.
  17. Weickert MO, Roden M, Isken F, Hoffmann D, Nowotny P, Osterhoff M, et al. Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans. Am J Clin Nutr. 2011;94(2):459–71.
  18. She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, et al. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab. 2007;6(3):181–94.
  19. Magkos F, Bradley D, Schweitzer GG, Finck BN, Eagon JC, Ilkayeva O, et al. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes. 2013;62(8):2757–61.
  20. McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE, et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes. 2013;8(1):52–61.
  21. Weiss R, Dziura JD, Burgert TS, Taksali SE, Tamborlane WV, Caprio S. Ethnic differences in beta cell adaptation to insulin resistance in obese children and adolescents. Diabetologia. 2006;49(3):571–9.
  22. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–7.
  23. Cali AM, Caprio S. Prediabetes and type 2 diabetes in youth: An emerging epidemic disease? Curr Opin Endocrinol Diabetes Obes. 2008;15(2):123–7.
  24. Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: Epidemiology and treatment. Curr Diab Rep. 2014;14(8):508.
  25. Gandica R, Zeitler P. Update on youth-onset type 2 diabetes: Lessons learned from the treatment options for type 2 diabetes in adolescents and youth clinical trial. Adv Pediatr. 2016;63(1):195–209.
  26. Morgan AR. Determining genetic risk factors for pediatric type 2 diabetes. Curr Diab Rep. 2012;12(1):88–92.
  27. Hammoud NM, de Valk HW, van Rossem L, Biesma DH, Wit JM, Visser GH. Growth and BMI during the first 14 y of life in offspring from women with type 1 or type 2 diabetes mellitus. Pediatr Res. 2017;81(2):342–8.
  28. Lovejoy JC. The influence of dietary fat on insulin resistance. Curr Diab Rep. 2002;2(5):435–40.
  29. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia. 1991;34(12):891–8.
  30. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
  31. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–44.
  32. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstrom J, Tuomilehto J. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52(10):2532–8.
  33. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348(21):2082–90.
  34. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348(21):2074–81.
  35. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD, et al. Efficacy and safety of low-carbohydrate diets: A systematic review. JAMA. 2003;289(14):1837–50.
  36. Warren JM, Henry CJ, Simonite V. Low glycemic index breakfasts and reduced food intake in preadolescent children. Pediatrics. 2003;112(5):e414.
  37. Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr. 2002;76(5):911–22.
  38. Montonen J, Knekt P, Jarvinen R, Aromaa A, Reunanen A. Whole-grain and fiber intake and the incidence of type 2 diabetes. Am J Clin Nutr. 2003;77(3):622–9.
  39. Guerrero-Romero F, Simental-Mendia LE, Hernandez-Ronquillo G, Rodriguez-Moran M. Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial. Diabetes Metab. 2015;41(3):202–7.
  40. Pereira MA, Jacobs DR, Jr., Van Horn L, Slattery ML, Kartashov AI, Ludwig DS. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: The CARDIA Study. JAMA. 2002;287(16):2081–9.
  41. Spriet LL, Watt MJ. Regulatory mechanisms in the interaction between carbohydrate and lipid oxidation during exercise. Acta Physiol Scand. 2003;178(4):443–52.
  42. McGee SL, Howlett KF, Starkie RL, Cameron-Smith D, Kemp BE, Hargreaves M. Exercise increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes. 2003;52(4):926–8.
  43. Santoro C, Cosmas A, Forman D, Morghan A, Bairos L, Levesque S, et al. Exercise training alters skeletal muscle mitochondrial morphometry in heart failure patients. J Cardiovasc Risk. 2002;9(6):377–81.
  44. Dabelea D, Stafford JM, Mayer-Davis EJ, D’Agostino R, Jr., Dolan L, Imperatore G, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA. 2017;317(8):825–35.
  45. Luk AO, Lau ES, So WY, Ma RC, Kong AP, Ozaki R, et al. Prospective study on the incidences of cardiovascular-renal complications in Chinese patients with young-onset type 1 and type 2 diabetes. Diabetes Care. 2014;37(1):149–57.
  46. Al-Saeed AH, Constantino MI, Molyneaux L, D’Souza M, Limacher-Gisler F, Luo C, et al. An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: The impact of youth-onset type 2 diabetes. Diabetes Care. 2016;39(5):823–9.
  47. Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, et al. Long-term complications and mortality in young-onset diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36(12):3863–9.
  48. Deedwania PC. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep. 2003;3(4):289–92.
  49. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep. 2003;3(4):279–88.
  50. Watts K, Beye P, Siafarikas A, Davis EA, Jones TW, O’Driscoll G, et al. Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents. J Am Coll Cardiol. 2004;43(10):1823–7.
  51. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: From the perspective of a vicious triangle. Int J Obes Relat Metab Disord. 2002;26 Suppl 2:S28–38.
  52. Delahanty LM. Weight loss in the prevention and treatment of diabetes. Prev Med. 2017;11(104):120–123.
  53. Kratzsch J, Dehmel B, Pulzer F, Keller E, Englaro P, Blum WF, et al. Increased serum GHBP levels in obese pubertal children and adolescents: Relationship to body composition, leptin and indicators of metabolic disturbances. Int J Obes Relat Metab Disord. 1997;21(12):1130–6.
  54. Long SD, O’Brien K, MacDonald KG, Jr., Leggett-Frazier N, Swanson MS, Pories WJ, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994;17(5):372–5
  55. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB J. 2004;18(3):439–56.
  56. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. Endocrinol Metab Clin North Am. 2002;31(1):173–89.
  57. Leahy LG. Medication-assisted weight loss in the age of obesity. J Psychosoc Nurs Ment Health Serv. 2017;55(8):21–6. doi:10.3928/02793695-20170718-02.
  58. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
  59. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–35.
  60. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.
  61. Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9(6):567–76.
  62. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168(2):178–84.
  63. Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, et al. Metformin in obese children and adolescents: The MOCA trial. J Clin Endocrinol Metab. 2013;98(1):322–9.
  64. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: A pilot study. Acta Paediatr. 2003;92(6):666–70.
  65. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364–82.
  66. Herbst A, Kapellen T, Schober E, Graf C, Meissner T, Holl RW. Impact of regular physical activity on blood glucose control and cardiovascular risk factors in adolescents with type 2 diabetes mellitus—A multicenter study of 578 patients from 225 centres. Pediatr Diabetes. 2015;16(3):204–10.
  67. Smith JD, Mills E, Carlisle SE. Treatment of pediatric type 2 diabetes. Ann Pharmacother. 2016;50(9):768–77.
  68. Narasimhan S, Weinstock RS. Youth-onset type 2 diabetes mellitus: Lessons learned from the TODAY study. Mayo Clin Proc. 2014;89(6):806–16.
  69. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study. Diabetes Care. 2007;30(4):790–4.
  70. Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: A randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther. 2009;31(4):806–15.
  71. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
  72. Gu S, Shi J, Tang Z, Sawhney M, Hu H, Shi L, et al. Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: A meta-analysis. PLoS One. 2015;10(5):e0126704.
  73. Owen OE, Reichard Jr. GA, Boden G, Patel MS, Trapp VE. Interelationships among key tissues in the utilization of metabolic substrates. In: Diabetes, Obesity, and Vascular Disease. Metabolic and Molecular Interrelationships Part 2, Katzen HM and Mahler RJ (Eds). Advances in Modern Nutrition, Volume 2, Halsted Press, John Wiley & Sons, NY, 1978.
  74. Meyer C, Stumvoll M, Dostou J, Welle S, Haymond M, Gerich J. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol 282: E428–E434, 2002.
  75. Lehninger AL, Nelson DL, Cox MM (Eds.). Principles of Biochemistry. 2nd Edition, New York, Worth Publishers, 1993.
  76. Wagenmakers AJ. Protein and amino acid metabolism in human muscle. Adv Exp Med Biol 441: 307– 319, 1998.
  77. Elmadfa I, Meyer AL. Animal proteins as important contributors to a healthy human diet. Annu Rev Anim Biosci 5: 111–131, 2017.
  78. Tosukhowong P, Boonla C, Dissayabutra T, et al. Biochemical and clinical effects of Whey protein supplementation in Parkinson’s disease: A pilot study. J Neurol Sci 367: 162–170, 2016.
  79. Kirchberg FF, Harder U, Weber M, et al. J Clin Endocrinol Metab 100(1): 149–158, 2015.
  80. Adeya-Andany MM, Calvo-Castro I, Fernandez-Fernandez C, Donapetry-Garcaa C, Pedre-Pineiro AM. Significance of l-carnitine for human health. IUBMB Life 69(8): 578–594, 2017.
  81. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulinresistant state. Adv Nutr 2(6): 445–456, 2011.
  82. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789, 1963.
  83. Randle PJ. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14: 263–283, 1998.
  84. Jeukendrup AE. Regulation of fat metabolism in skeletal muscle. Ann NY Acad Sci 967: 217–235, 2002.
  85. Liu YQ, Tornheim K, Leahy JL. Glucose-fatty acid cycle to inhibit glucose utilization and oxidation is not operative in fatty acid cultured islets. Diabetes 48: 1747–1753, 1999.
  86. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276: E1–E18, 1999.
  87. Rosa G, Manco M, Vega N, et al. Decreased muscle acetyl-coenzyme A carboxylase 2 mRNA and insulin resistance in formerly obese subjects. Obes Res 11: 1306–1312, 2003.
  88. Laybutt DR, Schmitz-Peiffer C, Saha AK, et al. Muscle accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 277: E1070–E1076, 1999.
  89. Jequier E. Effect of lipid oxidation on glucose utilization in humans. Am J Clin Nutr 67: 527S–5301S, 1998.
  90. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737–1747, 1983.
  91. Felber JP. Significance of the Randle-mechanism in the etiology of diabetes type II. Hormone Metab Res – Suppl 22: 11–17, 1990.
  92. Saloranta C, Koivisto V, Widen E, et al. Contribution of muscle and liver to glucose-fatty acid cycle in humans. Am J Physiol 264: E599–E605, 1993.
  93. Wolfe RR. Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr 67 (suppl 3): 515S–526S, 1998.
  94. Schmitz-Peiffer C. Signalling aspects of insulin resistance in skeletal muscle: Mechanisms induced by lipid oversupply. Cell Signal 12: 583–594, 2000.
  95. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes mellitus and obesity. Exp Clin Endocrinol Diabetes 109 (suppl 2): S189–S201, 2001.
  96. McGarry JD. Glucose-fatty acid interactions in health and disease. Am J Clin Nutr 67(3 Suppl): 500S–504S, 1998
  97. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 10(12): 723–736, 2014.
  98. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H. An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 78(4): 734–741, 2003.
  99. Nuttall FQ, Schweim K, Hoover H, Gannon MC. Effect of the LoBAG30 diet on blood glucose control in people with type 2 diabetes. Br J Nutr 99(3): 511–519, 2008.
  100. Gannon MC, Hoover H, Nuttall FQ. Further decrease in glycated hemoglobin following ingestion of a LoBAG30 diet for 10 weeks compared to 5 weeks in people with untreated type 2 diabetes. Nutr Metab (Lond) 7: 64, 2010 Jul.
  101. Brinkworth GD, Noakes M, Parker B, Foster P, Clifton PM. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: One-year follow-up of a randomised trial. Diabetologia 47(10): 1677–1686, 2004 Oct.
  102. Sargrad KR, Homko C, Mozzoli M, Boden G. Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, hemoglobin A1c, and blood pressure in patients with type 2 diabetes mellitus. J Am Diet Assoc 105(4): 573–580, 2005.
  103. Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: A 12 month randomised controlled trial. Diabetologia 54(4): 731–740, 2011.
  104. Newgard CB, An J, Bain JR, Muehlbauer MJ, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9(4): 311–326, 2009. doi:10.1016/j.cmet.2009.02.002
  105. Laferrare B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 3(80): 80re2, 2011 Apr.
  106. Peppa M, Goldberg T, Cai W, Rayfield E, Vlassara H. Glycotoxins: A missing link in the “relationship of dietary fat and meat intake in relation to risk of type 2 diabetes in men”. Diabetes Care 25(10): 1898–1899, 2002.
  107. Fretts AM, Follis JL, Nettleton JA, et al. Consumption of meat is associated with higher fasting glucose and insulin concentrations regardless of glucose and insulin genetic risk scores: A meta-analysis of 50,345 Caucasians. Am J Clin Nutr 102(5): 1266–1278, 2015 Nov.
  108. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 15: 773–784, 1992.
  109. Bebernitz GR, Schuster HF. The impact of fatty acid oxidation on energy utilization: Targets and therapy. Curr Pharm Des 8: 1199–1227, 2002.
  110. Moneva MH, Dagogo-Jack S. Multiple targets in the management of Type 2 diabetes. Curr Drug Targets 3: 203–221, 2002.
  111. Ram VJ. Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes. Drugs Today 39: 609–632, 2003.
  112. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393–416, 2004.
  113. Blachere JC, Perusse F, Bukowiecki LJ. Lowering plasma fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic rats. Metabolism 50: 945–951, 2001.
  114. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 41: 1400–1408, 1992.
  115. Santomauro ATMG, Boden G, Silva MER, et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects. Diabetes 48: 1836–1841, 1991.
  116. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41: 1127–1132, 1998.
  117. Saloranta C, Taskinen MR, Widen E, et al. Metabolic consequences of sustained suppression of free fatty acids by Acipimox in patients with NIDDM. Diabetes 42: 1559–1566, 1993.
  118. Kaur R, Dahiya L, Kumar M. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus. Eur J Med Chem 141: 473–505, 2017 Dec.
  119. Stacpoole PW, Greene YJ. Dichloroacetate. Diabetes Care 15: 785–791, 1992.
  120. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in noninsulin-dependent diabetes mellitus. N Engl J Med 333: 550–554, 1995.
  121. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: A clinical review with a focus on dual therapy. Clin Ther 12: 2991–3026, 2003.
  122. Hess AM, Sullivan DL. Metformin for prevention of type 2 diabetes. Ann Pharmacother 38: 1283– 1285, 2004.
  123. Yasuda N, Inoue T, Nagakura T, et al. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J Pharmacol Exp Ther 310: 614–619, 2004.
  124. Guigas B, Detaille D, Chauvin C, et al. Metformin inhibits mitochondrial permeability transition and cell death: A pharmacological in vitro study. Biochem J 382(3): 877–884, 2004.
  125. Salpeter SR, Greyber E, Paternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus. Systematic review and meta-analysis. Arch Intern Med 163: 2594–2602, 2003.
  126. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: Cause or coincidence? A review to case reports. J Intern Med 255: 179–187, 2004.
  127. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 80: 239– 240, 2004.
  128. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment – Na?ve patients with type 2 diabetes. Curr Med Res Opin 20: 883–889, 2004.
  129. Milagro FI, Martinez JA. Effects of the oral administration of beta3-adrenergic agonist on lipid metabolism in alloxan-diabetic rats. J Pharm Pharmacol 52: 851–856, 2000.
  130. Edvardsson U, von Lowenhielm HB, Panfilov O, Nystrom AC, Nilsson F, Dahllof B. Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 3: 468–478, 2003.
  131. Sanchez JC, Converset V, Nolan A, et al. Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 3: 1500–1520, 2003.
  132. Kersten S. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 440: 223–234, 2002.
  133. Berkowitz K, Peters R, Kjos SL, et al. Effect of Troglitazone on insulin sensitivity and pancreatic ?-cell function in women at high risk for NIDDM. Diabetes 45: 1572–1579, 1996.
  134. Fulgencio JP, Kohl C, Girad J, Pegorier JP. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45: 1556–1562, 1996.
  135. Thomas T, Pfeiffer AFH. Foods for the prevention of diabetes: How do they work? Diabetes/Metab Res Rev 28: 25–49, 2012.
  136. Fogarty DC, Vassalo I, Di Cara A, et al. A 48-hour Vegan diet challenge in healthy women and men induces a branch-chain amino acid related, health associated, metabolic signature. Mol Nutr Food Res 2017 Oct. doi:10.1002/mnfr.201700703.
  137. Nicolson GL. Metabolic syndrome and mitochondrial function: Molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. J Cell Biochem 100(6): 1352–1369, 2007 Apr.
  138. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127: 1580–1589, 1990.
  139. Opara EC, Hubbard VS, Burch W, et al. Characterization of the insulinotropic potency of polyunsaturated fatty acids. Endocrinology 130: 657–662, 1992.
  140. Elks ML. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology 133: 208–214, 1993.
  141. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93: 870–876, 1994.
  142. Opara EC, Garfinkel M, Hubbard VS, et al. Effect of fatty acids on insulin release: Role of chain length and degree of unsaturation. Am J Physiol 266 (Endocrinol. Metab. 29): E635–E639, 1994.
  143. Opara EC, Burch W, et al. Characterization of glutamine-regulated pancreatic hormone release. Surg Forum 41: 16–19, 1990.
  144. Malaisse WJ, Sener A, Carpinelli AR. The stimulus-secretion coupling of glucose-induced insulin release. XLVI. Physiological role of L-glutamine as a fuel for pancreatic islets. Mol Cell Endocrinol 20: 171–189, 1980.
  145. Opara EC, Hubbard VS, Burch WM, et al. Addition of L-glutamine to a linoleate perifusate prevents the fatty acid-induced desensitization of pancreatic islet response to glucose. J Nutr Biochem 4: 357–361, 1993.
  146. Surwit RS, Kuhn CM, Cochrane C, Feinglos MN. Diet-induced type 2 diabetes in C57BL/6J mice. Diabetes 40: 82–87, 1988.
  147. Surwit RS, Feinglos MN, Rodin J, et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J mice. Metabolism 44: 645–651, 1995.
  148. Schmidt-Nielsen, K., Harnes, H.B., and Hackel, D.B. 1964. Diabetes mellitus in the sand rat induced by the standard laboratory diets. Science 143:689–90.
  149. Reaven, G.M., Risser, T.R., Chen, Y.D., and Reaver, E.P. 1979. Characterization of a model of dietaryinduced hypertriglyceridemia in young nonobese rats. J Lipid Res 20:3718.
  150. Storlien, L.H., James, D.E., Burleigh, K.M., Chisholm, D.J., and Kraegen, E.W. 1986. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251:E576–83.
  151. Kraegen E.W., James, D.E., Storlien, L.H., Burleigh, K.M., and Chisholm, D.J. 1986. In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: Assessment by euglycaemic clamp plus deoxyglucose administration. Diabetologia 29:192–8.
  152. Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A., and Feinglos, M.N. 1988. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:1163–7.
  153. Bray, G.A., Stern, J.S., and Castonguay, T.W. 1992. Effect of adrenalectomy and high-fat diet on the fatty Zucker rat. Am J Physiol 262: E32–9.
  154. Opara, E.C., Petro, A., Tevrizian, A., Feinglos, M.N., and Surwit, R.S. 1996. l-Glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6J mice. J Nutr 126:273–9. Hu, F.B., Van Dam, R.M., and Liu, S. 2001. Diet and risk of type II diabetes: The role of types of fat and carbohydrate. Diabetologia 44:805–17.
  155. Mayer-Davis, E.J., Monaco, J.H., Hoen, H.M., Carmichael, S., Vitolins, M.Z., Rewers, M.J., Haffner, S.M., Ayad, M.F., Bergman, R.N., and Karter, A.J. 1997. Dietary fat and insulin sensitivity in a triethnic population: The role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr 65:79–87.
  156. Marshall, J.A., Hoag, S., Shetterly, S., and Hamman, R.F. 1994. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 17:50–6.
  157. Feskens, E.J. and Kromhout, D. 1990. Habitual dietary intake and glucose tolerance in euglycaemic men: The Zutphen Study. Int J Epidemiol 19:953–9.
  158. Hu, F.B., Manson, J.E., Stampfer, M.J., Colditz, G., Liu, S., Solomon, C.G., and Willett, W.C. 2001. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790–7.
  159. Schulze, M.B. and Hu, F.B. 2005. Primary prevention of diabetes: What can be done and how much can be prevented? Annu Rev Public Health 26:445–67.
  160. Summers, L.K., Fielding, B.A., Bradshaw, H.A., Ilic, V., Beysen, C., Clark, M.L., Moore, N.R., and Frayn, K.N. 2002. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 45:369–77.
  161. Lovejoy, J.C., Smith, S.R., Champagne, C.M., Most, M.M., Lefevre, M., DeLany, J.P., Denkins, Y.M., Rood, J.C., Veldhuis, J., and Bray, G.A. 2002. Effects of diets enriched in saturated (palmitic), monounsaturated (oleic), or trans (elaidic) fatty acids on insulin sensitivity and substrate oxidation in healthy adults. Diabetes Care 25:1283–88.
  162. Vessby, B., Uusitupa, M., Hermansen, K., Riccardi, G., Rivellese, A.A., Tapsell, L.C., Nalsen, C., et al. 2001. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 44:312–19.
  163. Van Dam, R.M., Willett, W.C., Rimm, E.B., Stampfer, M.J., and Hu, F.B. 2002. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25:417–24.
  164. Marshall, J.A. and Bessesen, D.H. 2002. Dietary fat and the development of type 2 diabetes. Diabetes Care 25:620–2.
  165. Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainem, H., Ilanne-Parikka, P., et al. 2001. Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–50.
  166. Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403.
  167. Imamura, F., Micha, R., Wu, J.H., deOliveira Otto, M.C., Otite, F.O., Abioye, A.I., and Mozaffarian, D. 2016. Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucoseinsulin homeostasis: A systematic review and meta-analysis of randomized controlled feeding trials. PLoS Med. 13:e1002087.
  168. Jenkins, D.J., Wolever, T.M., Taylor, R.H., Barker, H., Fielden, H., Baldwin, J.M., Bowling, A.C., Newman, H.C., Jenkins, A.L., and Goff, D.V. 1981. Glycemic index of foods: A physiological basis for carbohydrate exchange. Am J Clin Nutr 34:362–6.
  169. Livesey, G., Taylor, R., Livesey, H., and Liu, S. 2013. Is there a dose-response relation of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of prospective cohort studies. Am J Clin Nutr 97:584–96.
  170. Barclay, A.W., Petocz, P., McMillan-Price, J., Flood, V.M., Privan, T., Mitchell, P., and Brand-Miller, J.C. 2008. Glycemic index, glycemic load, and chronic disease risk—A meta-analysis of observational studies. Am J Clin Nutr 87:627–37.
  171. Dong, J.Y., Zhang, L., Zhang, Y.H., and Qin, L.Q. 2011. Dietary glycaemic index and glycemic load in relation to the risk of type 2 diabetes: A meta-analysis of prospective cohort studies. Br J Nutr 106:1649–54.
  172. Sluijs, I., Beulens, J.W., van der Schouw, Y.T., van der A, D.L., Buckland, G., Kuijsten, A., Schulze, M.B., et al. 2013. Dietary glycemic index, glycemic load, and digestible carbohydrate intake are not associated with risk of type 2 diabetes in eight European countries. J Nutr 143:93–9.
  173. Bhupathiraju, S.N., Tobias, D.K., Malik, V.S., Pan, A., Hruby, A., Manson, J.E., Willett, W.C., and Hu, F.B. 2014. Glycemic index, glycemic load, and risk of type 2 diabetes: Results from 3 large US cohorts and an updated meta-analysis. Am J Clin Nutr 100:218–32.
  174. Ardisson Korat, A.V., Willett, W.C., and Hu, F.B. 2014. Diet, lifestyle, and genetic risk factors for type 2 diabetes: A review from the Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals’ Follow-Up Study. Curr Nutr Rep 3:345–54. Bazzano, L.A., Li, T.Y., Joshipura, K.J., and Hu, F.B. 2008. Intake of fruit, vegetables, and fruit juices and risk of diabetes in women. Diabetes Care 31:1311–17.
  175. Carter, P., Gray, L.J., Troughton, J., Khunti, K., and Davies, M.J. 2010. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: Systematic review and meta-analysis. BMJ 341:c4229.
  176. Muraki, I., Imamura, F., Manson, J.E., Hu, F.B., Willett, W.C., van Dam, R.M., and Sun, Q. 2013. Fruit consumption and risk of type 2 diabetes: Results from three prospective longitudinal cohort studies. BMJ 347:f5001.
  177. de Munter, J.S., Hu, F.B., Spiegelman, D., Franz, M., and van Dam, R.M. 2007. Whole grain, bran, and germ intake and risk of type 2 diabetes: A prospective cohort study and systematic review. PLoS Med 4:e261.
  178. Schulze, M.B., Schulz, M., Heidemann, C., Schienkiewitz, A., Hoffman, K., and Boeing, H. 2007. Fiber and magnesium intake and incidence of type 2 diabetes: A prospective study and meta-analysis. Arch Intern Med 167:956–65.
  179. Krishnan, S., Rosenberg, L., Singer, M., Hu, F.B., Djousse, L., Cupples, L.A., and Palmer, J.R. 2007. Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. Arch Intern Med 167:2304–9.
  180. Hu, E.A., Pan, A., Malik, V., and Sun, Q. 2012. White rice consumption and risk of type 2 diabetes: Meta-analysis and systematic review. BMJ 344:e1454.
  181. Sun, Q., Spiegelman, D., van Dam, R.M., Holmes, M.D., Malik, V.S., Willett, W.C., and Hu, F.B. 2010. White rice, brown rice, and risk of type 2 diabetes in US men and women. Arch Intern Med 170:961–9.
  182. Schulze, M.B., Manson, J.E., Willett, W.C., and Hu, F.B. 2003. Processed meat intake and incidence of type 2 diabetes in younger and middle-aged women. Diabetologia 46:1465–73.
  183. Aune, D., Ursin, G., and Veierod, M.B. 2009. Meat consumption and the risk of type 2 diabetes: A systematic review and meta-analysis of cohort studies. Diabetologia 52:2277–87.
  184. Pan, A., Sun, Q., Bernstein, A.M., Schulze, M.B., Manson, J.E., Willett, W.C., and Hu, F.B. 2011. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am J Clin Nutr 94:1088–96.
  185. Fung, T.T., Hu, F.B., Pereira, M.A., Liu, S., Stampfer, M.J., Colditz, G.A., and Willett, W.C. 2002. Whole-grain intake and the risk of type 2 diabetes: A prospective study in men. Am J Clin Nutr 76:535–40.
  186. Mozaffarian, D., Hao, T., Rimm, E.B., Willett, W.C., and Hu, F.B. 2011. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 364:2392–404.
  187. Weickert, M.O., Mohlig, M., Schofl, C., Arafat, A.M., Otto, B., Viehoff, H., Koebnick, C., Kohl, A., Spranger, J., and Pfeiffer, A.F. 2006. Cereal fiber improves whole-body insulin sensitivity in overweight and obese women. Diabetes Care 29:775–80.
  188. Newby, N.K., Muller, D., Hallfrisch, J., Qiao, N., Andres, R., and Tucker, K.L. 2003. Dietary patterns and changes in body mass index and waist circumference in adults. Am J Clin Nutr 77:1417–25.
  189. Pereira, M.A., Jacobs, D.R. Jr, Van Horn, L., Slattery, M.L., Kartashov, A.I., and Ludwig, D.S. 2002. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: The CARDIA Study. JAMA 287:2081–9.
  190. Choi, H.K., Willett, W.C., Stampfer, M.J., Rimm, E., and Hu, F.B. 2005. Dairy consumption and risk of type 2 diabetes mellitus in men: A prospective study. Arch Intern Med 165:997–1003.
  191. Liu, S., Choi, H.K., Ford, E., Song, Y., Klevak, A., Buring, J.E., and Manson, J.E. 2006. A prospective study of dairy intake and risk of type 2 diabetes in women. Diabetes Care 29:1579–84.
  192. Jiang, R., Manson, J.E., Stampfer, M.J., Liu, S., Willett, W.C., and Hu, F.B. 2002. Nut and peanut butter consumption and risk of type 2 diabetes in women. JAMA 288:2554–60.
  193. Pan, A., Sun, Q., Manson, J.E., Willett, W.C., and Hu, F.B. 2013. Walnut consumption is associated with lower risk of type 2 diabetes in women. J Nutr 143:512–8.
  194. Bes-Rastrollo, M., Wedick, N.M., Martinez-Gonzalez, M.A., Li, T.Y., Sampson, L., and Hu, F.B. 2009. Prospective study of nut consumption, long-term weight change, and obesity risk in women. Am J Clin Nutr 89:1913–9.
  195. O’Neil, C.E., Keast, D.R., Nicklas, T.A., and Fulgoni, V.L. 3rd. 2011. Nut consumption is associated with decreased health risk factors for cardiovascular disease and metabolic syndrome in U.S. adults: NHANES 199-2004. J Am Coll Nutr 30:502–10.
  196. Imamura, F., O’Connor, L., Ye, Z., Mursu, J., Hayashino, Y., Bhuparthiraju, S.N., and Forouhi, N.G. 2015. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: Systematic review, meta-analysis, and estimation of population attributable fraction. BMJ 351:h3576.
  197. Palmer, J.R., Boggs, D.A., Krishnan, S., Hu, F.B., Singer, M., and Rosenberg, L. 2008. Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. Arch Intern Med 168:1487–92.
  198. Schulze, M.B., Manson, J.E., Ludwig, D.S., Colditz, G.A., Stampfer, M.J., Willett, W.C., and Hu, F.B. 2004. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middleaged women. JAMA 292:927–34.
  199. Montonen, J., Jarvinen, R., Knekt, P., Heliovaara, M., and Reunanen, A. 2007. Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. J Nutr 137:1447–54.
  200. Odegaard, A.O., Koh, W.P., Arakawa, K., Yu, M.C., and Pereira, M.A. 2010. Soft drink and juice consumption and risk of physician-diagnosed incident type 2 diabetes: The Singapore Chinese Health Study. Am J Epidemiol 171:701–8.
  201. Malik, V.S., Pan, A., Willett, W.C., and Hu, F.B. 2013. Sugar-sweetened beverages and weight gain in children and adults: A systematic review and meta-analysis. Am J Clin Nutr 98:1084–102.
  202. Romaguera, D., Norat, T., Wark, P.A., Vergnaud, A.C., Schulze, M.B., van Woudenbergh, G.J., Drogan, D., et al. 2013. Consumption of sweet beverages and type 2 diabetes incidence in European adults: Results from EPIC-InterAct. Diabetologia 56:1520–30.
  203. Paynter, N.P., Yeh, H.C., Voutilainen, S., Schmidt, M.I., Heiss, G., Folsom, A.R., Brancati, F.L., and Kao, W.H. 2006. Coffee and sweetened beverage consumption and the risk of type 2 diabetes mellitus. Am J Epidemiol 164:1075–1084.
  204. Ding, M., Bhupathiraju, S.N., Chen, M., van Dam, R.M., and Hu, F.B. 2014. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: A systematic review and meta-analysis and a dose-response meta-analysis. Diabetes Care 37:569–86.
  205. van Dam, R.M., Willett, W.C., Manson, J.E., and Hu, F.B. 2006. Coffee, caffeine, and risk of type 2 diabetes: A prospective cohort study in younger and middle-aged U.S. women. Diabetes Care 29:398–403.
  206. van Dam, R.M. and Hu, F.B. 2005. Coffee consumption and risk of type 2 diabetes: A systematic review. JAMA 294:97–104.
  207. Huxley, R., Lee, C.M., Barzi, F., Timmermeister, L., Czernichow, S., Perovic, V., Grobbee, D.E., Batty, D., and Woodward, M. 2009. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus. Arch Intern Med 169:2053–63.
  208. Bhupathiraju, S.N., Pan, A., Manson, J.E., Willett, W.C., van Dam, R.M., and Hu, F.B. 2014. Changes in coffee intake and subsequent risk of type 2 diabetes: Three large cohorts of US men and women. Diabetologia 57:1346–54.
  209. Salazar-Martinez, E., Willett, W.C., Ascherio, A., Manson, J.E., Leitzmann, M.F., Stampfer, M.J., and Hu, F.B. 2004. Coffee consumption and risk of type 2 diabetes mellitus. Ann Intern Med 140:1–8.
  210. Tuomilehto, J., Hu, J., Bidel, S., Lindstrom, J., and Jousilahti, P. 2004. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA 291:1213–9.
  211. Pereira, M.A., Parker, E.D., and Folsom, A.R. 2006. Coffee consumption and risk of type 2 diabetes mellitus: An 11-year prospective study of 28812 postmenopausal women. Arch Intern Med 166:1311–6.
  212. Lane, J., Hwang, A., Feinglos, M., and Surwit, R. 2007. Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administration of caffeine in coffee. Endoc Pract 13:239–43.
  213. Iso, H., Date, C., Wakai, K., Fukui, M., Tamakoshi, A., and JACC Study Group. 2006. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med 144:554–62.
  214. Santos, R.M. and Lima, D.R. 2016. Coffee consumption, obesity, and type 2 diabetes: A min-review. Eur J Nutr 55:1345–58.
  215. Grosso, G., Stepaniak, U., Micek, A., Topor-Madry, R., Pikhart, H., Szafraniec, K., and Pajak, A. 2015. Association of daily coffee and tea consumption and metabolic syndrome: Results from the Polish arm of the HAPIEE study. Eur J Nutr 54:1129–37.
  216. Mozaffarian, D. 2016. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity. Circulation 133:187–225.
  217. Howard, B.V., Van Horn, L., Hsia, J., Manson, J.E., Stefanick, M.L., Wassertheil-Smoller, S., Kuller, L.H., et al. 2006. Low-fat dietary pattern and risk of cardiovascular disease. The Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295:655–66.
  218. Estruch, R., Ros, E., Salas-Salvado, J., Covas, M.I., Corella, D., Aros, F., Gomez-Gracia, E., et al. 2013. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368:1279–90.
  219. Pan, A.N., Sun, Q., Bernstein, A.M., Manson, J.E., Willett, W.C., and Hu, F.B. 2013. Changes in red meat consumption and subsequent risk of type 2 diabetes: Three cohorts of US men and women. JAMA Intern Med 173:1328–35.
  220. Song, Y., Manson, J.E., Buring, J.E., and Liu, S. 2004. A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women. Diabetes Care 27:2108–15.
  221. Bendinelli, B., Palli, D., Masala, G., Sharp, S.J., Schulze, M.B., Guevara, M., van Der, A.D., et al. 2013. Association between dietary meat consumption and incident type 2 diabetes: The EPIC-InterAct study. Diabetologia 56:47–59.
  222. van Dam, R.M., Rimm, E.B., Willett, W.C., Stampfer, M.J., and Hu, F.B. 2002. Dietary patterns and risk of type 2 diabetes mellitus in U.S. men. Ann Intern Med 136:201–9.
  223. Ley, S.H., Hamdy, O., Mohan, V., and Hu, F.B. 2014. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 383:1999–2007.
  224. Fung, T.T., Schulze, M., Manson, J.E., Willett, W.C., and Hu, F.B. 2004. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med 164:2235–40.
  225. Liese, A.D., Nichols, M., Sun, X., D’Agostino, R.B., and Haffner, S.M. 2009. Adherence to the DASH diet is inversely associated with incidence of type 2 diabetes: The Insulin Resistnace Atherosclerosis Study. Diabetes Care 32:1434–6.
  226. Salas-Salvado, J., Bullo, M., Estruch, R., Ros, E., Covas, M.I., Ibarrola-Jurado, N., Corella, D., et al. 2014. Prevention of diabetes with Mediterranean diets. Ann Intern Med 160:1–10.
  227. Salas-Salvado, J., Bullo, M., Babio, N., Martinez-Gonzalez, M.A., Ibarrola-Jurado, N., Basora, J., Estruch, R., et al. 2011. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 34:14–9.
  228. Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services. 2015. Dietary Guidelines for Americans: 2015–2020. 8th Ed. Available from https://health.gov/ dietaryguidelines/2015/guidelines/. Accessed 15 August 2017.
  229. The InterAct Consortium. 2011. Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Diabetes Care 34:1913–8.
  230. Martinez-Gonzalez, M.A., de la Fuente-Arrilaga, C., Nunez-Cordoba, J.M., Basterra-Gortari, F.J., Beunza, J.J., Vazquez, Z., Benito, S., Tortosa, A., Bes-Rastrollo, M. 2008. Adherence to Mediterranean diet and risk of developing diabetes: Prospective cohort study. BMJ 336:1348–51.
  231. Sandouk, Z. and Lansang, M.C. 2017. Diabetes with obesity – Is there an ideal diet? Cleve Clin J Med 84:S4–14.
  232. Babio, N., Toledo, E., Estruch, R., Ros, E., Martinez-Gonzalez, M.A., Castaner, O., Bullo, M., et al. 2014. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 186:E649–57.
  233. Appel, L.J., Sacks, F.M., Carey, V.J., Obarzanek, E., Swain, J.F., Miller, ER 3rd, Conlin, P.R., et al. 2005. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids. JAMA 294:2455–64.
  234. Haring, B., von Ballmoos, M.C., Appel, L.J., and Sacks, F.M. 2014. Healthy dietary interventions and lipoprotein(a) plasma levels: Results from the Omni Heart Trial. PLoS One 9:e114859.
  235. Hollis, J.F., Gullion, C.M., Stevens, V.J., Brantley, P.J., Appel, L.J., Ard, J.D., Champagne, C.M., et al. 2008. Weight loss during the intensive intervention phase of the weight-loss maintenance trial. Am J Prev Med 35:118–26.
  236. Ard, J.D., Grambow, S.C., Slentz, C.A., Kraus, W.E., and Svetkey, L.P. 2004. The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care 27:340–7.
  237. Gadgil, M.D., Appel, L.J., Yeung, E., Anderson, C.A., Sacks, F.M., and Miller, E.R. 3rd. 2013. The effects of carbohydrate, unsaturated fat, and protein intake on measures of insulin sensitivity. Diabetes Care 36:1132–7.
  238. De Koning, L., Chiuve, S.E., Fung, T.T., Willett, W.C., Rimm, E.B., and Hu, F.B. 2011. Diet-quality scores and the risk of type 2 diabetes in men. Diabetes Care 34:1150–6.
  239. Tonstad, S., Butler, T., Yan, R., and Fraser, G.E. 2009. Type of vegetarian diet, body weight, and prevalence of type 2 diabetes. Diabetes Care 32:791–6.
  240. Tonstad, S., Stewart, K., Oda, K., Batech, M., Herring, R.P., and Fraser, G.E. 2013. Vegetarian diets and incidence of diabetes in the Adventist Health Study-2. Nutr Metab Cardiovasc Dis 23:292–9.
  241. Wing, R.R., Bolin, P., Brancati, F.L., Bray, G.A., Clark, J.M., Coday, M., Crow, R.S., et al. 2013. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–54.
  242. American Diabetes Association. 2017. Obesity management for the treatment of type 2 diabetes. Sec. 7. In Standards of Medical Care in Diabetes—2017. Diabetes Care 40(Suppl. 1):S57–63. Pastors, J.G., Warshaw, H., Daly, A., Franz, M., and Kulkarni, K. 2002. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 25:608–13.
  243. Look AHEAD Research Group. 2014. Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD Study. Obesity 22:5–13.
  244. Franz, M.J., Monk, A., Barry, B., McClain, K., Weaver, T., Cooper, N., Upham, P., Bergenstal, R., and Mazze, R.S. 1995. Effectiveness of medical nutrition therapy provided by dieticians in the management of non-insulin-dependent diabetes mellitus: A randomized, controlled clinical trial. J Am Diet Assoc 95:1009–17.
  245. Jensen, M.D., Ryan, D.H., Apovian, C.M., Ard, J.D., Comuzzie, A.G., Donato, K.A., Hu, F.B., et al. 2014. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol 63 (25 Part B):2985–3023.
  246. Garvey, T.W., Machanick, J.I., Brett, E.M., Garber, A.J., Hurley, D.L., Jastreboff, A.M., Nadolsky, K., et al. 2016. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for comprehensive medical care of patients with obesity-executive summary. Endoc Pract 22:1–203.
  247. Franz, M.J., Boucher, J.L., Rutten-Ramos, S., and VanWormer, J.J. 2015. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: A systematic review and metaanalysis of randomized clinical trials. J Acad Nutr Diet 115:1447–63.
  248. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol Protein, and Amino Acids [Internet]. Washington, DC, National Academies Press, 2005. Available from http://www.iom.edu/Reports/2002/Dietary-Reference-Intakes-for-EnergyCarbohydrate-Fiber-Fat-Fatty-Acids-Cholesterol-Protein-and-Amino-Acids.aspx. Accessed 19 August 2017.
  249. American Diabetes Association. 2017. Lifestyle management. Sec. 4. In Standards of medical care in diabetes—2017. Diabetes Care 40(Suppl 1):S33–43.
  250. Brunzell, J.D., Lerner, R.L., Porte, D. Jr., and Bierman, E.L. 1974. Effect of a fat free, high carbohydrate diet on diabetic subjects with fasting hyperglycemia. Diabetes 23:139–42.
  251. Farquhar, J.W., Frank, A., Gross, R.C., and Reaven, G.M. Glucose, insulin, and triglyceride responses to high and low carbohydrate diets in man. J Clin Invest 45:1648–56.
  252. Ginsberg, H., Olefsky, J.M., Kimmerling, G., Crapo, P., and Reaven, G.M. 1976. Induction of hypertriglyceridemia by a low-fat diet. J Clin Endocrinol Metab 42, 729–35.
  253. Coulston A., Hollenbeck, C.B., Swislocki, A.L., and Reaven, G.M. 1989. Persistence of the hypertriglyceridemic effect of high-carbohydrate, low-fat diets in patients with non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Care 12:94–101.
  254. Chen Y.D., Swami, S., Skowronski, R., Coulston, A.M., and Reaven, G.M. 1993. Effect of variations in dietary fat and carbohydrate intake on postprandial lipemia in patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76:347–51.
  255. Chen, Y.D., Coulston, A.M., Zhou, M.Y., Hollenbeck, C.B., and Reaven, G.M. 1995. Why do low-fat high-carbohydrate diets accentuate postprandial lipemia in patients with NIDDM? Diabetes Care 18:10–6.
  256. Nordmann, A.J., Nordmann, A., Briel, M., Keller, U., Yancy, W.S. Jr., Brehm, B.J., and Bucher, H.C. 2006. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors. Arch Intern Med 166:285–93.
  257. Brehm, B.J., Lattin, B.L., Summer, S.S., Boback, J.A., Gilchrist, G.M., Jandacek, R. J., and D’Alessio, D.A. 2009. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care 32:115–20.
  258. Esposito, K., Maiorino, M.I., Ciotola, M., Di Palo, C., Scognamiglio, P., Gicchino, M., Ptetrizzo, M., et al. 2009. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: A randomized trial. Ann Intern Med 151:306–14.
  259. Golay, A., Allaz, A.F., Morel, Y., de Tonnac, N., Tankova, S., and Reaven G. 1996. Similar weight loss with low-or high-carbohydrate diets, Am J Clin Nutr 63:174–8.
  260. Samaha, F.F., Iqbal, N., Seshadri, P., Chicano, K.L., Daily, D.A., McGrory, J., Williams, T., Williams, M., Gracely, E.J., and Stern, L. 2003. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348:2074–81.
  261. Stern, L., Iqbal, N., Seshadri, P., Chicano, K.L., Daily, D.A., McGrory, J., Williams, M., Gracely, E.J., and Samaha, F.F. 2004. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Ann Intern Med 140:778–85.
  262. Yancy, W. Jr, Olsen, M.K., Guyton, J.R., Bakst, R.P., and Westman, E.C. 2004. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia. Ann Intern Med 140:769–77.
  263. Atkins, R.C., Dr. Atkins’ New Diet Revolution. New York: Simon & Schuster; 1998.
  264. Hu, T., Mills, K.T., Yao, L., Demanelis, K., Eloustaz, M., Yancy, W.S. Jr., Kelly, T.N., He, J., and Bazzano, L.A. 2012. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: A meta-analysis of randomized controlled clinical trials. Am J Epidemiol 176(Suppl):S44–54.
  265. Kirk, J.K., graves, D.E., Craven, T.E., Lipkin, E.W., Austin, M., and Margolis, K.L. 2008. Restrictedcarbohydrate diets in patients with type 2 diabetes: A meta-analysis. J Am Diet Assoc 108:91–100.
  266. Wolever, T. and Mehling, C. 2003. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, tracylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 77:61221.
  267. Thomas. D. and Elliott, E.J. 2009. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 1:CD006296.
  268. Giacco, R., Parillo, M., Riellese, A.A., Lasorella, G., Giacco, A., D’Episcopo, and Riccardi, G. 2000. Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 23:1461–6.
  269. Gilbertson, H.R., Brand-Miller, J.C., Thorburn, A.W., Evans, S., Chondros, P., and Werther, G.A. 2001. The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange on glycemic control in children with type 1 diabetes. Diabetes Care 24:1137–43.
  270. Rizkalla, S.W., Taghrid, L., Laromiquiere, M., Huet, D., Boillot, J., Riqoir, A., Elgrably, F., and Slama, G. 2004. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a lowglycemic index diet in type 2 diabetic men: A randomized controlled trial. Diabetes Care 27:1866–72.
  271. Layman, D.K., Shiue, H., Sather, C., Erickson, D.J., and Baum, J. 2003. Increased dietary protein modifies glucose and insulin homeostasis in adult women during weight loss. J Nutr 133:405–10.
  272. Parker, B., Noakes, M., Luscombe, N., and Clifton, P. 2002. Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care 25:425–30.
  273. Gannon, M.C., Nutall, J.A., Damberg, G., Gupta, V., and Nuttall, F.Q. 2001. Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. J Clin Endocrinol Metab 86:1040–7.
  274. Gannon, M.C., Nutall, F.Q., Saeed, A., Jordan, K., and Hoover, H. 2003 An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 78:734–41.
  275. Ajala, O., English, P., and Pinkney, J. 2013. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 97:505–16.
  276. Johnston, C.S., Day, C.S., and Swan, P.D. 2002. Postprandial thermogenesis is increased 100% on a high-protein, low-fat diet versus a high-carbohydrate, low-fat diet in healthy, young women. J Am Coll Nutr 21:55–61.
  277. O’Connell, T.M. 2013. The complex role of the branched chain amino acids in diabetes and cancer. Metabolites 3:931–45.
  278. Yoon, M. 2016. The emerging role of the branched-chain amino acids in insulin resistance and metabolism. Nutrients 8:405.
  279. Newgard, C.B., An, J., Bain, J.R., Muehlbauer, M.J., Stevens, R.D., Lien, L.F., Haqq, A.M., et al. 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9:311–26.
  280. Tai, E.S., Tan, M.L., Stevens, R.D., Low, Y.L., Muehlbauer, M.J., Goh, D.L., Ilkayeva, O.R., et al. 2010. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53:757–67.
  281. Huffman, K.M., Shah, S.H., Stevens, R.D., Bain, J.R., Muehlbauer, M., Slentz, C.A., Tanner, C.J., et al. 2009. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32:1678–83.
  282. Saris, W.H.M. 2001. Very-low-calorie diets and sustained weight loss. Obes Res 9(Suppl 4):295S–301S.
  283. Tsai, A.G. and Walden, T.A. 2006. The evolution of very-low-calorie diets: An update and meta-analysis. Obesity 14:1283–93.
  284. Chang, J. and Kashyap, S.R. 2014. The protein-sparing modified fast for obese patients with type 2 diabetes: What to expect. Cleve Clin J Med 81:557–65.
  285. Paisey, R.B., Frost, J., Harvey, P., Paisey, A., Bower, L., Paisey, R.M., Taylor, P., and Belka, I. 2002. Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes. J Hum Nutr Diet 15:121–7.
  286. Palgi, A., Read, J.L., Greenberg, I., Hoefer, M.A., Bistrian, B.R., and Blackburn, G.L. 1985. Multidisciplinary treatment of obesity with a protein-sparing modified fast: Results in 668 outpatients. AJPH 75:1190–4.
  287. Hughes, T.A., Gwynne, J.T., Switzer, B.R., Herbst, C., and White, G. 1984. Effects of caloric restriction and weight loss on glycemic control. Insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 77:7–17.
  288. Mishra, S., Xu, J., Agarwal, U., Gonzales, J., Levin, S., and Barnard, N.D. 2013. A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: The GEICO study. Eur J Clin Nutr 67:718–24.
  289. Bailey, C.J. and Turner, R.C. 1996. Drug therapy: Metformin. N Engl J Med 334:574–9.
  290. Glucophage (metformin hydrochloride){package insert}, Princeton, NF: Bristol-Myers Squibb, December, 1998.
  291. Lien, L.F., Bethel, M.A., and Feinglos, M.N. 2004. In-hospital management of type 2 diabetes mellitus. Med Clin N Am 88:1085–105.
  292. Saltiel, A.R. and Olefsky, J.M. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661–9.
  293. American Diabetes Association. 2017. Pharmacologic approaches to glycemic treatment. Sec. 8 In Standards of medical care in diabetes – 2017. Diabetes Care 40(Suppl. 1):S64–74.
  294. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Blumki, E., Hantel, S., Mattheus, M., et al. 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–28.
  295. Lee, Y. and Jun, H. 2014. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 63:9–19.
  296. Vilsboll, T., Krarup, T., Deacon, C.F., Madsbad, S., and Holst, J.J. 2001. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–13.
  297. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steq, P.G., Davidson, J., Hirshberg, B., Ohman, P., et al. 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–26.
  298. Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., Fleck, P.R., et al. 2015. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomized, double-blind trial. Lancet 385:2067–76.
  299. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., et al. 2016. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–22.
  300. Nathan D. Insulin treatment of type 2 diabetes mellitus. In: Porte D, Sherwin R, Baron A, editors. Ellenberg & Rifkin’s Diabetes Mellitus, 6th edition. New York: McGraw-Hill; 2003. p. 515–22.
  301. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpem, A. Krempf, M., Lau, D.C., et al. 2015. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11–22.
  302. Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjoth, T.V., Andreasen, A.H., Jensen, C.B., and DeFronzo, R.A. 2015. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA 314:687–99.
  303. Fidler, M.C., Sanchez, M., Raether, B., Weissman, N.J., Smith, S.R., Shanahan, W.R., Anderson, C.M., and BLOSSOM Clinical Trial Group. 2011. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM Trial. J Clin Endocrinol Metab 96:3067–77.
  304. O’Neill, P.M., Smith, S.R., Weissman, N.J., Fidler, M.C., Sanchez, M., Zhang, J., Raether, B., Anderson, C.M., and Shanahan, W.R. 2012. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM Study. Obesity 20:1426–36.
  305. Greenway, F.L., Fujioka, K., Plodkowski, R.A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D.D., Dunayevich, E., COR-I Study Group. 2010. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595–605.
  306. LeBlanc, E.S., O’Connor, E., Whitlock, E.P., Patnode, C.D., and Kapka, T. 2011. Effectiveness of primary care-relevant treatments for obesity in adults: A systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 155:434–47.
  307. Torgerson, J.S., Hauptman, J., Boldrin, M.N., and Sjostrom, L. 2004. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 27:155–61.
  308. Allison, D. B., Gadde, K.M., Garvey, W.T., Peterson, C.A., Schwiers, M.L., Najarian, T., Tam, P.Y., Troupin, B., and Day, W.W. 2011. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity 20:330–42.
  309. Rubino, F., Nathan, D.M., Eckel, R.H., Schauer, P.R., Alberti, K.G., Zimmet, P.Z., Del Prato, S., et al. 2016. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care 39:861–77.
  310. Laferrere, B., Reilly, D., Arias, S., Swerdlow, N., Gorroochurn, P., Bawa, B., Bose, M., et al. 2011. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 3:80re2.
  311. Opara EC, Petro A, Tevrizian A, Feinglos MN, Surwit RS. l-Glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6J mice. J Nutr 126: 273–279, 1996.
  312. Ballard TC, Farag A, Branum GD, et al. Effect of l-glutamine on impaired glucose regulation during intravenous lipid administration. Nutrition 12: 349–354, 1996.
  313. Borel MJ, Williams PE, Jabbour K, et al. Parenteral glutamine infusion alters insulin-mediated glucose metabolism. J Parent Ent Nutr 22: 280–285, 1998.
  314. Katz J, Golden S, Wals PA. Stimulation of hepatic glycogen synthesis by amino acids. Proc Natl Acad Sci USA 73: 3433–3437, 1976.
  315. Katz J, Golden S, Wals PA. Glycogen synthesis by rat hepatocytes. Biochem J 180: 389–402, 1979.
  316. Varnier M, Leese GP, Thompson J, et al. Stimulatory effect of glutamine on glycogen accumulation in human skeletal muscle. Am J Physiol 269: E309–E315, 1995.
  317. Kraus U, Bertrand L, Maisin L, Rosa M, Hue L. Signalling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur J Biochem 269: 3742–3750, 2002.
  318. Cersosimo E, William P, Hoxworth B. Glutamine blocks lipolysis and ketogenesis of fasting. Am J Physiol 250: E248–E252, 1986.
  319. Dechelotte P, Damaun D, Rongier, et al. Absorption and metabolic effects of enterally administered glutamine in humans. Am J Physiol 260: G677–G682, 1991.
  320. Lavoinne A, Baquet A, Hue L. Stimulation of glycogen synthesis and lipogenesis by glutamine in isolated rat hepatocytes. Biochem J 248: 429–437, 1987.
  321. Chan C, Berthiaume F, Lee K, Yarmush ML. Metabolic flux analysis of hepatocyte function in hormone- and amino acid-supplemented plasma. Metab Eng 5: 1–15, 2003.
  322. Taghizadeh M, Jamilian M, Mazloomi M, Sanami M, Asemi Z. A randomized-controlled clinical trial investigating the effect of omega-3 fatty acids and vitamin E co-supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes. J Clin Lipidol 10(2): 386–393, 2016.
  323. Eriksson J, Saloranta C, Widen E, et al. Non-esterified fatty acids do not contribute to insulin resistance in persons at risk of developing Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 34: 192–197, 1991.
  324. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: A re-examination. Diabetes 49: 677–683, 2000.
  325. Kumar R, Nandhini LP, Kamalanathan S, Sahoo J, Vivekanadan M. Evidence for current diagnostic criteria of diabetes mellitus. World J Diabetes. 2016 Sept 15. 7(17): 396–405.
  326. De Groot LJ, Chrousos G, Dungan K, et al., editors. NCBI Bookshelf. Endotext [Internet]. South Dartmouth (MA): MDText.com; 2000.
  327. Chakraborty S, Bhattacharyya R, Banerjee D. Chapter six – Infections: A possible risk factor for type 2 diabetes. Adv Clin Chem. 2017. 80: 227–251.
  328. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med 2006. 241(12): 1323–1331. doi:10.1177/1535370216654227.
  329. Dorcely B, Katz K, Jagannathan R, Chiang SS, Oluwadare B, Goldberg IJ, Bergman M. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017. 10: 345–361.
  330. Haring HU. Novel phenotype of prediabetes. Diabetologia. 2016. 59: 1806–1818.
  331. Dagogo-Jack S. Editorial: The continuum of dysglycemia: Predicting progression from diabetes to type 2 diabetes. J Diabetes Complications. 2017. 31: 1249–1251.
  332. National Diabetes Statistics Report, 2017. Estimates of diabetes and its burden in the United States. 2017. 1–19.
  333. American Diabetes Association. Statistics about Diabetes. Overall numbers, diabetes, and prediabetes.
  334. NCD Risk factor collaboration. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016. 387: 1513–1530.
  335. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993. 329 (14): 977–986.
  336. Geloneck MM, Forbes BJ, Shaffer J, Ying G, Binenbaum G. Ocular complications in children with diabetes mellitus. Ophthalmology. 2015. 122 (12): 2457–2464.
  337. Borgnakke WS, Ylostalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: Systematic review of epidemiological observational evidence. J Clin Periodontol. 2013: 40 (Suppl 14): 10.1111.
  338. Negrato CA, Tarzia O, Jovanovic L, Montenegro E. Periodontal disease and diabetes mellitus. J Appl Oral Sci. 2013. 21 (1): 1–12.
  339. Holmstrup P, Damgaard C, Olsen I, Klinge B, Flyvbjerg A, Nielsen CH, Hansen PR. Comorbidity of periodontal disease: Two sides of the same coin? An introduction for the clinician. J Oral Microbiol. 2017. Jun 14. 9 (1): 1332710. doi:10.1080/20002297.2017.1332710. eCollection 2017.
  340. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunologic mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunol. 2015. Feb. 144(2): 171–185
  341. Hardigan T, Ward R, Ergul A. Cerebrovascular complications of diabetes: Focus on cognitive dysfunction. Clin Sci (Lond). 2016. Oct 01. 130 (20): 1807–1822.
  342. Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr Diab Rep. 2016. Sept. 16(9): 87.
  343. De la Monte SM. Relationships between diabetes and cognitive impairment. Endocrinol Metab Clin North Am. 2014. Mar. 43(1): 245–267.
  344. Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, Dermanovic-Dobrota V, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017. Nov. 124(11): 1431–1454.
  345. Heiss WD, Rosenberg GA, Thiel A, Berlot R, De Reuck. Neuroimaging in vascular cognitive impairment: A state-of the-art-review. BMC Med. 2016. 14: 174.
  346. Holt RIG. Diabetes and depression. Curr Diab Rep. 14(6): 491.
  347. Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM, Zagrean L. The association between diabetes mellitus and depression. J Med Life. 2016. Apr-June. 9(2): 120–125.
  348. Danna SM, Graham E, Burns RJ, Deschenes SS, Schmitz N. Association between depressive symptoms and cognitive functions in persons with diabetes mellitus: A systematic review. PLoS One. 2016. 11(8): e0160809.
  349. Beverly EA, Ritholz MD, Shepherd C, Weinger K. The psychosocial challenges and care of older adults with diabetes: “Can’t do what I used to do; can’t be who I once was”. Curr Diab Rep. 2016. June. 16(6): 48.
  350. Ducat L, Rubenstein A, Philipson LH, Anderson BJ. A review of the mental health issues of diabetes conference. Diab Care. 2015. 38: 333–338.
  351. Fisher VL, Tahrani AA. Cardiac autonomic neuropathy in patients with diabetes mellitus: Current perspectives. Diab Metab Synd Obes. 2017. 10: 419–434.
  352. De Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement form the American heart association and American diabetes association. Diab Care. 2014. 37: 2843–2863.
  353. Kittnar O. Electrocardiographic changes in diabetes mellitus. Physiol Res. 2015. 64 (Suppl 5): S559–S566.
  354. Koektuerk B, Aksoy M, Horlitz M, Bozdag-Turan I, Turan RG. Role of diabetes in heart rhythm disorders. World J Diab. 2016. 10; 7(3): 45–49.
  355. Foris LA, Bhimji SS. Diabetic gastroparesis. Stat Pearls. Treasure Island FL. StatPearls Publishing. 2017 Jun–2017 Oct. PMID 28613545.
  356. Bharucha AE. Epidemiology and natural history of gastroparesis. Gastroenterol Clin of North Am. 2015. March. 44 (1): 9–19.
  357. Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: Diagnosis and management. Neuroendocrin. 2013. 8: 267–280.
  358. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: Worldwide difference of prevalence and risk factors. J Nephropharmacol. 2016. 5(1): 49–56.
  359. Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J Diab Res. Vol 2017 (2017), Article ID 8637138. doi:10.1155/2017/8637138.
  360. Haas M. The revised (2013) BANFF classification for antibody-mediated rejection of renal allografts: Update, difficulties, and future considerations. Am J Transplant. 2016. 16: 1352–1357.
  361. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010. Apr. 21(4): 556–563. doi:10.1681/ASN.2010010010. Epub 2010 Feb 18.
  362. Naidoo P, Liu VJ, Mautone M, Bergin S. Lower limb complications of diabetes mellitus: A comprehensive review with clinicopathological insights form a dedicated high risk diabetic foot multidisciplinary team. Br J Radiol. 2015. 88(1053): 20150135 (ISSN: 1748-880X).
  363. Bodman MA, Dulebohn SC. Neuropathy, diabetic. StatPearls [Internet}. Treasure Island (FL): StatPearls Publishing. 2017-. 2017 Oct 6.
  364. Kucera T, Shaikh HH, Sponer P. Charcot neuropathic arthropathy of the foot: A literature review and single-center experience. J Diab Res. 2016. 2016: 1–10. doi:10.1155/2016/3207043.
  365. Arellano-Valdez F, Urrutia-Osorio M, Arroyo C, Soto-Vega E. A comprehensive review of urologic complications in patients with diabetes. Springerplus. 2014. Sept 23. 3: 549. doi:10.1186/2193-1801-3-549. eCollection 2014.
  366. Lue TF, Brant WO, Shindel A, Bella AJ. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, et al., Editors. Sexual dysfunction in diabetes. Endotext [Internet]. South Dartmouth (MA): MDText.com, 2000.
  367. D’Alfonso TM, Ginter PS, Shin SJ. A review of inflammatory processes of the breast with a focus on diagnosis in core biopsy samples. J Pathol Translat Med. 2015. 49: 279–287.
  368. Akahori H, Kaneko M, Kiyohara K, Terahata S, Sugimoto T. A rare case of diabetic mastopathy in a diabetic man with type 2 diabetes mellitus. Inter Med. 2009. 48: 915–919.
  369. Honda M, Mori Y, Nishi T, Mizuguchi K, Ishibashi M. diabetic mastopathy in bilateral breasts in an elderly Japanese woman with type 2 diabetes: A case report and a review of the literature in Japan. Intern Med. 2007. 46(18): 1573–6. Epub 2007 Sep 14.
  370. Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M. Type 2 diabetes and breast cancer: The interplay between impaired glucose metabolism and oxidant stress. Oxidat Med Cellul Longev. 2015. (2015): 183928. doi:10.1155/2015/183928.
  371. Fang H, Yao B, Yan Y, Xu H, Liu Y, Tang H, Zhou J, et al. Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis of observational studies. Diab Technol Therap. 2013. 15 (11): 914–922.
  372. Joshi S, Liu M, Turner N. Diabetes and its link with cancer: Providing the fuel and spark to launch an aggressive growth regime. Biomed Res Int. 2015. ID 390863.
  373. Mao Y, Tao M, Jia X, Xu H, Chen K, Tang H, Li D. Effect of diabetes mellitus on survival in patients with pancreatic cancer: A systematic review and meta-analysis. Sci Rep. 5:17102. doi:10.1038.
  374. Leung V, Ragbir-Toolsie K. Perioperative management of patients with diabetes. Health Serv Ins. 2017. 10: 1–5.
  375. Okonkwo UA, DiPietro LA. Diabetes and wound angiogenesis. Int J Mol Sci. 2017. 18: 1419. doi:10.3390.
  376. Kalaitzoglou E, Popescu I, Bunn RC, Fowlkes JL, Thrailkill KM. Effects of type 1 diabetes on osteoblasts, osteocytes, and osteoclasts. Curr Osteoporos Rep. 2016. Dec. 14 (6): 310–319.
  377. Jiao H. Diabetes and its effect on bone and fracture healing. Curr Osteoporos. 2015. Oct. 13 (5): 327–335.
  378. Gizzo S, Patrelli TS, Rossanese M, Noventa M, Berretta R, Di Gangi S, Bertin M, Gangemi M, Nardelli GB. An update on diabetic women obstetrical outcomes linked to preconception and pregnancy glycemic profile: A systematic literature review. Sci World J. 2013. Art ID 254901. doi:10.1155/2013/254901.
  379. Baz B, Riveline JP, Gautier JF. Endocrinology of pregnancy. Gestational diabetes mellitus: Definition, aetiological and clinical aspects. Eur J Endocrinol. 2016. 174: R43–R51.
  380. Liebl A, Khunti K, Orozco-Beltran D, Yale JF. Health economic evaluation of type 2 diabetes mellitus: A clinical practice focused review. Clin Med Ins: Endocrin and Diab. 2015. 8: 13–19.
  381. Wu J, Ward E, Threatt E, Lu ZK. Progression to type 2 diabetes and its effect on health care costs in low income and insured patients with pre-diabetes: A retrospective study using Medicaid claims data. J Manag Care Spec Pharm. 2017. 23(3): 309–316.
  382. Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implication for diabetes prevention. Diab Care. 2014. 37: 2557–2564.
  383. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diab Care. 2013. 36: 1033–1046.
  384. Flegal, K. M. et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315, 2284–2284 (2016).
  385. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet Lond. Engl. (2017). doi:10.1016/ S0140-6736(17)32129-3
  386. Colquitt, J. L., Pickett, K., Loveman, E. & Frampton, G. K. Surgery for weight loss in adults. Cochrane Database Syst. Rev. 8, CD003641–CD003641 (2014).
  387. Mingrone, G. et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366, 1577–1585 (2012).
  388. Schauer, D. P. Gastric bypass has better long-term outcomes than gastric banding. Evid. Based Med. 20, 18 (2014).
  389. Dixon, J. B. et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA 299, 316–323 (2008).
  390. O’Brien, P. E. et al. Laparoscopic adjustable gastric banding in severely obese adolescents: A randomized trial. JAMA 303, 519–526 (2010).
  391. Benoit, S. C., Hunter, T. D., Francis, D. M. & De La Cruz-Munoz, N. Use of bariatric outcomes longitudinal database (BOLD) to study variability in patient success after bariatric surgery. Obes. Surg. 24, 936–943 (2014).
  392. Buchwald, H. & Buchwald, J. N. Evolution of operative procedures for the management of morbid obesity 1950-2000. Obes. Surg. 12, 705–717 (2002).
  393. Saber, A. A., Elgamal, M. H. & McLeod, M. K. Bariatric surgery: The past, present, and future. Obes. Surg. 18, 121–128 (2008).
  394. Douglas, I. J., Bhaskaran, K., Batterham, R. L. & Smeeth, L. Bariatric surgery in the United Kingdom: A cohort study of weight loss and clinical outcomes in routine clinical care. PLoS Med. 12, e1001925 (2015).
  395. Hao, Z. et al. Does gastric bypass surgery change body weight set point? Int. J. Obes. Suppl. 6, S37–S43 (2016).
  396. Schauer, P. R., Nor Hanipah, Z. & Rubino, F. Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world’s leading diabetes organizations. Cleve. Clin. J. Med. 84, S47–S56 (2017).
  397. Adams, T. D. et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357, 753–761 (2007).
  398. Angrisani, L. et al. Bariatric surgery worldwide 2013. Obes. Surg. 25, 1822–1832 (2015).
  399. Schauer, P. R., Mingrone, G., Ikramuddin, S. & Wolfe, B. Clinical outcomes of metabolic surgery: Efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 39, 902–911 (2016).
  400. Khorgami, Z. et al. Trends in utilization of bariatric surgery, 2010-2014: Sleeve gastrectomy dominates. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 13, 774–778 (2017).
  401. Courcoulas, A. P. et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 15213, 2416–2425 (2013).
  402. Cooper, T. C., Simmons, E. B., Webb, K., Burns, J. L. & Kushner, R. F. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes. Surg. 25, 1474–1481 (2015).
  403. Buchwald, H. et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 292, 1724–1737 (2004).
  404. Magro, D. O. et al. Long-term weight regain after gastric bypass: A 5-year prospective study. Obes. Surg. 18, 648–651 (2008).
  405. Capella, J. F., York, N., York, N. & Capella, R. F. The weight reduction operation of choice: Vertical banded gastroplasty or gastric bypass. Am. J. Surg. 171, 74–79 (1996).
  406. Nicoletti, C. F. et al. Influence of excess weight loss and weight regain on biochemical indicators during a 4-year follow-up after Roux-en-Y gastric bypass. Obes. Surg. 25, 279–284 (2015).
  407. Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683–2693 (2004).
  408. Mechanick, J. I. et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariat. Obesity 17, S3–S72 (2009). Aills, L., Blankenship, J., Buffington, C., Furtado, M. & Parrott, J. ASMBS allied health nutritional guidelines for the surgical weight loss patient. Surg. Obes. Relat. Dis. 4, S73–108 (2008).
  409. Ben-Porat, T. et al. Nutritional deficiencies after sleeve gastrectomy: Can they be predicted preoperatively? Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 11, 1029–1036 (2015).
  410. Caron, M. et al. Long-term nutritional impact of sleeve gastrectomy. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 13, 1664–1673 (2017).
  411. Frame-Peterson, L. A., Megill, R. D., Carobrese, S. & Schweitzer, M. Nutrient deficiencies are common prior to bariatric surgery. Nutr. Clin. Pract. Off. Publ. Am. Soc. Parenter. Enter. Nutr. 32, 463–469 (2017).
  412. Clements, R. H. et al. Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am. Surg. 72, 1196–1202; discussion 1203–1204 (2006).
  413. Higa, K., Ho, T., Tercero, F., Yunus, T. & Boone, K. B. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 7, 516–525 (2011).
  414. Gasteyger, C., Suter, M., Gaillard, R. C. & Giusti, V. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. Am J Clin Nutr 87, 1128–1133 (2008).
  415. Gletsu-Miller, N. & Wright, B. N. Mineral malnutrition following bariatric surgery. Adv. Nutr. 4, 506– 517 (2013).
  416. De Luis, D. A. et al. Micronutrient status in morbidly obese women before bariatric surgery. Surg. Obes. Relat. Dis. 9, 323–327 (2013).
  417. Sonchez, A. et al. Micronutrient deficiencies in morbidly obese women prior to bariatric surgery. Obes. Surg. 26, 361–368 (2016).
  418. Miller, G. D., Norris, A. & Fernandez, A. Changes in nutrients and food groups intake following laparoscopic Roux-en-Y gastric bypass (RYGB). Obes. Surg. 24, 1926–1932 (2014).
  419. Dagan, S. S. et al. Nutritional status prior to laparoscopic sleeve gastrectomy surgery. Obes. Surg. 26, 2119–2126 (2016).
  420. Lefebvre, P. et al. Nutrient deficiencies in patients with obesity considering bariatric surgery: A crosssectional study. Surg. Obes. Relat. Dis. 10, 540–546 (2014).
  421. Peterson, L. A. et al. Malnutrition in bariatric surgery candidates: Multiple micronutrient deficiencies prior to surgery. Obes. Surg. 26, 833–838 (2016).
  422. Leahy, C. R. & Luning, A. Review of nutritional guidelines for patients undergoing bariatric surgery. AORN J. 102, 153–160 (2015).
  423. Thorell, A. et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J. Surg. 40, 2065–2083 (2016).
  424. Awad, S., Varadhan, K. K., Ljungqvist, O. & Lobo, D. N. A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clin. Nutr. Edinb. Scotl.32, 34–44 (2013).
  425. Lemanu, D. P. et al. Randomized clinical trial of enhanced recovery versus standard care after laparoscopic sleeve gastrectomy. Br. J. Surg. 100, 482–489 (2013).
  426. Ronellenfitsch, U. et al. The effect of clinical pathways for bariatric surgery on perioperative quality of care. Obes. Surg. 22, 732–739 (2012).
  427. Stocker, D. J. Management of the bariatric surgery patient. Endocrinol. Metab. Clin. North Am. 32, 437–457 (2003).
  428. Ortega, J., Ortega-Evangelio, G., Cassinello, N. & Sebastia, V. What are obese patients able to eat after Roux-en-Y gastric bypass? Obes. Facts 5, 339–348 (2012).
  429. Giusti, V. et al. Energy and macronutrient intake after gastric bypass for morbid obesity: A 3-y observational study focused on protein consumption. Am. J. Clin. Nutr. 103, 18–24 (2016).
  430. Dagan, S. S. et al. Do bariatric patients follow dietary and lifestyle recommendations during the first postoperative year? Obes. Surg. 27, 2258–2271 (2017).
  431. McGrice, M. & Don Paul, K. Interventions to improve long-term weight loss in patients following bariatric surgery: Challenges and solutions. Diabetes Metab. Syndr. Obes. Targets Ther. 8, 263–274 (2015).
  432. Garg, T. et al. A postoperative nutritional consult improves bariatric surgery outcomes. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 12, 1052–1056 (2016).
  433. Gudzune, K. A. et al. Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obes. Surg. 23, 1581–1589 (2013).
  434. Boyce, S. G., Goriparthi, R., Clark, J., Cameron, K. & Roslin, M. S. Can Composite nutritional supplement based on the current guidelines prevent vitamin and mineral deficiency after weight loss surgery? Obes. Surg. 26, 966–971 (2016).
  435. Moize, V. L., Pi-Sunyer, X., Mochari, H. & Vidal, J. Nutritional pyramid for post-gastric bypass patients. Obes. Surg. 20, 1133–1141 (2010).
  436. Soares, F. L. et al. Food quality in the late postoperative period of bariatric surgery: An evaluation using the bariatric food pyramid. Obes. Surg. 24, 1481–1486 (2014). doi:10.1007/s11695-014-1198-x.
  437. Nannipieri, M. et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J. Clin. Endocrinol. Metab. 96, E1372–1379 (2011).
  438. Bradley, D. et al. Gastric bypass and banding equally improve insulin sensitivity and ? cell function. J. Clin. Invest. 122, 4667–4674 (2012).
  439. Laferrere, B. et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 2479–2485 (2008).
  440. Poitou Bernert, C. et al. Nutritional deficiency after gastric bypass: Diagnosis, prevention and treatment. Diabetes Metab. 33, 13–24 (2007).
  441. Brolin, R. E. et al. Malabsorptive gastric bypass in patients with superobesity. J. Gastrointest. Surg. 6, 195–205 (2002).
  442. Gandarillas, M., Hodgkinson, S. M., Riveros, J. L. & Bas, F. Effect of three different bariatric obesity surgery procedures on nutrient and energy digestibility using a swine experimental model. Exp. Biol. Med. Maywood NJ 240, 1158–1164 (2015).
  443. Damms-Machado, A. et al. Pre- and postoperative nutritional deficiencies in obese patients undergoing laparoscopic sleeve gastrectomy. Obes. Surg. 22, 881–889 (2012).
  444. van Rutte, P. W. J., Aarts, E. O., Smulders, J. F. & Nienhuijs, S. W. Nutrient deficiencies before and after sleeve gastrectomy. Obes. Surg. 24, 1639–1646 (2014).
  445. Behrns, K. E., Smith, C. D. & Sarr, M. G. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig. Dis. Sci. 39, 315–320 (1994).
  446. Verger, E. O. et al. Micronutrient and protein deficiencies after gastric bypass and sleeve gastrectomy: A 1-year Follow-up. Obes. Surg. 26, 785–796 (2016).
  447. Moizo, V. et al. Long-term dietary intake and nutritional deficiencies following sleeve gastrectomy or Roux-En-Y gastric bypass in a Mediterranean population. J. Acad. Nutr. Diet. 113, 400–410 (2013).
  448. Aron-Wisnewsky, J. et al. Nutritional and protein deficiencies in the short term following both gastric bypass and gastric banding. PLoS One 11, e0149588 (2016).
  449. Faria, S. L., De Oliveira Kelly, E., Lins, R. D. & Faria, O. P. Nutritional management of weight regain after bariatric surgery. Obes. Surg. 20, 135–139 (2010).
  450. Faria, S. L., Faria, O. P., Buffington, C., de Almeida Cardeal, M. & Ito, M. K. Dietary protein intake and bariatric surgery patients: A review. Obes. Surg. 21, 1798–1805 (2011).
  451. Schollenberger, A. E. et al. Impact of protein supplementation after bariatric surgery: A randomized controlled double-blind pilot study. Nutr. Burbank Los Angel. Cty. Calif 32, 186–192 (2016).
  452. Layman, D. K. The role of leucine in weight loss diets and glucose homeostasis. J. Nutr. 133, 261S–267S (2003).
  453. Layman, D. K. Protein quantity and quality at levels above the RDA improves adult weight loss. J. Am. Coll. Nutr. 23, 631S–636S (2004).
  454. Layman, D. K., Shiue, H., Sather, C., Erickson, D. J. & Baum, J. Increased dietary protein modifies glucose and insulin homeostasis in adult women during weight loss. J. Nutr. 133, 405–410 (2003).
  455. Volek, J. S. & Sharman, M. J. Cardiovascular and hormonal aspects of very-low-carbohydrate ketogenic diets. Obes. Res. 12 Suppl 2, 115S–23S (2004).
  456. Farnsworth, E. et al. Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am. J.Clin. Nutr. 78, 31–39 (2003).
  457. Shai, I. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229–41 (2008).
  458. Heber, D. et al. Endocrine and nutritional management of the post-bariatric surgery patient: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 95, 4823–4843 (2010).
  459. Moize, V. et al. Related to protein intolerance up to 1 year following Roux-en-Y gastric bypass. 23–28 (2003).
  460. Schinkel, E. R. et al. Impact of varying levels of protein intake on protein status indicators after gastric bypass in patients with multiple complications requiring nutritional support. Obes. Surg. 16, 24–30 (2006).
  461. Skroubis, G. et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes. Surg. 12, 551–558 (2002).
  462. Coupaye, M. et al. Nutritional consequences of adjustable gastric banding and gastric bypass: A 1-year prospective study. Obes. Surg. 19, 56–65 (2009).
  463. Flancbaum, L., Belsley, S., Drake, V., Colarusso, T. & Tayler, E. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract 10, 1033–1037 (2006).
  464. Yanoff, L. B. et al. Inflammation and iron deficiency in the hypoferremia of obesity. Int. J. Obes. 2005 31, 1412–1419 (2007).
  465. Menzie, C. M. et al. Obesity-related hypoferremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. J. Am. Diet. Assoc. 108, 145–148 (2008).
  466. Guralnik, J. M., Eisenstaedt, R. S., Ferrucci, L., Klein, H. G. & Woodman, R. C. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104, 2263–2268 (2004).
  467. Jouregui-Lobera, I. Iron deficiency and bariatric surgery. Nutrients 5, 1595–1608 (2013).
  468. Muooz, M., Botella-Romero, F., G?mez-Ram?rez, S., Campos, A. & Garc?a-Erce, J. A. Iron deficiency and anaemia in bariatric surgical patients: Causes, diagnosis and proper management. Nutr. Hosp. 24, 640–654 (2009).
  469. Cheng, H. L. et al. The relationship between obesity and hypoferraemia in adults: A systematic review. Obes. Rev. Off. J. Int. Assoc. Study Obes. 13, 150–161 (2012).
  470. Cepeda-Lopez, A. C. et al. The effects of fat loss after bariatric surgery on inflammation, serum hepcidin, and iron absorption: A prospective 6-mo iron stable isotope study. Am. J. Clin. Nutr. 104, 1030– 1038 (2016).
  471. Marin, F. A. et al. Micronutrient supplementation in gastric bypass surgery: Prospective study on inflammation and iron metabolism in premenopausal women. Nutr. Hosp. 34, 369–375 (2017).
  472. Vanarsa, K. et al. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis Res. Ther. 14, R182 (2012).
  473. Weiss, G. & Goodnough, L. T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011–1023 (2005).
  474. Gillon, S., Jeanes, Y. M., Andersen, J. R. & V?ge, V. Micronutrient status in morbidly obese patients prior to laparoscopic sleeve gastrectomy and micronutrient changes 5 years post-surgery. Obes. Surg. 27, 606–612 (2017).
  475. Song, A. & Fernstrom, M. H. Nutritional and psychological considerations after bariatric surgery. Aesthet. Surg. J. 28, 195–199 (2008).
  476. Brolin, R. E. et al. Are vitamin B12 and folate deficiency clinically important after roux-en-Y gastric bypass? J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract 2, 436–442 (1998).
  477. Schroder, O. et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol. 100, 2503–2509 (2005).
  478. Kulnigg, S. et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am. J. Gastroenterol. 103, 1182–1192 (2008).
  479. Shankar, P., Boylan, M. & Sriram, K. Micronutrient deficiencies after bariatric surgery. Nutr. Burbank Los Angel. Cty. Calif 26, 1031–1037 (2010).
  480. von Drygalski, A. & Andris, D. A. Anemia after bariatric surgery: More than just iron deficiency. Nutr. Clin. Pract. Off. Publ. Am. Soc. Parenter. Enter. Nutr. 24, 217–226 (2009).
  481. Madan, A. K., Orth, W. S., Tichansky, D. S. & Ternovits, C. A. Vitamin and trace mineral levels after laparoscopic gastric bypass. Obes. Surg. 16, 603–606 (2006).
  482. Stein, J., Stier, C., Raab, H. & Weiner, R. Review article: The nutritional and pharmacological consequences of obesity surgery. Aliment. Pharmacol. Ther. 40, 582–609 (2014).
  483. Gletsu-Miller, N. et al. Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery. Int. J. Obes. 2005 36, 328–335 (2012).
  484. Prohaska, J. R., Wittmers, L. E. & Haller, E. W. Influence of genetic obesity, food intake and adrenalectomy in mice on selected trace element-dependent protective enzymes. J. Nutr. 118, 739–746 (1988).
  485. Ruz, M. et al. Zinc absorption and zinc status are reduced after Roux-en-Y gastric bypass: A randomized study using 2 supplements. Am. J. Clin. Nutr. 94, 1004–1011 (2011).
  486. Di Martino, G. et al. Relationship between zinc and obesity. J. Med. 24, 177–183 (1993).
  487. Salle, A. et al. Zinc deficiency: A frequent and underestimated complication after bariatric surgery. Obes. Surg. 20, 1660–1670 (2010).
  488. Whittaker, P. Iron and zinc interactions in humans. Am. J. Clin. Nutr. 68, 442S–446S (1998). Himbert, C., Ose, J., Delphan, M. & Ulrich, C. M. A systematic review of the interrelation between dietand surgery-induced weight loss and vitamin D status. Nutr. Res. N. Y. N 38, 13–26 (2017).
  489. Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z. & Holick, M. F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72, 690–693 (2000).
  490. Marceau, P. et al. Duodenal switch: Long-term results. Obes. Surg. 17, 1421–1430 (2007).
  491. Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266–281 (2007).
  492. Sonchez-Hern?ndez, J. et al. Effects of bariatric surgery on vitamin D status and secondary hyperparathyroidism: A prospective study. Obes. Surg. 15, 1389–1395 (2005).
  493. Yu, E. W. et al. Two-year changes in bone density after Roux-en-Y gastric bypass surgery. J. Clin. Endocrinol. Metab. 100, 1452–1459 (2015).
  494. Vilarrasa, N. et al. Evaluation of bone mineral density loss in morbidly obese women after gastric bypass: 3-year follow-up. Obes. Surg. 21, 465–472 (2011).
  495. Compher, C. W., Badellino, K. O. & Boullata, J. I. Vitamin D and the bariatric surgical patient: A review. Obes. Surg. 18, 220–224 (2008).
  496. Stroh, C. et al. A nationwide survey on bariatric surgery in Germany—results 2005–2007. Obes. Surg. 19, 105–112 (2009).
  497. Goldner, W. S. et al. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: A comparison with non-obese controls. Obes. Surg. 18, 145–150 (2008).
  498. Slater, G. H. et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract 8, 48–55; discussion 54–55 (2004).
  499. Aasheim, E. T. et al. Vitamin status after bariatric surgery: A randomized study of gastric bypass and duodenal switch. Am J Clin Nutr 90, 15–22 (2009).
  500. Koch, T. R. & Finelli, F. C. Postoperative metabolic and nutritional complications of bariatric surgery. Gastroenterol. Clin. North Am. 39, 109–124 (2010).
  501. Lakhani, S. V. et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr. Res. N. Y. N 28, 293–298 (2008).
  502. Belogolovkin, V. et al. Impact of prior bariatric surgery on maternal and fetal outcomes among obese and non-obese mothers. Arch. Gynecol. Obstet. 285, 1211–1218 (2012).
  503. Lesko, J. & Peaceman, A. Pregnancy outcomes in women after bariatric surgery compared with obese and morbidly obese controls. Obstet. Gynecol. 119, 547–554 (2012).
  504. Santulli, P. et al. Obstetrical and neonatal outcomes of pregnancies following gastric bypass surgery: A retrospective cohort study in a French referral centre. Obes. Surg. 20, 1501–1508 (2010).
  505. Kjor, M. M., Lauenborg, J., Breum, B. M. & Nilas, L. The risk of adverse pregnancy outcome after bariatric surgery: A nationwide register-based matched cohort study. Am. J. Obstet. Gynecol. 208, 464. e1–5 (2013).
  506. Bebber, F. E. et al. Pregnancy after bariatric surgery: 39 pregnancies follow-up in a multidisciplinary team. Obes. Surg. 21, 1546–1551 (2011).
  507. American College of Obstetricians and Gynecologists. ACOG Committee opinion no. 549: Obesity in pregnancy. Obstet. Gynecol. 121, 213–217 (2013).
  508. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA 2016; 315:2284–2291.
  509. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: A systematic review and meta-analysis. JAMA 2004; 292:1724–1737.
  510. National Institutes of Health Consensus Development Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991; 115:956–961.
  511. Kremen AJ, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg 1954; 140:439–448.
  512. Wilkinson LH, Peloso OA. Gastric (reservoir) reduction for morbid obesity. Arch Surg 1981; 116:602–605.
  513. Hallberg D, Forsell O. Ballongband vid behandling av massiv ?verwikt. Svinsk Kirurgi 1985; 344:106–108.
  514. Kuzmak LI. Silicone gastric banding: A simple and effective operation for morbid obesity. Contemp Surg 1986; 28:13–18. Himpens J, Cadiere GB, Bazi M, Vouche M, Cadiere B, Dapri G. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011; 146:802–807.
  515. Kuzmak LI, Yap IS, McGuire L, Dixon JS, Young MP. Surgery for morbid obesity: Using an inflatable gastric band. AORN J 1990; 51:1307–1324.
  516. Dargent J. Surgical treatment of morbid obesity by adjustable gastric band: The case for a conservative strategy in the case of failure – a 9-year series. Obes Surg 2004; 14:986–990.
  517. Parikh MS, Fielding GA, Ren CJ. U.S. experience with 749 laparoscopic adjustable gastric bands. Surg Endosc 2005; 19:1631–1635.
  518. Belachew M, Belva P, Desaive C. Long-term results of laparoscopic adjustable gastric banding for the treatment of morbid obesity. Obes Surg 2002; 12:567–568.
  519. OBrien P, Dixon J. Laparoscopic adjustable gastric banding in the treatment of morbid obesity. Arch Surg 2003; 138:377–382.
  520. Puzziferri NP, Roshek TB, Mayo HB, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: A systematic review. JAMA 2014; 312:934–942.
  521. Regan JP, Inabnet WB, Gagner M, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 2003; 13:861–864.
  522. Braghetto I, Korn O, Valladares H, et al. Laparoscopic sleeve gastrectomy: Surgical technique, indications and clinical results. Obes Surg 2007; 17:1442–1450.
  523. Villagr?n R, Smith G, Rodriguez W, et al. Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy: Incidence, analysis and follow-up in 1236 consecutive cases. Obes Surg 2016; 26:2555–2561.
  524. Parikh M, Adelsheimer A, Somoza E, et al. Factor VIII elevation may contribute to portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy: A multicenter review of 40 patients. Surg Obes Relat Dis 2017; 13:1835–1839.
  525. Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis 2009; 5:469–475.
  526. Hamoui N, Anthone GJ, Kaufman HS, Crookes PF. Sleeve gastrectomy in the high-risk patient. Obes Surg 2006; 16:1445–1449.
  527. Weiner RA, Weiner S, Pomhoff I, et al. Laparoscopic sleeve gastrectomy – influence of sleeve size and resected gastric volume. Obes Surg 2007; 17:1297–1305.
  528. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc 2006; 20:859–863.
  529. Switzer NJ, Prasad S, Debru E, Church N, Mitchell P, Gill RS. Sleeve gastrectomy and type 2 diabetes mellitus: A systematic review of long-term outcomes. Obes Surg 2016; 26:1616–1621.
  530. Switzer NJ, Karmali S. The sleeve gastrectomy and how and why it can fail? Surgery Curr Res 2014; 4: 180–183.
  531. Mason EE. Gastric bypass. Ann Surg 1969; 170:329–339.
  532. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222; 339–352.
  533. Christou NV, Look D, MacLean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244:734–740.
  534. Sugerman HJ, Kellum JM, DeMaria EJ. Conversion of proximal to distal gastric bypass for failed gastric bypass for superobesity. J Gastrointest Surg 1997; 1:517–525.
  535. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: Preliminary report of five cases. Obesity Surg.1994; 4:353–357.
  536. Carrasquilla C, English WJ, Esposito P, Gianos J. Total stapled, total intra-abdominal (TSTI) laparoscopic Roux-en-Y gastric bypass: One leak in 1,000 cases. Obes Surg 2004; 14:613–617.
  537. McCarty TM, Arnold DT, Lamont JP, Fisher TL, Kuhn JA. Optimizing outcomes in bariatric surgery: Outpatient laparoscopic gastric bypass. Ann Surg 2005; 242: 494–501.
  538. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 2017; 377:1143–1155.
  539. Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V. Bilio-pancreatic by-pass for obesity. II. Initial experience in man. Br J Surg 1979; 66:618–620.
  540. Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M, Biron S. Biliopancreatic diversion with duodenal switch. World J Surg 1998; 22:947–954.
  541. Hess DS, Hess DW, Oalkley RS. The biliopancreatic diversion with duodenal switch: Results beyond 10 years. Obes Surg 2005; 15:408–416.
  542. Marceau P, Biron S, Marceau S, et al. Long-term metabolic outcomes 5 to 20 years after biliopancreatic diversion. Obes Surg 2015; 25:1584–1593. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatice diversion. World J Surg 1998; 22:936–946.
  543. Sjostrom L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683–2693.
  544. Sjostrom L, Narbro K, Sj?str?m CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741–752.
  545. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307(1):56–65.
  546. Sj?str?m L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311:2297–2304.
  547. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015; 386:964–973.
  548. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes— 5-year outcomes. N Engl J Med 2017; 376:641–651.
  549. Risstad H, S?vik TT, Engstr?m M, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: A randomized clinical trial. JAMA Surg 2015; 150:352–361.
  550. Sanmiguel C, Gupta A, Mayer EA. Gut microbiome and obesity: A plausible explanation for obesity. Curr Obes Rep. 2015 Jun; 4(2): 250–261.
  551. Gorard P. Gut microbiota and obesity. Cell Mol Life Sci. 2016 Jan; 73(1): 147–162.
  552. Omer E, Atassi H. The microbiome that shapes us: Can it cause obesity? Curr Gastroenterol Rep. 2017 Oct 27; 19(12): 59.
  553. Murugesan S, Nirmalkar K, Hoyo-Vadillo C, Garcoa-Espitia M, Ram?rez-S?nchez D, Garcoa-Mena J. Gut microbiome production of short-chain fatty acids and obesity in children. Eur J Clin Microbiol Infect Dis. 2017 Dec 2.
  554. Portune KJ, Ben?tez-P?ez A, Del Pulgar EM, Cerrudo V, Sanz Y. Gut microbiota, diet, and obesityrelated disorders- The good, the bad, and the future challenges. Mol Nutr Food Res. 2017 Jan; 61(1).
  555. Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbiome and obesity: Moving beyond associations. Cell Host Microbe. 2017 Nov 8; 22(5): 589–599.
  556. Chen J, He X, Huang J. Diet effects in gut microbiome and obesity. J Food Sci. 2014 Apr; 79(4): R442–451.
  557. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Feb; 14(2): 112–120.
  558. Caricilli AM, Saad MJ. Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care. 2014 Jul; 17(4): 312–318.
  559. Li X, Shimizu Y, Kimura I. Gut microbial metabolite short-chain fatty acids and obesity. Biosci Microbiota Food Health. 2017 Aug 25; 36(4): 135–140.
  560. Cho I, Yamanishi S, Cox L, Meth? BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, Li H, Alekseyanko AV, Blaser MJ. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012 Aug 30; 488(7413): 621–626.
  561. Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother. 2012 Nov; 56(11): 5811–5820.
  562. Esteve E, Ricart W, Fern?ndez-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: Did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011 Sep; 14(5): 483–490.
  563. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Karkoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011 Jul; 94(1): 58–65. Wostmann BS. Intestinal bile acids and cholesterol absorption in the germfree rat. J Nutr. 1973 Jul; 103(7): 982–990.
  564. Rabot S, Membrez M, Bruneau A, G?rard P, Harach T, Moser M, Raymond E, Mansourian R, Chou CJ. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010 Dec; 24(12): 4948–4959.
  565. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011 May; 130(2): 202–212.
  566. Dao MC, Cl?ment K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur J Intern Med. 2018 Feb; 48: 18–24.
  567. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 Jul; 56(7): 1761–1772.
  568. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013 May 28; 110(22): 9066–9071.
  569. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011 Oct 7; 334(6052): 105–108.
  570. Duncan SH, Belenquer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol. 2007 Feb; 73(4): 1073–1078.
  571. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33): 14691–14696.
  572. Zhang C, Zhang M, Pang X, Zhao Y, Wang L, Zhao L. Structural resilience of the gut microbiota in adult mice under high- fat dietary perturbations. ISME J. 2012 Oct; 6(10): 1848–1857.
  573. Lam YY, Ha CW, Campbell CR, Mitchell AJ Dinudom A, Oscarsson J, Cook DI, Hunt NH, Caterson ID, Holmes AJ, Storlien LH. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One. 2012; 7(3): e34233.
  574. Mujico JR, Baccan GC, Gheorghe A, D?az LE, Marcos A. Changes in gut microbiota due to supplemented fatty acids in diet-induced obese mice. Br J Nutr. 2013 Aug; 110(4): 711–720.
  575. Haghikia A, J?rg S, Duscha A, Berg J, Manzel A, Waschbisch A, Hammer A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. Immunity. 2016 Apr 19; 44(4): 951–953.
  576. Tremaroli V, B?ckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012 Sep 13; 489(7415): 242–249.
  577. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005 Jan; 589(1): 47–65.
  578. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb; 5(2): 220–230.
  579. Costabile A, Klinder A, Fava F, Napolitano A, Fogliano V, Leonard C, Gibson GR, Tuohy KM. Wholegrain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: A double-blind, placebo-controlled, crossover study. Br J Nutr. 2008 Jan; 99(1): 110–120.
  580. Carvalho-Wells AL, Helmolz K, Nodet C, Molzer C, Leonard C, McKevith B, Thielecke F, Jackson KG, Tuohy KM. Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: A human feeding study. Br J Nutr. 2010 Nov; 104(9): 1353–1356.
  581. Mart?nez I, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013 Feb; 7(2): 269–280.
  582. Petry N, Egli I, Chassard C, Lacroix C, Hurrell R. Inulin modifies the bifidobacteria population, fecal lactate concentration, and fecal pH but does not influence iron absorption in women with low iron status. Am J Clin Nutr. 2012 Aug; 96(2), 325–331.
  583. Garcoa-Peris P, Velasco C, Lozano MA, Moreno Y, Paron L, de la Cuerda C, Bret?n I, Camblor M, Garc?a-Hern?ndez J, Guarner F, Hern?ndez M. Effect of a mixture of inulin and fructooligosaccharide on Lactobacillus and Bifidobacterium intestinal microbiota of patients receiving radiotherapy: A randomised, double- blind, placebo-controlled trial. Nutr Hosp. 2012 Nov-Dec; 27(6): 1908–1915. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013 Aug; 62(8): 1112–1121.
  584. Kleessen B, Schwarz S, Boehm A, Fuhrmann H, Richter A, Henle T, Krugger M. Jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota of healthy volunteers. Br J Nutr. 2007 Sep; 98(3): 540–549.
  585. Davis LM, Martinez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One. 2011; 6(9): e25200.
  586. Mart?nez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. PLoS One. 2010 Nov 29; 5(11): e15046.
  587. Lin HV, Frassetto K, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, Marsh DJ. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012; 7(4): e35240.
  588. Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016; 93(1): 59–65
  589. John GK, Mullin GE. The gut microbiome and obesity. Curr Oncol Rep. 2016 Jul; 18(7): 45.
  590. Million M, Angelakis E, Paul M, Armougom F, Leibovici L, Raoult D. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog. 2012 Aug; 53(2): 100–108.
  591. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013 Feb; 34(1): 39–58
  592. Yin YN, Yu QF, Fu N, Liu XW, Lu FG. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol. 2010 Jul 21; 16(27): 3394–3401.
  593. Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010 Jun; 64(6), 636–643.
  594. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR., Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007 Nov; 50(11): 2374–2383.
  595. Genta S, Cabrera W, Habib N, Pons J, Carillo IM, Grau A, Sanchez S. Yacon syrup: Beneficial effects on obesity and insulin resistance in humans. Clin Nutr. 2009 Apr; 28(2): 182–187.
  596. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009 Jun; 89(6): 1751–1759.
  597. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27; 5(178): 178ra41.
  598. Zhang H, DiBaise JK, Zuccolo A, Kudma D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009 Feb 17; 106(7): 2365–2370.
  599. Furet JP, Kong LC, Tap J, Poitou C, Bouillot JL, Mariat D, Corthier G, Doro J, Henegar C, Rizkalla S, Cloment K. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: Links with metabolic and low-grade inflammation markers. Diabetes. 2010 Dec; 59(12): 3049–3057. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease
  600. Study 2013. Lancet. 2014;384(9945):766–781.
  601. Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf). 2005;27(2):156–164.
  602. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–2291.
  603. Centers for Disease Control and Prevention (CDC) Defining Overweight and Obesity. Updated April 27, 2012 Available at: www.cdc.gov/obesity/adult/defining.html
  604. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293:1861–1867.
  605. Campos P, Saguy A, Ernsberger P, Oliver E, Gaesser G. The epidemiology of overweight and obesity: Public health crisis or moral panic? Int J Epidemiol. 2006;35:55–60.
  606. Sims EAH. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499–1504. Willett WC, Hu FB, Thun M. Overweight, obesity, and all-cause mortality. JAMA. 2013;309:1681–1682.
  607. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis. JAMA. 2013;309:71–82.
  608. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–543.
  609. Kovesdy CP, Furth SL, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: Hidden consequences of the epidemic. Future Sci OA. 2017;3(3):FSO159. doi:10.415.
  610. Chao Hse-Huang, Liao Yin-To, Chen Vincent Chin-Hung, Li Cheng-Jui, McIntyre Roger S, Lee Yena, Weng Jun-Cheng. Correlation between brain circuit segregation and obesity. Behav Brain Res. 2018;337:218–227. doi:10.1016/j.bbr.2017.09.017.
  611. MacLean PS, Wing RR, Davidson T, et al. NIH working group report: Innovative research to improve maintenance of weight loss. Obesity. 2015;23(1):7–15.
  612. Parsons WB. Controlled-release diethylpropion hydrochloride used in a program for weight reduction. Clin Ther. 1981;3(5):329–335.
  613. Carney DE, Tweddell ED. Double blind evaluation of long acting diethylpropion hydrochloride in obese patients from a general practice. Med J Aust. 1975;1(1):13–15.
  614. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
  615. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–1041.
  616. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123–1128.
  617. Garvey WT, Ryan DH, Bohannon NJ, et al. Weight loss therapy in type 2 diabetes: Effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309–3316.
  618. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436.
  619. Hollander P, Gupta AK, Plodkowski R, et al. CORDiabetes Study Group. Effects of naltrexone sustained release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
  620. Davies MJ, Bergenstal R, Bode B, et al. NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
  621. Velazquez A, Apovian CM. Pharmacological management of obesity. Minerva Endocrinol. 2017. doi:10.23736/S0391-1977.17.02654-2.
  622. US Preventive Services Task Force. Screening for obesity in adults: Recommendations and rationale. Ann Intern Med. 2003;139(11):930–932.
  623. Apovian CM, Aronne LJ, Bessesen DH, et al.; Endocrine Society. Pharmacological management of obesity: An endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
  624. Wadden TA, Berkowitz RI, Sarwer DB, Prus- Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med. 2001;161(2):218–227.
  625. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events. A systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602.
  626. Greenway FL, Fujioka K, Plodkowski RA, et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
  627. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
  628. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.
  629. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
  630. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160–167. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, Erwin PJ, Montori VM. Treatment of pediatric obesity: A systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008;93(12):4600–4605.
  631. Hendricks EJ, Rothman RB. RE: Pulmonary hypertension associated with use of phentermine? Yonsei Med J. 2011;52(5):869–870.
  632. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.
  633. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–749.
  634. Liotta AS, Advis JP, Krause JE, et al. Demonstration of in vivo synthesis of pro-opiomelanocortin-, betaendorphin-, and alpha-melanotropin-like species in the adult rat brain. J Neurosci. 1984;4(4):956–965.
  635. Brady LS, Smith MA, Gold PW, Herkenham M. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology. 1990;52(5):441–447.
  636. Fan W, Voss-Andreae A, Cao W-H, Morrison SF. Regulation of thermogenesis by the central melanocortin system. Peptides. 2005;26(10):1800–1813.
  637. Pennock RL, Hentges ST. Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons. J Neurosci. 2011;31(1):281–288.
  638. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–39.
  639. Contrave (naltrexone HCl/bupropion HCl) prescribing information. Deerfield, IL: Takeda Pharmaceuticals America; 2014.
  640. Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12(11):1813–1826.
  641. Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly approved treatment option for chronic weight management in obese adults. Pharm Ther. 2016;41(3):164–172.
  642. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon?like peptide?1 receptor agonists on body weight: A meta?analysis. Exp Diabetes Res. 2012;2012:672658.
  643. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: A critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14.
  644. Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, nondiabetic adults. Int J Obes (2005). 2014;38(6):784–793.
  645. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48(4):612–615.
  646. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665–670.
  647. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–673.
  648. Ladenheim EE. Liraglutide and obesity: A review of the data so far. Drug Des Devel Ther. 2015;9:1867–1875.
  649. Saxenda [package insert]. Novo Nordisk: Plainsboro, NJ, 2015.
  650. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add?on to glucose?lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA?RENAL): A randomized clinical trial. Diabetes Care. 2016;39:222–230.
  651. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta?analysis. BMJ Open. 2013;3. doi:10.1136/bmjopen-2012-001986.
  652. FDA Center for Drug Evaluation and Research Belviq NDA 022529 drug label, June 27, 2012.
  653. Gustafson A, King C, Rey JA. Lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity. Pharm Ther. 2013;38(9):525–534.
  654. Smith SR, Weisserman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
  655. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure–activity relationship of (1r)-8-chloro2,3,4,5-tetrahydro-1-methyl-1h-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008;51:305–313.
  656. Geyer MA, Vollenweider FX. Serotonin research: Contributions to understanding psychosis. Trends Pharmacol Sci. 2008;29:445–453. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257–2267.
  657. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998;16(12 pt 2):2013–2017.
  658. Derosa G, Maffioli P, Salvadeo SA, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother. 2010;11(12):1971–1982.
  659. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: Insights from yesterday, today, and future trends. Popul Health Manag 2017; 20(1): 6–12.
  660. Hurt RT, Kulisek C, Buchanan LA, McClave SA. The obesity epidemic: Challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol 2010; 6(12): 780–92.
  661. Smith SR, Lovejoy JC, Greenway F, et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001; 50(4): 425–35.
  662. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol 1997; 145(7): 614–9.
  663. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17(9): 961–9.
  664. Welborn TA, Dhaliwal SS. Preferred clinical measures of central obesity for predicting mortality. Eur J Clin Nutr 2007; 61(12): 1373–9.
  665. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010; 139(2): 448–55.
  666. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350(25): 2549–57.
  667. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23(4): 591–601.
  668. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996; 45(12): 1684–93.
  669. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46(10): 1579–85.
  670. Jensen MD, Johnson CM. Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metabolism 1996; 45(5): 662–6.
  671. Goodpaster BH, Krishnaswami S, Harris TB, et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med 2005; 165(7): 777–83.
  672. Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001; 154(2): 497–504.
  673. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002; 23(9): 706–13.
  674. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002; 967: 363–78.
  675. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94(2): 206–18.
  676. Ebbert JO, Jensen MD. Fat depots, free fatty acids, and dyslipidemia. Nutrients 2013; 5(2): 498–508.
  677. Tchoukalova YD, Koutsari C, Votruba SB, et al. Sex- and depot-dependent differences in adipogenesis in normal-weight humans. Obesity (Silver Spring) 2010; 18(10): 1875–80.
  678. Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000; 71(4): 885–92.
  679. Tchoukalova YD, Koutsari C, Karpyak MV, Votruba SB, Wendland E, Jensen MD. Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr 2008; 87(1): 56–63.
  680. Snijder MB, Dekker JM, Visser M, et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: The Hoorn study. Diabetes Care 2004; 27(2): 372–7.
  681. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000; 278(5): E941–8.
  682. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113(11): 1582–8.
  683. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. Am J Clin Nutr 1995; 61(2): 274–8.
  684. Poonawalla AH, Sjoberg BP, Rehm JL, et al. Adipose tissue MRI for quantitative measurement of central obesity. J Magn Reson Imaging 2013; 37(3): 707–16.
  685. Wagner DR, Heyward VH. Techniques of body composition assessment: A review of laboratory and field methods. Res Q Exerc Sport 1999; 70(2): 135–49.
  686. Duren DL, Sherwood RJ, Czerwinski SA, et al. Body composition methods: Comparisons and interpretation. J Diabetes Sci Technol 2008; 2(6): 1139–46.
  687. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution. Ageing Res Rev 2009; 8(4): 339–48.
  688. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000; 21(6): 697–738.
  689. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4(6): 499–502.
  690. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72(3): 1150–62.
  691. Kvist H, Chowdhury B, Grangard U, Tylen U, Sjostrom L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: Predictive equations. Am J Clin Nutr 1988; 48(6): 1351–61.
  692. Goss AM, Darnell BE, Brown MA, Oster RA, Gower BA. Longitudinal associations of the endocrine environment on fat partitioning in postmenopausal women. Obesity (Silver Spring) 2012; 20(5): 939–44.
  693. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39(9): 897–901. Reyes-Vidal CM, Mojahed H, Shen W, et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 2015; 100(8): 2946–55.
  694. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: Effects of race. Metabolism 1996; 45(9): 1119–24.
  695. Kanaley JA, Giannopoulou I, Tillapaugh-Fay G, Nappi JS, Ploutz-Snyder LL. Racial differences in subcutaneous and visceral fat distribution in postmenopausal black and white women. Metabolism 2003; 52(2): 186–91.
  696. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: An update. Physiol Rev 2013; 93(1): 359–404.
  697. Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM, Jr. Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obesity Rev 2016; 17(3): 262–75.
  698. Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 1997; 46(3): 456–62.
  699. Conway JM, Yanovski SZ, Avila NA, Hubbard VS. Visceral adipose tissue differences in black and white women. Am J Clin Nutr 1995; 61(4): 765–71.
  700. Miller WC, Lindeman AK, Wallace J, Niederpruem M. Diet composition, energy intake, and exercise in relation to body fat in men and women. Am J Clin Nutr 1990; 52(3): 426–30.
  701. Atlantis E, Martin SA, Haren MT, Taylor AW, Wittert GA. Lifestyle factors associated with age-related differences in body composition: The Florey Adelaide Male Aging Study. Am J Clin Nutr 2008; 88(1): 95–104.
  702. Larson DE, Hunter GR, Williams MJ, Kekes-Szabo T, Nyikos I, Goran MI. Dietary fat in relation to body fat and intraabdominal adipose tissue: A cross-sectional analysis. Am J Clin Nutr 1996; 64(5): 677–84.
  703. Tucker LA, Kano MJ. Dietary fat and body fat: A multivariate study of 205 adult females. Am J Clin Nutr 1992; 56(4): 616–22.
  704. Bowen L, Taylor AE, Sullivan R, et al. Associations between diet, physical activity and body fat distribution: A cross sectional study in an Indian population. BMC Public Health 2015; 15: 281.
  705. Koppes LL, Boon N, Nooyens AC, van Mechelen W, Saris WH. Macronutrient distribution over a period of 23 years in relation to energy intake and body fatness. Br J Nutr 2009; 101(1): 108–15.
  706. Soenen S, Westerterp-Plantenga MS. Changes in body fat percentage during body weight stable conditions of increased daily protein intake vs. control. Physiol Behav 2010; 101(5): 635–8.
  707. Vinknes KJ, de Vogel S, Elshorbagy AK, et al. Dietary intake of protein is positively associated with percent body fat in middle-aged and older adults. J Nutr 2011; 141(3): 440–6.
  708. de Souza RJ, Bray GA, Carey VJ, et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: Results from the POUNDS LOST trial. Am J Clin Nutr 2012; 95(3): 614–25.
  709. Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ, Zamora S. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans. Int J Obes (2005) 2006; 30(6): 899–905.
  710. Garaulet M, Perez-Llamas F, Perez-Ayala M, et al. Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area: Relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr 2001; 74(5): 585–91.
  711. Paniagua JA, Gallego de la Sacristana A, Romero I, et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007; 30(7): 1717–23.
  712. Romaguera D, Norat T, Mouw T, et al. Adherence to the Mediterranean diet is associated with lower abdominal adiposity in European men and women. J Nutr 2009; 139(9): 1728–37.
  713. Moliner-Urdiales D, Ruiz JR, Ortega FB, et al. Association of objectively assessed physical activity with total and central body fat in Spanish adolescents; the HELENA Study. Int J Obes (2005) 2009; 33(10): 1126–35.
  714. Janssen I, Katzmarzyk PT, Boyce WF, et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. Obes Rev 2005; 6(2): 123–32.
  715. Abe T, Sakurai T, Kurata J, Kawakami Y, Fukunaga T. Subcutaneous and visceral fat distribution and daily physical activity: Comparison between young and middle aged women. Br J Sports Med 1996; 30(4): 297–300.
  716. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: Findings from a systematic review. Int J Obes (2005) 2008; 32(4): 619–28.
  717. Ross R, Rissanen J, Pedwell H, Clifford J, Shragge P. Influence of diet and exercise on skeletal muscle and visceral adipose tissue in men. J Appl Physiol 1996; 81: 2445–55.
  718. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: A randomized controlled trial. Obes Res 2004; 12(5): 789–98.
  719. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after dietinduced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133(2): 92–103.
  720. Slentz CA, Houmard JA, Kraus WE. Exercise, abdominal obesity, skeletal muscle, and metabolic risk: Evidence for a dose response. Obesity (Silver Spring) 2009; 17 Suppl 3: S27–33.
  721. Cleland VJ, Schmidt MD, Dwyer T, Venn AJ. Television viewing and abdominal obesity in young adults: Is the association mediated by food and beverage consumption during viewing time or reduced leisure-time physical activity? Am J Clin Nutr 2008; 87(5): 1148–55.
  722. Chang PC, Li TC, Wu MT, et al. Association between television viewing and the risk of metabolic syndrome in a community-based population. BMC Public Health 2008; 8: 193.
  723. Hu FB. Sedentary lifestyle and risk of obesity and type 2 diabetes. Lipids 2003; 38(2): 103–8.
  724. Wannamethee SG, Shaper AG, Whincup PH. Alcohol and adiposity: Effects of quantity and type of drink and time relation with meals. Int J Obes 2005; 29(12): 1436–44.
  725. Canoy D, Wareham N, Luben R, et al. Cigarette smoking and fat distribution in 21,828 British men and women: A population-based study. Obes Res 2005; 13(8): 1466–75.
  726. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2(2): 73–86.
  727. Sachdev HS, Fall CH, Osmond C, et al. Anthropometric indicators of body composition in young adults: Relation to size at birth and serial measurements of body mass index in childhood in the New Delhi birth cohort. Am J Clin Nutr 2005; 82(2): 456–66.
  728. Komiya H, Mori Y, Yokose T, Tajima N. Smoking as a risk factor for visceral fat accumulation in Japanese men. Tohoku J Exp Med 2006; 208(2): 123–32.
  729. Molenaar EA, Massaro JM, Jacques PF, et al. Association of lifestyle factors with abdominal subcutaneous and visceral adiposity: The Framingham Heart Study. Diabetes Care 2009; 32(3): 505–10.
  730. Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: Does thiazolidinedioneinduced adipose tissue redistribution provide a clue to the answer? Diabetologia 2007; 50(6): 1127–39.
  731. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26(11): 3148–52.
  732. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: A meta analysis. J Clin Endocrinol Metab 2009; 94(1): 130–7.
  733. Bouchard C, Tremblay A, Despres JP, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990; 322(21): 1477–82.
  734. Bouchard C, Despres JP, Mauriege P. Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 1993; 14(1): 72–93.
  735. Bouchard C, Tremblay A. Genetic influences on the response of body fat and fat distribution to positive and negative energy balances in human identical twins. J Nutr 1997; 127(5 Suppl): 943s–7s.
  736. Heard-Costa NL, Zillikens MC, Monda KL, et al. NRXN3 is a novel locus for waist circumference: A genome-wide association study from the CHARGE Consortium. PLoS Genetics 2009; 5(6): e1000539.
  737. Schleinitz D, Bottcher Y, Bluher M, Kovacs P. The genetics of fat distribution. Diabetologia 2014; 57(7): 1276–86.
  738. Fox CS, Liu Y, White CC, et al. Genome-wide association for abdominal subcutaneous and visceral adipose reveals a novel locus for visceral fat in women. PLoS genetics 2012; 8(5): e1002695.
  739. Bjorntorp P, Grimby G, Sanne H, Sjostrom L, Tibblin G, Wilhelmsen L. Adipose tissue fat cell size in relation to metabolism in weight-stabile, physically active men. Horm Metab Res 1972; 4(3): 182–6.
  740. Haller H, Leonhardt W, Hanefeld M, Julius U. Relationship between adipocyte hypertrophy and metabolic disturbances. Endokrinologie 1979; 74(1): 63–72.
  741. O’Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010; 5(4): e9997.
  742. Bjorntorp P, Bengtsson C, Blohme G, et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971; 20(10): 927–35. Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest 1973; 52(4): 929–41.
  743. Ryden M, Andersson DP, Bergstrom IB, Arner P. Adipose tissue and metabolic alterations: Regional differences in fat cell size and number matter, but differently: A cross-sectional study. J Clin Endocrinol Metab 2014; 99(10): E1870–6.
  744. Tchoukalova YD, Votruba SB, Tchkonia T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A 2010; 107(42): 18226–31.
  745. Joe AW, Yi L, Even Y, Vogl AW, Rossi FM. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem Cells (Dayton, Ohio) 2009; 27(10): 2563–70.
  746. Bjorntorp P. Sjostrom L. Number and size of adipose tissue fat cells in relation to metabolism in human obesity. Metabolism 1971; 20(7): 703–13.
  747. Arner E, Westermark PO, Spalding KL, et al. Adipocyte turnover: Relevance to human adipose tissue morphology. Diabetes 2010; 59(1): 105–9.
  748. Laforest S, Labrecque J, Michaud A, Cianflone K, Tchernof A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Critical reviews in clinical laboratory sciences 2015; 52(6): 301–13.
  749. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54(2): 254–60.
  750. Despres JP, Nadeau A, Tremblay A, et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38(3): 304–9.
  751. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000; 43(12): 1498–506.
  752. Joffe BI, Goldberg RB, Feinstein J, Kark A, Seftel HC. Adipose cell size in obese Africans: Evidence against the existence of insulin resistance in some patients. J Clin Pathol 1979; 32(5): 471–4.
  753. McLaughlin T, Sherman A, Tsao P, et al. Enhanced proportion of small adipose cells in insulinresistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007; 50(8): 1707–15.
  754. Veilleux A, Caron-Jobin M, Noel S, Laberge PY, Tchernof A. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes 2011; 60(5): 1504–11.
  755. Hardy OT, Perugini RA, Nicoloro SM, et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surg Obes Relat Dis 2011; 7(1): 60–7.
  756. Anand SS, Tarnopolsky MA, Rashid S, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One 2011; 6(7): e22112.
  757. Petaja EM, Sevastianova K, Hakkarainen A, Orho-Melander M, Lundbom N, Yki-Jarvinen H. Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype. Obesity (Silver Spring) 2013; 21(6): 1174–9.
  758. Johannsen DL, Tchoukalova Y, Tam CS, et al. Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: Testing the “adipose tissue expandability” hypothesis. Diabetes Care 2014; 37(10): 2789–97.
  759. Jansen HJ, Vervoort GM, van der Graaf M, Stienstra R, Tack CJ. Liver fat content is linked to inflammatory changes in subcutaneous adipose tissue in type 2 diabetes patients. Clin Endocrinol (Oxf) 2013; 79(5): 661–6.
  760. Arner P, Arner E, Hammarstedt A, Smith U. Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS One 2011; 6(4): e18284.
  761. Anthanont P, Ramos P, Jensen MD, Hames KC. Family history of type 2 diabetes, abdominal adipocyte size and markers of the metabolic syndrome. Int J Obes 2017; 41(11): 1621–6.
  762. Fried SK, Kral JG. Sex differences in regional distribution of fat cell size and lipoprotein lipase activity in morbidly obese patients. Int J Obes 1987; 11(2): 129–40.
  763. Mundi MS, Karpyak MV, Koutsari C, Votruba SB, O’Brien PC, Jensen MD. Body fat distribution, adipocyte size, and metabolic characteristics of nondiabetic adults. J Clin Endocrinol Metab 2010; 95(1): 67–73.
  764. Drolet R, Richard C, Sniderman AD, et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes 2008; 32(2): 283–91. Ostman J, Arner P, Engfeldt P, Kager L. Regional differences in the control of lipolysis in human adipose tissue. Metabolism 1979; 28(12): 1198–205.
  765. Rebuffe-Scrive M, Anderson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots in severely obese men and women. Metabolism 1990; 39(10): 1021–5.
  766. Tchernof A, Belanger C, Morisset AS, et al. Regional differences in adipose tissue metabolism in women: Minor effect of obesity and body fat distribution. Diabetes 2006; 55(5): 1353–60.
  767. Boivin A, Brochu G, Marceau S, Marceau P, Hould FS, Tchernof A. Regional differences in adipose tissue metabolism in obese men. Metabolism 2007; 56(4): 533–40.
  768. Jacobsson B, Smith U. Effect of cell size on lipolysis and antilipolytic action of insulin in human fat cells. J Lipid Res 1972; 13(5): 651–6.
  769. Richelsen B. Increased alpha 2- but similar beta-adrenergic receptor activities in subcutaneous gluteal adipocytes from females compared with males. Eur J Clin Invest 1986; 16(4): 302–9.
  770. Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 1989; 38(5): 453–8.
  771. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1): S57–63.
  772. Trayhurn P, Beattie JH. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60(3): 329–39.
  773. Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36(7): 461–70.
  774. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: What do we know? J Clin Endocrinol Metab 2004; 89(6): 2569–75.
  775. Garg A, Misra A. Lipodystrophies: Rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33(2): 305–31.
  776. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005; 149(1): 54–60.
  777. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983; 32(2): 117–23.
  778. Bjorntorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis (Dallas, Tex) 1990; 10(4): 493–6.
  779. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1(7285): 785–9.
  780. Guo ZK, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999; 48: 1586–92.
  781. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 2007; 9(1): 1–10.
  782. Jensen MD, Sarr MG, Dumesic DA, Southorn PA, Levine JA. Regional uptake of meal fatty acids in humans. Am J Physiol Endocrinol Metab 2003; 285(6): E1282–8.
  783. Votruba SB, Mattison RS, Dumesic DA, Koutsari C, Jensen MD. Meal fatty acid uptake in visceral fat in women. Diabetes 2007; 56(10): 2589–97.
  784. Ali AH, Koutsari C, Mundi M, et al. Free fatty acid storage in human visceral and subcutaneous adipose tissue: Role of adipocyte proteins. Diabetes 2011; 60(9): 2300–7.
  785. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999; 48(8): 1586–92.
  786. Santosa S, Hensrud DD, Votruba SB, Jensen MD. The influence of sex and obesity phenotype on meal fatty acid metabolism before and after weight loss. Am J Clin Nutr 2008; 88(4): 1134–41.
  787. Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83(9): 3025–30.
  788. Ludtke A, Genschel J, Brabant G, et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol 2005; 100(10): 2218–24.
  789. Einstein FH, Atzmon G, Yang XM, et al. Differential responses of visceral and subcutaneous fat depots to nutrients. Diabetes 2005; 54(3): 672–8.
  790. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56(4): 1010–3.
  791. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002; 5(5): 545–9.
  792. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 1993; 42: 1567–73.
  793. Jensen MD. Gender differences in regional fatty acid metabolism before and after meal ingestion. J Clin Invest 1995; 96(5): 2297–303.
  794. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48(1): 10–4.
  795. Marin P, Rebuffe-Scrive M, Bjorntorp P. Uptake of triglyceride fatty acids in adipose tissue in vivo in man. Eur J Clin Invest 1990; 20(2): 158–65.
  796. Romanski SA, Nelson RM, Jensen MD. Meal fatty acid uptake in adipose tissue: Gender effects in nonobese humans. Am J Physiol Endocrinol Metab 2000; 279(2): E455–62.
  797. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993; 92(1): 91–8.
  798. Saloranta C, Franssila-Kallunki A, Ekstrand A, Taskinen MR, Groop L. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34(6): 409–15.
  799. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976; 12(6): 563–71.
  800. Hennes MM, Shrago E, Kissebah AH. Receptor and postreceptor effects of free fatty acids (FFA) on hepatocyte insulin dynamics. Int J Obes 1990; 14(10): 831–41.
  801. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994; 93(2): 870–6.
  802. Ramnanan CJ, Edgerton DS, Rivera N, et al. Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. Diabetes 2010; 59(6): 1302–11.
  803. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995; 95(1): 158–66.
  804. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88(4): 787–835, ix.
  805. McGarry JD. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51(1): 7–18.
  806. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1- associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103(2): 253–9.
  807. Kanaley JA, Shadid S, Sheehan MT, Guo Z, Jensen MD. Relationship between plasma free fatty acid, intramyocellular triglycerides and long-chain acylcarnitines in resting humans. J Physiol 2009; 587(Pt 24): 5939–50.
  808. Chung JO, Koutsari C, Blachnio-Zabielska AU, Hames KC, Jensen MD. Intramyocellular ceramides: Subcellular concentrations and fractional De Novo synthesis in postabsorptive humans. Diabetes 2017; 66(8): 2082–91.
  809. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144(9): 4154–63.
  810. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006; 55 Suppl 2: S16–23.
  811. Rutkowski JM, Stern JH, Scherer PE. The cell biology of fat expansion. J Cell Biol 2015; 208(5): 501–12.
  812. Zierath JR, Livingston JN, Thorne A, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: Relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 1998; 41(11): 1343–54.
  813. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2001; 280(6): E1000–6.
  814. Hellmer J, Marcus C, Sonnenfeld T, Arner P. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 1992; 75(1): 15–20.
  815. Jansson PA, Smith U, Lonnroth P. Interstitial glycerol concentration measured by microdialysis in two subcutaneous regions in humans. Am J Physiol 1990; 258(6 Pt 1): E918–22.
  816. Jensen MD. Lipolysis: Contribution from regional fat. Annu Rev Nutr 1997; 17: 127–39.
  817. Arner P. Catecholamine-induced lipolysis in obesity. Int J Obes Relat Metab Disord 1999; 23 Suppl 1: 10–3.
  818. Ahlborg G, Felig P, Hagenfeldt L, Hendler R, Wahren J. Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest 1974; 53(4): 1080–90.
  819. Burguera B, Proctor D, Dietz N, Guo Z, Joyner M, Jensen MD. Leg free fatty acid kinetics during exercise in men and women. Am J Physiol Endocrinol Metab 2000; 278(1): E113–7. Stich V, De Glisezinski I, Crampes F, et al. Activation of alpha(2)-adrenergic receptors impairs exerciseinduced lipolysis in SCAT of obese subjects. Am J Physiol Regul Integr Comp Physiol 2000; 279(2): R499–504.
  820. Ross R, Rissanen J. Mobilization of visceral and subcutaneous adipose tissue in response to energy restriction and exercise. Am J Clin Nutr 1994; 60(5): 695–703.
  821. Kamel EG, McNeill G, Van Wijk MC. Change in intra-abdominal adipose tissue volume during weight loss in obese men and women: Correlation between magnetic resonance imaging and anthropometric measurements. Int J Obes Relat Metab Disord 2000; 24(5): 607–13.
  822. Strasser B, Spreitzer A, Haber P. Fat loss depends on energy deficit only, independently of the method for weight loss. Ann Nutr Metab 2007; 51(5): 428–32.
  823. Singh P, Somers VK, Romero-Corral A, et al. Effects of weight gain and weight loss on regional fat distribution. Am J Clin Nutr 2012; 96(2): 229–33.
  824. Gurr MI, Jung RT, Robinson MP, James WP. Adipose tissue cellularity in man: The relationship between fat cell size and number, the mass and distribution of body fat and the history of weight gain and loss. Int J Obes 1982; 6(5): 419–36.
  825. Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med (Auckland, NZ) 2006; 36(3): 239–62.
  826. Calbet JAL, Ponce-Gonzalez JG, Calle-Herrero J, et al. Exercise preserves lean mass and performance during severe energy deficit: The role of exercise volume and dietary protein content. Front Physiol 2017; 8: 483.
  827. Milleo FQ, Campos AC, Santoro S, et al. Metabolic effects of an entero-omentectomy in mildly obese type 2 diabetes mellitus patients after three years. Clinics (Sao Paulo) 2011; 66(7): 1227–33.
  828. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002; 26(2): 193–9.
  829. Herrera MF, Pantoja JP, Velazquez-Fernandez D, et al. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: A randomized trial. Diabetes Care 2010; 33(7): 1413–8.
  830. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 2004; 292(14): 1724–37.
  831. Olbers T, Bjorkman S, Lindroos A, et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: A randomized clinical trial. Ann Surg 2006; 244(5): 715–22.
  832. Weiss R, Appelbaum L, Schweiger C, et al. Short-term dynamics and metabolic impact of abdominal fat depots after bariatric surgery. Diabetes Care 2009; 32(10): 1910–5.
  833. Reaven GM. Banting Lecture: Role of insulin resistance in human disease (Review). Diabetes. 1988;37:1595–1607.
  834. Bjorntorp P. Visceral obesity: A “civilization syndrome.” Obes Res. 1993;1:206–222 Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20–34.
  835. Kissebah AH. Relation of body fat distribution to metabolic complications of obesity. J Clin Endo Metab. 1982;54:254–260.
  836. Alberti K, Zimmet PZ. World Health Organization (WHO) consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med. 1998;15:539–553.
  837. Panel E. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
  838. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al., American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752.
  839. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet (London, England). 2005;366:1059–1062.
  840. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, Philip James WT, Loria CM, Smith SC. Harmonizing the metabolic syndrome A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention for the Study of Obesity. Circulation. 2009;120:1640–1645.
  841. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
  842. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359.
  843. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet (London, England). 2005;365:1415–1428.
  844. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304.
  845. Ferrannini E. Metabolic syndrome: A solution in search of a problem. J Clin Endocrinol Metab. 2007;92:396–398.
  846. Grundy SM. Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399–404.
  847. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51:3120–3127.
  848. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV, Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: The Strong Heart Study. Diabetes Care. 2003;26:861–867.
  849. Klein BEK, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25:1790–1794.
  850. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DSJ, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419.
  851. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (London, England). 2008;371:1927–1935.
  852. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care. 2005;28:1769–1778.
  853. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med. 2006;119:812–819.
  854. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol. 2007;49:403–414.
  855. Marceau P, Biron S, Hould F-S, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513–1517.
  856. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728.
  857. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–3147.
  858. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174.
  859. Johnson JL, Slentz CA, Duscha BD, McCartney J, Samsa GP, Houmard JA, Kraus WE. Gender and racial differences in lipoprotein subclass distribution; The STRRIDE study. Atherosclerosis. 2004;176:371–377.
  860. Despres JP, Couillard C, Gagnon J, Bergeron J, Leon AL, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Race, visceral adipose tissue, plasma lipids and lipoprotein lipase activity in men and women: The HERITAGE family study. Arter Thromb Vasc Biol. 2000;20:1932–1938.
  861. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D’Armiento M, D’Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome. JAMA. 2004;292:1440.
  862. Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nu?ez-Cordoba JM, MartinezGonzalez MA. Mediterranean diet inversely associated with the incidence of metabolic syndrome: The SUN prospective cohort. Diabetes Care. 2007;30:2957–2959.
  863. Salas-Salvado J, Fern?ndez-Ballart J, Ros E, Mart?nez-Gonz?lez M-A, Fit? M, Estruch R, Corella D, et al., PREDIMED Study Investigators. Effect of a mediterranean diet supplemented with nuts on metabolic syndrome status. Arch Intern Med. 2008;168:2449.
  864. Estruch R, Ros E, Salas-Salvad? J, Covas M-I, Corella D, Ar?s F, G?mez-Gracia E, et al. Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med. 2013;368:1279–1290.
  865. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of mediterranean diet on metabolic syndrome and its components. J Am Coll Cardiol. 2011;57:1299–1313.
  866. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28:2823–2831.
  867. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228–1230.
  868. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28:2926–2932.
  869. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Ebeling PR, Daly RM. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: Results from a National, Population-Based Prospective Study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab. 2012;97:1953–1961.
  870. Thomas GN, ? Hartaigh B, Bosch JA, Pilz S, Loerbroks A, Kleber ME, Fischer JE, Grammer TB, B?hm BO, M?rz W. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Diabetes Care. 2012;35:1158–1164.
  871. Anderssen SA, Carroll S, Urdal P, Holme I. Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: Results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports. 2007;17:687–695.
  872. Rector RS, Warner SO, Liu Y, Hinton PS, Sun GY, Cox RH, Stump CS, Laughlin MH, Dellsperger KC, Thomas TR. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Metab. 2007;293:E500–E506.
  873. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med. 1999;130:89–96.
  874. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med. 2000;132:605–611.
  875. Blair SN, Kohl HWIII, Paffenbarger RSJ, Clark DG, Cooper KH, Gibbons LW. Physical Fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989;262:2395–2401.
  876. Blair SN, Kohl HWIII, Barlow CE, Paffenbarger RSJ, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA. 1995;273:1093–1098. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sport Exerc. 2001;33:S484–492.
  877. Blair SN, Kohl HWIII, Barlow CE, Gibbons LW. Physical fitness and all-cause mortality in hypertensive men. Ann Med. 1991;23:307–312.
  878. Whaley MH, Kampert JB, Kohl HW III, Blair SN. Physical fitness and clustering of risk factors associated with the metabolic syndrome. Med Sci Sport Exerc. 1999;31:287–293.
  879. Katzmarzyk PT, Church TS, Blair SN. Cardiorespiratory fitness attenuates the effects of metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med. 2004;164:1092–1097.
  880. Kaplan NM. The deadly quartet: Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med. 1989;149:1514–1520.
  881. Carroll S, Cooke CB, Butterly RJ. Metabolic clustering, physical acitivity and fitness in nonsmoking, middle-aged men. Med Sci Sport Exerc. 2000;32:2079–2086.
  882. Irwin ML, Ainsworth BE, Mayer-Davis EJ, Addy CL, Pate RR, Durstine JL. Physical activity and the metabolic syndrome in a tri-ethnic sample of women. Obes Res. 2002;10:1030–1037.
  883. Lakka TA, Laaksonen DE, Lakka H, Mannikko N, Niskanen LK, Rauramaa R, Salonen JT. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sport Exerc. 2003;35:1279–1286.
  884. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, Toutouzas P, Stefanadis C. Impact of lifestyle habits on the prevalence of the metabolic syndrome amoung Greek adults from the ATTICA study. Am Hear J. 2004;147:106–112.
  885. Lee CD, Jackson AS, Blair SN. US weight guidelines: Is it also important to consider cardiorespiratory fitness? Intern J Obes Relat Metab Disord. 1998;22:2–7.
  886. Wei M, Kampert JB, Barlow CE, Nichaman MZ, Gibbons LW, Paffenbarger RSJ, Blair SN. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 1999;282:1547–1553.
  887. Farrell SW, Braun L, Barlow CE, Cheng YJ, Blair SN. Ther relation of body mass index, cardiorespiratory fitness and all-cause mortality in women. Obes Res. 2002;10:417–423.
  888. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69:373–380.
  889. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: A prospective study of men and women. Circulation. 2005;112:505–512.
  890. Katzmarzyk PT, Leon AL, Wilmore JH, Skinner JS, Rao DC, Rankinen T, Bouchard C. Targeting the metabolic syndrome with exercise: Evidence from the Heritage Family Study. Med Sci Sport Exerc. 2003;35:1703–1709.
  891. Gagnon J, Province MA, Bouchard C. The HERITAGE Family study: Quality assurance and quality control. Ann Epidemiol. 1996;6:520–529.
  892. Johnson JL, Slentz CA, Houmard JA, Samsa GP, Duscha BD, Aiken LB, McCartney JS, Tanner CJ, Kraus WE. Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol. 2007;100:1759–1766.
  893. Tjonna AE, Lee SJ, Rognmo ?, St?len TO, Bye A, Haram PM, Loennechen JP, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: A pilot study. Circulation. 2008;118:346–354.
  894. Bateman LA, Slentz CA, Willis LH, Shields AT, Piner LW, Bales CW, Houmard JA, Kraus WE. Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise - STRRIDE-AT/RT). Am J Cardiol. 2011;108:838–844.
  895. Pattyn N, Cornelissen VA, Eshghi SRT, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: A meta-analysis of controlled trials. Sports Med. 2013;43:121–133.
  896. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.
  897. Halber JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA, Andresw GR. The effectiveness of exercise training in lowering blood pressure: A meta-analysis of randomised controlled trials of 4 weeks or longer. J Hum Hypertens. 1997;11:641–649.
  898. Kelley GA. Aerobic exercise and resting blood pressure among women: A meta-analysis. Prev Med. 1999;28:264–275. Kelley GA, Sharpe KK. Aerobic exercise and resting blood pressure in older adults: A meta-analytic review of RCT’s. J Gerontol Ser A-Bio Sci Med Sci. 2001;56:298–303.
  899. Cornelissen VA, Buys R, Smart NA. Endurance exercise beneficially affects ambulatory blood pressure: A systematic review and meta-analysis. J Hypertens. 2013;31:639–648.
  900. Durstine JL, Haskell WL. Effects of exercise training on plasma lipids and lipoproteins. Exerc Sport Sci Rev. 1994;22:477–524.
  901. Leon AL, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sport Exerc. 2001;33:S502–515.
  902. Kraus WE, Houmard JA, Duscha BD, Knetgzer KJ, Wharton MB, McCartney J, Bales CW, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. New Engl J Med. 2002;347:1483–1492.
  903. Boule NG, Haddad E, Kenney GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in Type 2 Diabetes mellitus. JAMA. 2001;286:1218–1227.
  904. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis. Diabetes Care. 2006;29:2518–2527.
  905. Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: A metaanalysis. Diabetes Care. 2011;34:1228–1237.
  906. Group UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853.
  907. Group UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352:854–865.
  908. Ivy JL, Zderic TW, Donovan FL. Prevention and treatment of non-insulin-dependent diabetes mellitus. Exerc Sport Sci Rev. 1999;27:1–35.
  909. Dowse GK, Zimmet PZ, Gareeboo H, Alberti K, Tuomilehto CF, Finch PC, et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care. 1991;14:271–282.
  910. Pereira MA, Kriska AM, Joswiak ML, Dowse GK, Collins VR, Zimmet PZ, Gareeboo H, et al. Physical inactivity and glucose tolerance in the multiethnic island of mauritius. Med Sci Sport Exerc. 1995;27:1626–1634.
  911. Zimmet PZ, Collins VR, Dowse GK, Alberti K, Tuomilehto J, Gareeboo H, Chitson P. The relation of physical activity to cardiovascular disease risk factors in Mauritians. Am J Epidemiol. 1991;134:862–875.
  912. Mayer-Davis EJ, D’Agostino R, Karter AJ, Haffner S, Rewers MJ, Saad M, Bergman RN. Intensity and amount of physical activity in relation to insulin sensitivity: The Insulin Resistance Atherolsclerosis Study. JAMA. 1998;279.
  913. Kriska AM, LaPorte RE, Pettitt DJ, Charles MA, Nelson RG, Kuller LH, Bennett PH, et al. The association of physical activity with obesity, fat distribtution and glucose intolerance in Pima Indians. Diabetologia. 1993;36: 863–869.
  914. Manson JE, Nathan DM, Krolewski AS, Stampfer JM, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes amoung U.S. male physicians. JAMA. 1992;268: 63–67.
  915. Manson JE, Rimm EB, Stampfer JM, Colditz GA, Willett WC, Krolewski AS, Rosner B, et al. Physical activity and incidence of NIDDM in women. Lancet. 1991;338: 774–778.
  916. Lipman RL, Schnure JJ, Bradley EM, Lecocq FR. Impairment of peripheral glucose utilization in normal subjects by prolonged bed rest. J Lab Clin Med. 1970;76:221–230.
  917. Misbin RI, Moffa AM, Kappy MS. Insulin binding to monocytes in obese patients treated with carbohydrate restriction and changes in physical activity. J Clin Endo Metab. 1983;56:273–278.
  918. Stuart CA, Shamgraw RE, Prince MJ, Peters EJ, Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism. 1988;37:802–806.
  919. Heath GW, Gavin JR, Hinderliter JM, Hagberg JM, Bloomfield SA, Holloszy JO. Effects of exercise and lack of exercise on glucose tolerance and insulin sensitivity. J Appl Physiol. 1983;55:512–517.
  920. King DS, Dalsky GP, Clutter W, Young DA, Staten MA, Cryer PE, Holloszy JO. Effects of exercise and lack of exercise on insulin sensitivity and responsiveness. J Appl Physiol. 1988;64:1942–1946.
  921. Mikines KJ, Sonne B, Tronier B, Galbo H. Effects of training and detraining on insulin action in trained men. J Appl Physiol. 1989;66:704–711.
  922. Rogers MA, Yamamoto c, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Improvement in glucose tolerance after 1 wk of exercise in patients with mild NIDDM. Diabetes Care. 1988;11:613–618.
  923. Seals DR, Hagberg JM, Allen WK, Hurley BF, Dalsky GP, Ehsani AA, Holloszy JO. Glucose tolerance in young and older athletes and sedentary men. J Appl Physiol. 1984;56:1521–1525.
  924. Holloszy JO, Schultz J, Kusnierkiewicz J, Hagberg JM, Eshani AA. Effects of exercise on glucose tolerance and insulin resistance: Brief review and preliminary results. Acta Med Scand. 1986;711:55–65. Reitman JS, Vasquez B, Klimes I, Nagulesparan M. Improvement of glucose homeostasis after exercise training in NIDDM. Diabetes Care. 1984;7:434–441.
  925. Schneider SH, Amorosa AK, Khachadurian AK, Ruderman NB. Studies on the mechanism of improved glucose control during regular exercise in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1984;26:355–360.
  926. Dela F, Larsen JJ, Mikines KJ, Ploug T, Petersen LN, Galbo H. Insulin-stimulated muscle glucose clearance in patients with NIDDM: Effects of one-legged physical training. Diabetes. 1995;44:1010–1020.
  927. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
  928. Tuomilehto J, Lindstr?m J, Eriksson JG, Valle TT, H?m?l?inen H, Ilanne-Parikka P, Kein?nenKiukaanniemi S, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
  929. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care. 2003;26:2977–2982.
  930. Sigal RJ, Kenny GP, Boul? NG, Wells GA, Prud’homme D, Fortier M, Reid RD, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med. 2007;147:357–369.
  931. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K, Mikus CR, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial. JAMA. 2010;304:2253–2262.
  932. Braun B, Zimmermann B, Kretchmer N. Effects of exercise intensity on insulin sensitivity in women with NIDDM. J Appl Physiol. 1995;78:300–306.
  933. Hawley JA, Houmard JA. Introduction - Preventing insulin resistance throught exercise: A cellular approach. Med Sci Sport Exerc. 2004;36:1187–1190.
  934. Berggren JR, Hulver MW, Dohm GL, Houmard JA. Weight loss and exercise: Implications for muscle lipid metabolism and insulin action. Med Sci Sport Exerc. 2004;36:1191–1195.
  935. Bruce CR, Hawley JA. Improvements in insulin resistance with aerobic exercise training: A lipocentric approach. Med Sci Sport Exerc. 2004;36:1196–1201.
  936. Ivy JL. Muscle insulin resistance amended with exercise training: Role of GLUT4 expression. Med Sci Sport Exerc. 2004;36:1207–1211.
  937. Houmard JA, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Kraus WE. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96:101–106.
  938. Slentz CA, Duscha BD, Johnson JL, Ketchum K, Aiken LB, Samsa GP, Houmard JA, Bales CW, Kraus WE. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study. Arch Intern Med. 2004;164:31–39.
  939. Ross R, Dagnone D, Jones PJH, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: A randomized, controlled trial. Ann Intern Med. 2000;133:92–103.
  940. Binder EF, Birge SJ, Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. J Am Geriatr Soc. 1996;44:231–236.
  941. Ekelund LG, Haskell WL, Johnson JL, et al. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men: The Lipid Research Clincis Mortality Follow-up study. New Engl J Med. 1988;319:1379–1384.
  942. Meyers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality amount men referred for exercise testing. New Engl J Med. 2002;346:793–801.
  943. Weiner DA, Ryan TJ, Parsons L, et al. Long-term prognostic value of exercise testing in men and women from the Coronary Artery Surgery Study (CASS) registry. Am J Card. 1995;75:865–870.
  944. Slattery ML, Jacobs DRJ. Physical fitness and CVD mortality: The US Railroad Study. Am J Epidemiol. 1988;127:571–580.
  945. Peters RK, Cady LDJ, Bischoff DP, et al. Physical fitness and subsequent myocardial infarction in healthy workes. JAMA. 1993;249:3052–3056.
  946. Wyns W, Musschaert-Beauthier E, van Domburg R, et al. Prognostice value of symptom limited exercise testing in men with a high prevalence of coronary artery disease. Eur Hear J. 1985;6:939–945.
  947. Roger VL, Jacobsen SJ, Pellikka PA. Prognostic value of treadmill exercise testing: A population-based study in Olmsted county, Minnesota. Circulation. 98:2836–2841. Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, Al-Hani AJ, Black HR. Exercise capacity and the risk of death in women: The St. James women take heart project. Circulation. 2003;108:1554–1559.
  948. Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: Relative contribution of metabolic factors, diet & physical activity. Am J Med. 1998;105:145–150.
  949. Prentice AM, Jebb SA. Obesity in Britain: Gluttony or sloth? Br Med J. 1995;311:437–439.
  950. Mayer J, Marshall NB, Vitale JJ, Christensen JH, Mashayekhi MB, Stare FJ. Exercise, food intake and body weight in normal rats and genetically obese adult mice. Am J Physiol. 1954;177:544–548.
  951. Mayer J, Purnima R, Mitra KP. Relation between caloric intake, body weight, and physical work: Studies in an industrial male population in West Bengal. Am J Clin Nutr. 1956;4:169–175.
  952. Asikainen TM, et al. Randomized, controlled walking trials in post-menopausal women: The minimum dose to improve aerobic fitness. Br J Sport Med. 2002;36:189–194.
  953. Mark DB, Lauer MS. Exercise capacity: The prognostic variable that doesn’t get enough respect. Circulation. 2003;108:1534–1536.
  954. DeFronzo, R. A., Ferrannini, E., Groop L. et al. 2015. Type 2 diabetes mellitus. Nat Rev Dis Primers 1: 15019.
  955. Murea, M., Ma, L., Freedman, B. I. 2012. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud 9(1): 6–22.
  956. Choudhury, S. M., Tan, T. M., Bloom, S. R. 2016. Gastrointestinal hormones and their role in obesity. Curr Opin Endocrinol Diabetes Obes 23(1): 18–22.
  957. Ley, S. H., Hamdy, O., Mohan, V., Hu, F. B. 2014. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 383(9933): 1999–2007.
  958. Sami, W., Ansari, T., Butt, N. S., Hamid, M. R. 2017. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci (Qassim) 11(2): 65–71.
  959. Rehfeld, J. F. 1998. The new biology of gastrointestinal hormones. Physiol Rev 78(4): 1087–1108.
  960. Drucker, D. J. 2007. The role of gut hormones in glucose homeostasis. J Clin Invest 117(1): 24–32.
  961. Unger, R. H., and Eisentraut, A. M. 1969. Entero-insular axis. Arch Intern Med 123(3): 261–266.
  962. Creutzfeldt, W. 1979. The incretin concept today. Diabetologia 16(2): 75–85.
  963. Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., Creutzfeldt, W. 1993. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Clin Invest 91(1): 301–307. 11. Holst, J. J., Pedersen, J., Wewer Albrechtsen, N. J., Knop, F. K. 2017. The gut: A key to the pathogenesis of type 2 diabetes? Metab Syndr Relat Disord 15(6): 259–262.
  964. Small, C. J., Bloom, S. R. 2004. Gut hormones as peripheral anti-obesity targets. Curr Drug Targets CNS Neurol Disord 3(5): 379–388.
  965. Dakin, C. L., Small, C. J., Batterham, R. L. et al. 2004. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145(6): 2687–2695.
  966. Montgomery, I. A., Irwin, N., Flatt, P. R. 2013. Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression. Horm Metab Res 45(6): 471–473.
  967. Kosinski, J. R., Hubert, J., Carrington, P. E. et al. 2012. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring). 20(8): 1566–1571.
  968. De Silva, A., and Bloom, S. R. 2012. Gut hormones and appetite control: A focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6(1): 10–20.
  969. Secher, A., Jelsing, J., Baquero, A. F. et al. 2014. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124: 4473–4488.
  970. Breen, D. M., Rasmussen, B. A., C?t?, C. D., Jackson, V. M., Lam, T. K. 2013. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes 62(9): 3005–3013.
  971. Citi, C. D., Zadeh-Tahmasebi, M., Rasmussen, B. A., Duca, F. A., Lam, T. K. 2014. Hormonal signaling in the gut. J Biol Chem 289(17): 11642–11649.
  972. Duca, F. A., Bauer, P. V., Hamr, S. C., Lam, T. K. 2015. Glucoregulatory relevance of small intestinal nutrient sensing in physiology, bariatric surgery, and pharmacology. Cell Metab 22(3): 367–380.
  973. Reimann, F., Gribble, F. M. 2016. Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion. J Diabetes Investig 7(S1): 13–19.
  974. Cuenco, J., Minnion, J., Tan, T. et al. 2017. Degradation paradigm of the gut hormone, pancreatic polypeptide, by hepatic and renal peptidases. Endocrinology 158(6): 1755–1765.
  975. Brubaker, P. L., Schloos, J., Drucker, D. J. 1998. Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139(10): 4108–4114.
  976. Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., Marks, V. 1993. Glucagon-like peptide-1 (7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 138(1): 159–166.
  977. Trapp, S., Richards, J. E. 2013. The gut hormone glucagon-like peptide-1 produced in brain: Is this physiologically relevant? Curr Opin Pharmacol 13(6): 964–969.
  978. Vasu, S., Moffett, R. C., Thorens, B., Flatt, P. R. 2014. Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress. PLoS One 9(6): e101005.
  979. Drucker, D. J. 2005. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1(1): 22–31.
  980. Gautier, J. F., Fetita, S., Sobngwi, E., Sala?n-Martin, C. 2005. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31(3): 233–242.
  981. Vilsboll, T. 2009. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 11(3): 8–11.
  982. Moffett, R. C., Vasu, S., Thorens, B., Drucker, D. J., Flatt, P. R. 2014. Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell adaptation to pregnancy. PLoS One 9(6): e96863.
  983. Moffett, R. C., Vasu, S., Flatt, P. R. 2015. Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. Biochim Biophys Acta 1850(6): 1206–1214.
  984. Volz, A., G?ke, R., Lankat-Buttgereit, B., Fehmann, H. C., Bode, H. P., G?ke, B. 1995. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. FEBS Lett 373(1): 23–29. Farr, O. M., Sofopoulos, M., Tsoukas, M. A. 2016. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial. Diabetologia 59(5): 954–965.
  985. Mehta, A., Marso, S. P., Neeland, I. J. 2016. Liraglutide for weight management: A critical review of the evidence. Obesity Science & Practice 3(1): 1–14.
  986. Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., Davies, M. J. 2017. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixedtreatment comparison analysis. Diabetes Obes Metab 19(4): 524–536
  987. Trujillo, J. M., Nuffer, W., Ellis, S. L. 2015. GLP-1 receptor agonists: A review of head-to-head clinical studies. Ther Adv Endocrinol Metab 6(1): 19–28.
  988. Jones, A. G., Lonergan, M., Henley, W. E., Pearson, E. R., Hattersley, A. T., Shields, B. M. 2016. Should studies of diabetes treatment stratification correct for baseline HbA1c? PLoS One 11(4): e0152428.
  989. Lorenz, M., Evers. A, Wagner, M. 2013. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett 23(14): 4011–4018.
  990. Arnold, S., Jowett, J., Balance, J. 2015. Synergistic action of PE0139, a super-long-acting basal insulin & PB1023 a weekly GLP1 receptor agonist. Diabetes 64(S1): A44.
  991. Blundell, J., Finlayson, G., Axelsen, M. et al. 2017. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19(9): 1242–1251.
  992. Manandhar, B., Ahn, J. M. 2015. Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications. J Med Chem 58(3): 1020–1037.
  993. Patterson, S., de Kort, M., Irwin, N. et al. 2015. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide. Diabetes Obes Metab 17(8): 760–770.
  994. Lee, C. Y. 2016. Glucagon-Like peptide-1 formulation–The present and future development in diabetes treatment. Basic Clin Pharmacol Toxicol 118(3): 173–180.
  995. Jabbour, S., Pieber, T. R., Rosenstock, J., Hartoft-Nielsen, M. L., H?jbjerg, O. K., Davies, M. 2016. Robust dose-dependent glucose lowering and body weight (BW) reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes (T2D). Endocrine Reviews 37(S2): OR15-3.
  996. Kalra, S., Baruah, M. P., Sahay, R. K., Unnikrishnan, A. G., Uppal, S., Adetunji, O. 2016. Glucagonlike peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian J Endocrinol Metab 20(2): 254–267.
  997. Nauck, M. A., Friedrich, N. 2013. Do GLP-1–Based therapies increase cancer risk? Diabetes Care 36(2): S245–S252.
  998. Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., Butler, P. C. 2015. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastrenterology 141(1): 150–156.
  999. Nauck, M. A., Meier, J. J. 2014. Studying pancreatic risks caused by incretin-based therapies is it a game? it’s not a game! Endocrinology 8(4): 895–897.
  1000. Brown, J. C., Pederson, R. A. 1970. A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. Scand J Gastroenterol 5(6): 537–541.
  1001. Beck, B. 1989. Gastric inhibitory polypeptide: A gut hormone with anabolic functions. J Mol Endocrinol 2(3): 169–174.
  1002. Deacon, C. F., Ahr?n, B. 2011. Physiology of Incretins in Health and Disease. Rev Diabet Stud 8(3): 293–306.
  1003. Tromper, A., Tr?mper, K., H?rsch, D. 2002. Mechanisms of mitogenic and anti-apoptotic signalling by glucose dependent insulinotropic polypeptide in beta (INS-1) cells. J Endocrinol 174(2): 233–246.
  1004. Kim, S. J., Nian, C., Tsuneoka, M., Koda, Y., Fosh, C. H. 2005. Glucose dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta cell survival is dependent upon phosphatidyl inositol 3 kinase (PI3K)/protein kinase B (PKB) signalling, inactivation of forkhead transcription factor Foxo1, and down regulation of bax expression. J Biol Chem 280(23): 22297–22307.
  1005. Renner, S., Fehlings, C., Herbach, N. et al. 2010. Glucose intolerance and reduced proliferation of pancreatic ?-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 59(5): 1228–1238.
  1006. Irwin, N., Flatt, P. R. 2009. Therapeutic potential for GIP receptor agonists and antagonists. Best Pract Res Clin Endocrinol Metab 23(4): 499–512. Mentlein, R., Gallwitz, B., Schmidt, W. E. 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214(3): 829–835.
  1007. Gault, V. A., O’Harte, F. P., Flatt, P. R. 2003. Glucose-dependent insulinotropic polypeptide (GIP): Antidiabetic and anti-obesity potential? Neuropeptides 37(5): 253–263.
  1008. Shu, L., Matveyenko, A. V., Kerr-Conte, J., Cho, J. H., McIntosh, C. H., Maedler, K. 2009. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18(13): 2388–2399.
  1009. Pathak, V., Vasu, S., Flatt, P. R., Irwin, N. 2014. Effects of chronic exposure of clonal ?-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1. Diabetes Obes Metab 16(4): 357–365.
  1010. Hojberg, P. V., Vilsb?ll, T., Rab?l, R. et al. 2009. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52(2): 199–207.
  1011. Piteau, S., Olver, A., Kim, S. J. et al. 2007. Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 362(4): 1007–1012.
  1012. Fukase, N., Manaka, H., Sugiyama, K. et al. 1995. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetol 32(3): 465–469.
  1013. Millar, P. J., Pathak, V., Moffett, R. C. et al. 2016. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol Cell Endocrinol 420: 37–45.
  1014. Asmar, M., Arngrim, N., Simonsen, L. et al. 2016. The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss. Nutr Diabetes 6(5): e208.
  1015. Taylor, A. I., Irwin, N., McKillop, A. M., Patterson, S., Flatt, P. R., Gault, V. A. 2010. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. J Endocrinol 207: 87–93.
  1016. Hasib, A., Ming, T. N., Gault, V. A. et al. 2017. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice. Diabetologia 30(3): 541–552.
  1017. Fujita, Y., Wideman, R. D., Asadi, A. et al. 2010. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138(5): 1966–1975.
  1018. Khan, D., Vasu, S., Moffett, R. C., Irwin, N., Flatt, P. R. 2016. Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival. Mol Cell Endocrinol 436: 102–113.
  1019. Martin, C. M., Gault, V. A., McClean, S., Flatt, P. R., Irwin, N. 2012. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25. Biochem Pharmacol 84(3): 312–319.
  1020. Martin, C. M., Parthsarathy, V., Pathak, V., Gault, V. A., Flatt, P. R., Irwin, N. 2014. Characterisation of the biological activity of xenin-25 degradation fragment peptides. J Endocrinol 221(2): 193–200.
  1021. Martin, C. M., Parthsarathy, V., Hasib, A. et al. 2016. Biological activity and antidiabetic potential of C-Terminal octapeptide fragments of the gut-Derived hormone xenin. PLoS One 11(3): e0152818.
  1022. Parthsarathy, V., Irwin, N., Hasib, A. et al. 2016. A novel chemically modified analogue of xenin25 exhibits improved glucose-lowering and insulin-releasing properties. Biochim Biophys Acta 1860(4): 757–764.
  1023. Frias, J. P., Bastyr, E. J., Vignati, L. et al. 2017. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26(2): 343–352.
  1024. Yip, R. G., Boylan, M. O., Kieffer, T. J., Wolfe, M. M. 1998. Functional GIP receptors are present on adipocytes. Endocrinology 139(9): 4004–4007.
  1025. Falko, J. M., Crockett, S. E., Cataland, S., Mazzaferri, E. L. 1975. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab 41(2): 260–565.
  1026. Salera, M., Giacomoni P., Pironi, L. et al. 1982. Gastric inhibitory polypeptide release after oral glucose: Relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 55(2): 329–336.
  1027. Miyawaki, K., Yamada, Y., Ban, N. et al. 2002. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8(7): 738–742. Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., Wice, B. M. 2008. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 283: 18365–18376.
  1028. Gault, V. A., O’Harte, F. P. M., Harriott, P., Flatt, P. R. 2002. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290: 1420–1426.
  1029. Irwin, N., Gault, V. A., Green, B. D. et al. 2004. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol Chem 385(9): 845–352.
  1030. Irwin, N., McClean, P. L., O’Harte, F. P. M., Gault, V. A., Harriott, P., Flatt, P. R. 2007. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist, (Pro3 )GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia 50: 1532–1540.
  1031. Gault, V. A., Hunter, K., Irwin, N. et al. 2007. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes. Biol Chem 388: 173–179.
  1032. McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., Flatt, P. R. 2007. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab 293: E1746–E1755.
  1033. McClean, P. L., Gault, V. A., Irwin, N., McCluskey, J. T., Flatt, P. R. 2008. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. Diabetes Obes Metab 2008 10(4): 336–342.
  1034. Irwin, N., Gault, V., Flatt, P. R. 2010.Therapeutic potential of the original incretin hormone glucosedependent insulinotropic polypeptide: Diabetes, obesity, osteoporosis and Alzheimer’s disease? Expert Opin Investig Drugs 19(9): 1039–1048.
  1035. Sparre?Ulrich, A. H., Hansen, L. S., Svendsen, B. et al. 2016. Species?specific action of (Pro3)GIP–A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol 173(1): 27–38.
  1036. Pathak, V., Gault, V. A., Flatt, P. R., Irwin, N. 2015. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 401: 120–129.
  1037. Pathak, V., Vasu, S., Gault, V. A., Flatt, P. R., Irwin, N. 2015. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice. Diabetologia 58(9): 2144–2153.
  1038. Alaoa, I., Hewage, C. M., Malthouse, J. P., Parker, J. C., Gault, V. A., O’Harte, F. P. 2004. NMR structure of the glucose-dependent insulinotropic polypeptide fragment, GIP(1-30)amide. Biochem Biophys Res Commun 325(1): 281–286.
  1039. Hansen, L. S., Sparre?Ulrich, A. H., Christensen, M. et al. 2016. N?terminally and C?terminally truncated forms of glucose?dependent insulinotropic polypeptide are high?affinity competitive antagonists of the human GIP receptor. Br J Pharmacol 173(5): 826–838.
  1040. Gasbjerg, L. S., Christensen, M. B., Hartmann, B. et al. 2017. GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: A randomised, double-blinded, placebo-controlled, crossover study. Diabetologia 61(2): 413–423.
  1041. Sparre-Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S. et al. 2017. GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem Pharmacol 131: 78–88.
  1042. Irwin, N., McClean, P. L., Patterson, S., Hunter, K., Flatt, P. R. 2009. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesitydiabetes. Biol Chem 390(1): 75–80.
  1043. Montgomery, I. A., Irwin, N., Flatt, P. R. 2010. Active immunization against (Pro(3))GIP improves metabolic status in high-fat-fed mice. Diabetes Obes Metab 12(9): 744–751.
  1044. Irwin, N., Montgomery, I. A., Flatt, P. R. 2012. Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice. Br J Nutr 108(1): 46–56.
  1045. Boylan, M. O., Glazebrook, P. A., Tatalovic, M., Wolfe, M. M. 2015. Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. Am J Physiol Endocrinol Metab 309(12): E1008–E1018.
  1046. Ravn, P., Madhurantakam, C., Kunze, S. et al. 2013. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288(27): 19760–19772.
  1047. Konitzer, J. D., Pramanick, S., Pan, Q. 2017. Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor. MAbs 9(3): 536–549.
  1048. Nakamura, T., Tanimoto, H., Mizuno, Y., Tsubamoto, Y., Noda, H. 2012. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes Metab 14(6): 511–517.
  1049. Tsubamoto, Y., Nakamura, T., Kinoshita, H., Tanimoto, H., Noda, H. 2008. A novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL14959, prevents obesity and insulin resistance. Diabetologia 51: S373.
  1050. Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M., Park, A. J. 2016. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 77: 28–37.
  1051. Wynne, K., and Bloom, S. R. 2006. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2(11): 612–620.
  1052. Ghatei, M. A., Uttenthal, L. O., Christofides, N. D., Bryant, M. G., Bloom, S. R. 1983. Molecular forms of human enteroglucagon in tissue and plasma: Plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57: 488–495.
  1053. Pocai, A., Carrington, P. E., Adams, J. R. et al. 2009. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58(10): 2258–2266.
  1054. D’Alessio, D. 2011. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 13(l): 126–132.
  1055. Irwin, N., Franklin, Z. J., O’Harte, F. P. 2013a. desHis?Glu9-glucagon-[mPEG] and desHis?Glu9(Lys30PAL)- glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity. Eur J Pharmacol 709(1–3): 43–51.
  1056. O’Harte, F. P., Franklin, Z. J., Irwin, N. 2014. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. Diabetes Obes Metab 16(12): 1214–1222.
  1057. Pocai, A. 2013. Action and therapeutic potential of oxyntomodulin. Mol Metab 3(3): 241–251.
  1058. Baggio, L. L., Huang, Q., Brown, T. J., Drucker, D. J. 2004. Oxyntomodulin and glucagon like peptide 1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127(2): 546–558.
  1059. Tan, T., Behary, P., Tharakan, G. 2017. The effect of a subcutaneous infusion of GLP-1, OXM and PYY on energy intake and expenditure in obese volunteers. J Clin Endocrinol Metab 102(7): 2364–2372.
  1060. Pocai, A. 2012. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J Endocrinol 215(3): 335–346.
  1061. Kerr, B. D., Flatt, P. R., Gault, V. A. 2010. (D-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem Pharmacol 80(11): 1727–1735.
  1062. Pathak, N. M., Pathak, V., Lynch, A. M., Irwin, N., Gault, V. A., Flatt, P. R. 2015. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice. Mol Cell Endocrinol 412: 95–103.
  1063. Patel, V., Joharapurkar, A., Kshirsagar, S. 2017. Balanced coagonist of GLP-1 and glucagon receptors corrects dyslipidemia by improving FGF21 sensitivity in hamster model. Drug Res (Stuttg) 67(12): 730–736. [Epub ahead of print].
  1064. Mittermayer, F., Caveney, E., Claudia, O. D. et al. 2015. Addressing unmet medical needs in type 2 diabetes: A narrative review of drugs under development. Curr Diabetes Rev 11(1): 17–31.
  1065. Sonchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., M?ller, T. D., DiMarchi, R. D., Tsch?p, M. H. 2017 GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60(10): 1851–1861.
  1066. Finan, B., Clemmensen, C., M?ller, T. D. 2015. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 15(418): 42–45.
  1067. Irwin, N., Pathak, V., Pathak, N. M., Gault, V. A., Flatt, P. R. 2015. Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes. Diabetes Obes Metab 17(9): 887–895.
  1068. Bhat, V. K., Kerr. B. D., Flatt, P. R., Gault, V. A. 2013. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol 85(11): 1655–1662.
  1069. Mansur, S. A., Mieczkowska, A., Flatt, P. R. et al. 2016. A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus. Bone 87: 102–113.
  1070. Koop, I., Schindler, M., Bosshammer, A., Scheibner, J., Stange, E., Koop, H. 1996. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 39(5): 661–667.
  1071. Wank, S. A. 1995. Cholecystokinin receptors. Am J Physiol 269(5): G628–G646.
  1072. Gibbs, J., Young, R. C., Smith, G. P. 1997. Cholecystokinin decreases food intake in rats. Obes Res 5(3): 284–290.
  1073. Baldwin, B. A., Cooper, T. R., Parrot, R. F. 1982. Effect of cholecystokinin octapeptide on food intake in pigs. Proc Nutr Soc 41: 119.
  1074. Drewe, J., Gadient, A., Rovati, L. C., Beglinger, C. 1992. Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. Gastroenterology 102(5): 1654–1659.
  1075. Irwin, N., Frizelle, P., Montgomery, I. A., Moffett, R. C., O’Harte, F. P., Flatt, P. R. 2012. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia 55(10): 2747–2758.
  1076. Ahron, B., Pettersson, M., Uvn?s-Moberg, K., Gutniak, M., Efendic, S. 1991. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res Clin Pract 13: 153–161.
  1077. Lavine, J. A., Raess, P. W., Stapleton, D. S. et al. 2010. Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 151: 3577–3588.
  1078. Linnemann, A. K., Davis, D. B. 2016. Glucagon?like peptide?1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity. J Diabetes Investig 7(1): 44–49.
  1079. Migaud, M., Durieux, C., Viereck, J., Soroca-Lucas, E., Fourni?-Zaluski, M. C., Roques, B. P. 1996. The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17(4): 601–607.
  1080. O’Harte, F. P., Mooney, M. H., Kelly, C. M., Flatt, P. R. 1998. Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes 47: 1619–1624.
  1081. Irwin, N., Frizelle, P., O’Harte, F. P., Flatt, P. R. 2013. (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes. Biochim Biophys Acta 1830(8): 4009–4016.
  1082. Pathak, V., Irwin, N., Flatt, P. R. 2015. A Novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fatfed mice. Diabetes 64(8): 2996–3009.
  1083. Brennan, I. M., Feltrin, K. L., Horowitz, M. et al. 2005. Evaluation of interaction between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 288(6): 1477–1485.
  1084. Linnemann, A. K., Neuman, J. C., Battiola, T. J., Wisinski, J. A., Kimple, M. E., Davis, D. B. 2015. Glucagon-like peptide-1 regulates cholecystokinin production in ?-Cells to protect from apoptosis. Mol Endocrinol 29(7): 978–987.
  1085. Trevaskis, J. L., Sun, C., Athanacio, J. et al. 2015. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents. Diabetes Obes Metab 17(1): 61–73.
  1086. Mhalhal, T. R., Washington, M. C., Newman, K., Heath, J. C., Sayegh, A. I. 2017. Exogenous glucagonlike peptide-1 reduces body weight and cholecystokinin-8 enhances this reduction in diet-induced obese male rats. Physiol Behav 179: 191–199.
  1087. Price, S. L., Bloom, S. R. 2014. Protein PYY and its role in metabolism. Front Horm Res 42: 147–154.
  1088. Pedersen-Bjergaard, U., H?st, U., Kelbaek, H. 1996. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 56(6): 497–503.
  1089. Lomax, A. E., Linden, D. R., Mawe, G. M., Sharkey, K. A. 2006. Effects of gastrointestinal inflammation on enteroendocrine cells and enteric neural reflex circuits. Auton Neurosci 250(7): 126–127.
  1090. Lavine, J. A., Kibbe, C. R., Baan, M. et al. 2015. Cholecystokinin expression in the ?-cell leads to increased ?-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. Am J Physiol Endocrinol Metab 309(10): E819–E828.
  1091. Upchurch, B. H., Aponte, G. W., Leiter, A. B. 1994. Expression of peptide YY in all four islet cell types in the developing mouse pancreas suggests a common peptide YY-producing progenitor. Development 120(2): 245–252.
  1092. Shi, Y. C., Loh, K., Bensellam, M. 2015. Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice. Endocrinology 156(9): 3122–3136.
  1093. Le Roux, C. W., Batterham, R. L., Aylwin, S. J. 2006. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3–8. Dumont, Y., Fournier, A., St-Pierre, S., Quirion, R. 1995. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I] peptide YY3-36 as selective Y1 and Y2 radioligands. J Pharmacol Exp Ther 272(2): 673–680.
  1094. Stadlbauer, U., Woods, S. C., Langhans, W., Meyer, U. 2015. PYY3-36: Beyond food intake. Front Neuroendocrinol 38: 1–11.
  1095. Fenske, W. K., Bueter, M., Miras, A. D., Ghatei, M. A., Bloom, S. R., le Roux, C. W. 2012. Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. Int J Obes (Lond). 36(3): 379–384.
  1096. Persaud, S. J., Bewick, G. A. 2014. Peptide YY: More than just an appetite regulator. Diabetologia 57(9): 1762–1769.
  1097. Batterham, R. L., Bloom, S. R. 2003. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 994: 162–168.
  1098. Sloth, B., Holst, J. J., Flint, A., Gregersen, N. T., Astrup A. 2007. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292: E1062–E1068.
  1099. Gantz I., Erondu, N., Mallick, M. et al. 2007. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92(5): 1754–1757.
  1100. Acosta, A., Hurtado, M. D., Gorbatyuk, O. et al. 2011. Salivary PYY: A putative bypass to satiety. PLoS One 6(10): e26137.
  1101. Fazen, C., Valentin, D., Fairchild, T., Doyle, R. 2011. Oral delivery of the appetite suppressing peptide hPYY(3–36) through the vitamin B12 uptake pathway. J Medicinal Chem 54: 8707–8711.
  1102. Cegla, J., Cuenco, J., Minnion, J. et al. 2015. Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3-36 and its analogues in vivo. Lancet 385(1): S28.
  1103. Sam, A. H., Gunner, D. J., King, A. et al. 2012. Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology 143(2): 459–468.
  1104. Perugini, R. A., Malkani, S. 2011. Remission of type 2 diabetes mellitus following bariatric surgery: Review of mechanisms and presentation of the concept of ‘reversibility’. Curr Opin Endocrinol Diabetes Obes 18(2): 119–128.
  1105. Ardestani, A., Rhoads, D., Tavakkoli A. 2015. Insulin cessation and diabetes remission after bariatric surgery in adults with insulin-treated type 2 diabetes. Diabetes Care 38(4): 659–664.
  1106. Ramracheya, R. D., McCulloch, L. J., Clark, A. 2016. PYY-Dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-En-Y gastric bypass surgery. Cell Rep 15(5): 944–950.
  1107. Guida, C., Stephen, S., Guitton, R., Ramracheya, R. D. 2017. The role of PYY in pancreatic islet physiology and surgical control of diabetes. Trends Endocrinol Metab 28(8): 626–636.
  1108. Van Gaal, L., and Dirinck, E. 2016. Pharmacological approaches in the treatment and maintenance of weight loss. Diabetes Care 39(2): S260–S267.
  1109. Gault, V. A., Bhat, V. K., Irwin, N., Flatt, P. R. 2013. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem 288(49): 35581–35591
  1110. Pauling, L., H.A. Itano, et al. Sickle cell anemia, a molecular disease. Science, 1949. 109(2835): 443.
  1111. Ashley-Koch, A., Q. Yang, and R.S. Olney. Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGE review. Am J Epidemiol, 2000. 151(9): 839–45.
  1112. Stuart, M.J. and R.L. Nagel. Sickle-cell disease. Lancet, 2004. 364(9442): 1343–60.
  1113. Tsui, L.C., et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science, 1985. 230(4729): 1054–7.
  1114. Myerowitz, R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat, 1997. 9(3): 195–208.
  1115. MacDonald, M.E., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group Cell, 1993. 72(6): 971–83.
  1116. Makrythanasis, and S.E. Antonarakis. Pathogenic variants in non-protein-coding sequences. Clin Genet, 2013. 84(5): 422–8.
  1117. McKusick-Nathans Institute of Genetic Medicine, J.H.U. Online Mendelian Inheritance in Man. OMIM. 2017 November 15, 2017; Available from: https://www.omim.org/statistics/entry.
  1118. Manolio, T.A., et al. Finding the missing heritability of complex diseases. Nature, 2009. 461(7265): 747–53.
  1119. Eichler, E.E., et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet, 2010. 11(6): 446–50.
  1120. Scheuner, M.T., P.W. Yoon, and M.J. Khoury. Contribution of Mendelian disorders to common chronic disease: opportunities for recognition, intervention, and prevention. Am J Med Genet C Semin Med Genet, 2004. 125C(1): 50–65.
  1121. Yamagata, K., et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 1996. 384(6608): 458–60.
  1122. Yamagata, K., et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature, 1996. 384(6608): 455–8.
  1123. Vionnet, N., et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature, 1992. 356(6371): 721–2.
  1124. Malecki, M.T., et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet, 1999. 23(3): 323–8. Stoffers, D.A., et al. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet, 1997. 17(2): 138–9.
  1125. Horikawa, Y., et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet, 1997. 17(4): 384–5.
  1126. Winckler, W., et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes, 2007. 56(3): 685–93.
  1127. Lander, E.S., et al. Initial sequencing and analysis of the human genome. Nature, 2001. 409(6822): 860–921.
  1128. Klein, R.J., et al. Complement factor H polymorphism in age-related macular degeneration. Science, 2005. 308(5720): 385–9.
  1129. MacArthur, J., et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Res, 2017. 45(D1): D896–D901.
  1130. Patterson, C.C., et al. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet, 2009. 373(9680): 2027–33.
  1131. Zhang, Q. and Y. Wang. Trends in the association between obesity and socioeconomic status in U.S. adults: 1971 to 2000. Obes Res, 2004. 12(10): 1622–32.
  1132. Mitchell, N.S., et al. Obesity: overview of an epidemic. Psychiatr Clin North Am, 2011. 34(4): 717–32.
  1133. Hennekens, C.H. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation, 1998. 97(11): 1095–102.
  1134. Galton, F. English Men Of Science: Their Nature And Nurture. 1874, London, UK: Macmillan.
  1135. Locke, J. An essay concerning human understanding. 1690, London, UK: Thomas Bassett.
  1136. Moore, J.X., N. Chaudhary, and T. Akinyemiju. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, national health and nutrition examination survey, 1988–2012. Prev Chronic Dis, 2017. 14: E24.
  1137. Neel, J.V. Diabetes mellitus: A ‘thrifty’ genotype rendered detrimental by ‘progress’? Am J Hum Genet, 1962. 14: 353–62.
  1138. Esparza-Romero, J., et al. Differences in insulin resistance in Mexican and U.S. Pima Indians with normal glucose tolerance. J Clin Endocrinol Metab, 2010. 95(11): E358–62.
  1139. Schulz, L.O., et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care, 2006. 29(8): 1866–71.
  1140. Spiegelman, B.M. Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res, 1997. 2(11): 457–64.
  1141. Tontonoz, P., E. Hu, and B.M. Spiegelman. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell, 1994. 79(7): 1147–56.
  1142. Tontonoz, P., E. Hu, and B.M. Spiegelman. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev, 1995. 5(5): 571–6.
  1143. Vidal-Puig, A.J., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest, 1997. 99(10): 2416–22.
  1144. Werman, A., et al. Ligand-independent activation domain in the N terminus of peroxisome proliferatoractivated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem, 1997. 272(32): 20230–5.
  1145. Deeb, S.S., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998. 20(3): 284–7.
  1146. Ek, J., et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptorgamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia, 2001. 44(9): 1170–6.
  1147. Stumvoll, M., et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptorgamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes, 2001. 50(4): 876–81.
  1148. Xu, H.E., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell, 1999. 3(3): 397–403.
  1149. Luan, J., et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes, 2001. 50(3): 686–9.
  1150. Nieters, A., N. Becker, and J. Linseisen. Polymorphisms in candidate obesity genes and their interaction with dietary intake of n-6 polyunsaturated fatty acids affect obesity risk in a sub-sample of the EPICHeidelberg cohort. Eur J Nutr, 2002. 41(5): 210–21. Memisoglu, A., et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet, 2003. 12(22): 2923–9.
  1151. Robitaille, J., et al. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in FrenchCanadians. Int J Obes (Lond), 2007. 31(3): 411–7.
  1152. Franks, P.W., et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the diabetes prevention program. Diabetologia, 2007. 50(12): 2451–60.
  1153. Razquin, C., et al. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years’ follow-up of 774 subjects at high cardiovascular risk. Br J Nutr, 2009. 102(5): 672–9.
  1154. Tonjes, A. and M. Stumvoll. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care, 2007. 10(4): 410–4.
  1155. Ek, J., et al. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia, 1999. 42(7): 892–5.
  1156. Masud, S., S. Ye, and S.A.S. Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet, 2003. 40(10): 773–80.
  1157. Vessby, B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol, 2003. 14(1): 15–9.
  1158. Glew, R.H., et al. Abnormalities in the fatty-acid composition of the serum phospholipids of stroke patients. J Natl Med Assoc, 2004. 96(6): 826–32.
  1159. Maes, M., et al. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord, 1996. 38(1): 35–46.
  1160. Nakada, T., I.L. Kwee, and W.G. Ellis. Membrane fatty acid composition shows delta-6-desaturase abnormalities in Alzheimer’s disease. Neuroreport, 1990. 1(2): 153–5.
  1161. Goldring, M.B. and F. Berenbaum. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res, 2004(427 Suppl): S37–46.
  1162. Cho, H.P., M. Nakamura, and S.D. Clarke. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem, 1999. 274(52): 37335–9.
  1163. Cho, H.P., M.T. Nakamura, and S.D. Clarke. Cloning, expression, and nutritional regulation of the mammalian Delta-6 desaturase. J Biol Chem, 1999. 274(1): 471–7.
  1164. Calder, P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res, 2008. 52(8): 885–97.
  1165. Schmitz, G. and J. Ecker. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res, 2008. 47(2): 147–55.
  1166. Nakagawa, Y., et al. Fine mapping of the diabetes-susceptibility locus, IDDM4, on chromosome 11q13. Am J Hum Genet, 1998. 63(2): 547–56.
  1167. Chapman, K., et al. Osteoarthritis-susceptibility locus on chromosome 11q, detected by linkage. Am J Hum Genet, 1999. 65(1): 167–74.
  1168. Fallin, M.D., et al. Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet, 2004. 75(2): 204–19.
  1169. Huang, J.L., et al. Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. Hum Mol Genet, 2004. 13(21): 2691–7.
  1170. Schaeffer, L., et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet, 2006. 15(11): 1745–56.
  1171. Rzehak, P., et al. Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br J Nutr, 2009. 101(1): 20–6.
  1172. Gieger, C., et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet, 2008. 4(11): e1000282.
  1173. Tanaka, T., et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009. 5(1): e1000338.
  1174. Sankar, P., et al. Genetic research and health disparities. JAMA, 2004. 291(24): 2985–9. Mathias, R.A., et al. The impact of FADS genetic variants on omega6 polyunsaturated fatty acid metabolism in African Americans. BMC Genet, 2011. 12: 50.
  1175. Sergeant, S., et al. Differences in arachidonic acid levels and fatty acid desaturase (FADS) gene variants in African Americans and European Americans with diabetes or the metabolic syndrome. Br J Nutr, 2012. 107(4): 547–55.
  1176. Mathias, R.A., et al. Adaptive evolution of the FADS gene cluster within Africa. PLoS One, 2012. 7(9): e44926.
  1177. Jones, P.A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet, 2012. 13(7): 484–92.
  1178. Howard, T.D., et al. DNA methylation in an enhancer region of the FADS cluster is associated with FADS activity in human liver. PLoS One, 2014. 9(5): e97510.
  1179. Rahbar, E., et al. Uncovering the DNA methylation landscape in key regulatory regions within the FADS cluster. PLoS One, 2017. 12(9): e0180903.
  1180. Cordain, L., et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr, 2005. 81(2): 341–54.
  1181. Fenech, M. Genome health nutrigenomics and nutrigenetics—diagnosis and nutritional treatment of genome damage on an individual basis. Food Chem Toxicol, 2008. 46(4): 1365–70.
  1182. Ordovas, J.M. and V. Mooser. Nutrigenomics and nutrigenetics. Curr Opin Lipidol, 2004. 15(2): 101–8.
  1183. DeBusk, R.M., et al. Nutritional genomics in practice: where do we begin?. J Am Diet Assoc, 2005. 105(4): 589–98.
  1184. Simopoulos, A.P. Editorial. J Nutrigenet Nutrigenomics, 2008. 1: 2–3.
  1185. Nielsen, D.E. and A. El-Sohemy. A randomized trial of genetic information for personalized nutrition. Genes Nutr, 2012. 7(4): 559–66.
  1186. Psaty, B.M., et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet, 2009. 2(1): 73–80.
  1187. Morrison, A.C., et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet, 2013. 45(8): 899–901.
  1188. Fuchsberger, C., et al. The genetic architecture of type 2 diabetes. Nature, 2016. 536(7614): 41–47.
  1189. Phillips, C.M., et al. ACC2 gene polymorphisms, metabolic syndrome, and gene-nutrient interactions with dietary fat. J Lipid Res, 2010. 51(12): 3500–7.
  1190. Ferguson, J.F., et al. NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. Atherosclerosis, 2010. 211(2): 539–44.
  1191. Phillips, C.M., et al. Gene-nutrient interactions and gender may modulate the association between ApoA1 and ApoB gene polymorphisms and metabolic syndrome risk. Atherosclerosis, 2011. 214(2): 408–14.
  1192. Phillips, C.M., et al. Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome. J Nutr Biochem, 2012. 23(3): 239–44.
  1193. Garaulet, M., et al. PPARgamma Pro12Ala interacts with fat intake for obesity and weight loss in a behavioural treatment based on the Mediterranean diet. Mol Nutr Food Res, 2011. 55(12): 1771–9.
  1194. Abbott, C. R., M. Monteiro, C. J. Small, A. Sajedi, K. L. Smith, J. R. Parkinson, M. A. Ghatei et al., 2005. The inhibitory effects of peripheral administration of peptide YY(3–36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (1):127–31. doi:10.1016/j.brainres.2005.03.011.
  1195. Amori, R. E., J. Lau, and A. G. Pittas. 2007. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298 (2):194–206. doi:10.1001/jama.298.2.194.
  1196. Askari, H., G. Tykodi, J. Liu, and S. Dagogo-Jack. 2010. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. J Clin Endocrinol Metab 95 (8):3836–43. doi:10.1210/jc.2010-0296.
  1197. Astrup, A., S. Rossner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M. F.Rasmussen, M. E. Lean, and N. N. Study Group. 2009. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 374 (9701):1606–16. doi:10.1016/S0140-6736(09)61375-1.
  1198. Bado, A., S. Levasseur, S. Attoub, S. Kermorgant, J. P. Laigneau, M. N. Bortoluzzi, L. Moizo et al., 1998. The stomach is a source of leptin. Nature 394 (6695):790–3. doi:10.1038/29547.
  1199. Bagger, J. I., J. J. Holst, B. Hartmann, B. Andersen, F. K. Knop, and T. Vilsboll. 2015. Effect of oxyntomodulin, Glucagon, GLP-1, and combined Glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab 100 (12):4541–52. doi:10.1210/jc.2015-2335.
  1200. Bai, Y., S. Zhang, K. S. Kim, J. K. Lee, and K. H. Kim. 1996. Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones. J Biol Chem 271 (24):13939–42.
  1201. Barzilai, N., and G. Gupta. 1999. Interaction between aging and syndrome X: New insights on the pathophysiology of fat distribution. Ann N Y Acad Sci 892:58–72.
  1202. Batterham, R. L., M. A. Cohen, S. M. Ellis, C. W. Le Roux, D. J. Withers, G. S. Frost, M. A. Ghatei, and S. R. Bloom. 2003a. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (10):941–8. doi:10.1056/NEJMoa030204.
  1203. Batterham, R. L., M. A. Cowley, C. J. Small, H. Herzog, M. A. Cohen, C. L. Dakin, A. M. Wren, A. E. et al., 2002. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418 (6898):650–4. doi:10.1038/nature02666.
  1204. Batterham, R. L., J. M. Rosenthal, F. O. Zelaya, G. J. Barker, D. J. Withers, and S. C. Williams. 2007. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450 (7166):106–9. doi:10.1038/nature06212.
  1205. Batterham, R. L., C. W. Le Roux, M. A. Cohen, A. J. Park, S. M. Ellis, M. Patterson, G. S. Frost, M. A. Ghatei, and S. R. Bloom. 2003b. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88 (8):3989–92. doi:10.1210/jc.2003-030630.
  1206. Baumann, H., K. K. Morella, D. W. White, M. Dembski, P. S. Bailon, H. Kim, C. F. Lai, and L. A. Tartaglia. 1996. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A 93 (16):8374–8.
  1207. Baura, G. D., D. M. Foster, D. Porte, Jr., S. E. Kahn, R. N. Bergman, C. Cobelli, and M. W. Schwartz. 1993. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 92 (4):1824–30. doi:10.1172/JCI116773.
  1208. Beck, B. 2006. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci 361 (1471):1159–85. doi:10.1098/rstb.2006.1855.
  1209. Beglinger, C., B. Poller, E. Arbit, C. Ganzoni, S. Gass, I. Gomez-Orellana, and J. Drewe. 2008. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: A proof-of-concept study in healthy subjects. Clin Pharmacol Ther 84 (4):468–74.
  1210. Berntson, G. G., W. B. Zipf, T. M. O’Dorisio, J. A. Hoffman, and R. E. Chance. 1993. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14 (3):497–503.
  1211. Bjorbaek, C., K. El-Haschimi, J. D. Frantz, and J. S. Flier. 1999. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 274 (42):30059–65.
  1212. Blundell, J. E. 1984. Serotonin and appetite. Neuropharmacology 23 (12B):1537–51.
  1213. Bray, G. A. 1996. Health hazards of obesity. Endocrinol Metab Clin North Am 25 (4):907–19.
  1214. Breen, T. L., I. M. Conwell, and S. L. Wardlaw. 2005. Effects of fasting, leptin, and insulin on AGRP and POMC peptide release in the hypothalamus. Brain Res 1032 (1–2):141–8. doi:10.1016/j.brainres.2004.11.008.
  1215. Brothers, S. P., and C. Wahlestedt. 2010. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2 (11):429–39. doi:10.1002/emmm.201000100.
  1216. Brunicardi, F. C., R. L. Chaiken, A. S. Ryan, N. E. Seymour, J. A. Hoffmann, H. E. Lebovitz, R. E. Chance, R. L. Gingerich, D. K. Andersen, and D. Elahi. 1996. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 81 (10):3566–72. doi:10.1210/jcem.81.10.8855802.
  1217. Campfield, L. A., F. J. Smith, Y. Guisez, R. Devos, and P. Burn. 1995. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 269 (5223):546–9.
  1218. Chao, M. V. 2003. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci 4 (4):299–309. doi:10.1038/nrn1078.
  1219. Chehab, F. F., M. E. Lim, and R. Lu. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12 (3):318–20. doi:10.1038/ng0396-318.
  1220. Chemelli, R. M., J. T. Willie, C. M. Sinton, J. K. Elmquist, T. Scammell, C. Lee, J. A. Richardson, S. C. et al., 1999. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98 (4):437–51.
  1221. Chen, H., O. Charlat, L. A. Tartaglia, E. A. Woolf, X. Weng, S. J. Ellis, N. D. Lakey, J. et al., 1996. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84 (3):491–5.
  1222. Chen, H. Y., M. E. Trumbauer, A. S. Chen, D. T. Weingarth, J. R. Adams, E. G. Frazier, Z. Shen, D. J. et al., 2004. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145 (6):2607–12. doi:10.1210/en.2003-1596.
  1223. Chen, K. Y., R. Muniyappa, B. S. Abel, K. P. Mullins, P. Staker, R. J. Brychta, X. Zhao, M. et al., 2015. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab 100 (4):1639–45. doi:10.1210/jc.2014-4024.
  1224. Clement, K., C. Vaisse, N. Lahlou, S. Cabrol, V. Pelloux, D. Cassuto, M. Gourmelen, C. et al., 1998. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 (6674):398–401. doi:10.1038/32911.
  1225. Clemmensen, C., J. Chabenne, B. Finan, L. Sullivan, K. Fischer, D. Kuchler, L. Sehrer et al., 2014. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63 (4):1422–7. doi:10.2337/db13-1609.
  1226. Cohen, B., D. Novick, and M. Rubinstein. 1996. Modulation of insulin activities by leptin. Science 274 (5290):1185–8.
  1227. Considine, R. V., E. L. Considine, C. J. Williams, M. R. Nyce, S. A. Magosin, T. L. Bauer, E. L. Rosato, J.
  1228. Colberg, and J. F. Caro. 1995. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J Clin Invest 95 (6):2986–8. doi:10.1172/JCI118007.
  1229. Considine, R. V., M. K. Sinha, M. L. Heiman, A. Kriauciunas, T. W. Stephens, M. R. Nyce, J. P. Ohannesian et al., 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (5):292–5. doi:10.1056/NEJM199602013340503.
  1230. Cota, D., G. Marsicano, M. Tschop, Y. Grubler, C. Flachskamm, M. Schubert, D. Auer et al., 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (3):423–31. doi:10.1172/JCI17725.
  1231. Cowley, M. A., J. L. Smart, M. Rubinstein, M. G. Cerdan, S. Diano, T. L. Horvath, R. D. Cone, and M. J. Low. 2001. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411 (6836):480–4. doi:10.1038/35078085.
  1232. Cox, H. M. 2007. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton Neurosci 133 (1):76–85. doi:10.1016/j.autneu.2006.10.005.
  1233. Crawley, J. N., and M. C. Beinfeld. 1983. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 (5910):703–6.
  1234. Cummings, D. E., J. Q. Purnell, R. S. Frayo, K. Schmidova, B. E. Wisse, and D. S. Weigle. 2001. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (8):1714–9.
  1235. Dagogo-Jack, S., H. Askari, G. Tykodi, J. Liu, and I. Umamaheswaran. 2008. Dynamic responses to leptin secretagogues in lean, obese, and massively obese men and women. Horm Res 70 (3):174–81. doi:10.1159/000145018.
  1236. Dagogo-Jack, S., C. Fanelli, D. Paramore, J. Brothers, and M. Landt. 1996. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes 45 (5):695–8.
  1237. Dagogo-Jack, S., J. Liu, H. Askari, G. Tykodi, and I. Umamaheswaran. 2000. Impaired leptin response to glucocorticoid as a chronic complication of diabetes. J Diabetes Complications 14 (6):327–32.
  1238. Dagogo-Jack, S., G. Selke, A. K. Melson, and J. W. Newcomer. 1997. Robust leptin secretory responses to dexamethasone in obese subjects. J Clin Endocrinol Metab 82 (10):3230–3. doi:10.1210/jcem.82.10.4154.
  1239. Dakin, C. L., I. Gunn, C. J. Small, C. M. Edwards, D. L. Hay, D. M. Smith, M. A. Ghatei et al., 2001. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (10):4244–50. doi:10.1210/ endo.142.10.8430.
  1240. Dallman, M. F., A. M. Strack, S. F. Akana, M. J. Bradbury, E. S. Hanson, K. A. Scribner, and M. Smith. 1993. Feast and famine: Critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 14 (4):303–47. doi:10.1006/frne.1993.1010.
  1241. Date, Y., N. Murakami, K. Toshinai, S. Matsukura, A. Niijima, H. Matsuo, K. Kangawa, and M. Nakazato. 2002. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (4):1120–8.
  1242. Day, J. W., N. Ottaway, J. T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen et al., 2009. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5 (10):749–57. doi:10.1038/ nchembio.209.
  1243. de Lecea, L., T. S. Kilduff, C. Peyron, X. Gao, P. E. Foye, P. E. Danielson, C. Fukuhara et al., 1998. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95 (1):322–7.
  1244. DeFronzo, R. A., R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron. 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (5):1092–100.
  1245. Dicker, D. 2011. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care 34 Suppl 2:S276–8. doi:10.2337/dc11-s229.
  1246. Drucker, D. J. 2005. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1 (1):22–31. doi:10.1038/ncpendmet0017.
  1247. Farooqi, I. S., S. A. Jebb, G. Langmack, E. Lawrence, C. H. Cheetham, A. M. Prentice, I. A. Hughes et al., 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341 (12):879–84. doi:10.1056/NEJM199909163411204.
  1248. Farooqi, I. S., G. Matarese, G. M. Lord, J. M. Keogh, E. Lawrence, C. Agwu et al., 2002. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 (8):1093–103. doi:10.1172/JCI15693.
  1249. Farooqi, I. S., G. S. Yeo, J. M. Keogh, S. Aminian, S. A. Jebb, G. Butler, T. Cheetham, and S. O’Rahilly. 2000. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106 (2):271–9. doi:10.1172/JCI9397.
  1250. Fehm, H. L., R. Smolnik, W. Kern, G. P. McGregor, U. Bickel, and J. Born. 2001. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4–10) decreases body fat in humans. J Clin Endocrinol Metab 86 (3):1144–8. doi:10.1210/jcem.86.3.7298.
  1251. Field, B. C., O. B. Chaudhri, and S. R. Bloom. 2010. Bowels control brain: Gut hormones and obesity. Nat Rev Endocrinol 6 (8):444–53. doi:10.1038/nrendo.2010.93.
  1252. Flegal, K. M., M. D. Carroll, C. L. Ogden, and C. L. Johnson. 2002. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288 (14):1723–7. Flier, J. S. 1998. Clinical review 94: What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 83 (5):1407–13. doi:10.1210/jcem.83.5.4779.
  1253. Freeman, D. J., J. Norrie, M. J. Caslake, A. Gaw, I. Ford, G. D. Lowe, D. S. O’Reilly, C. J. Packard, N. Sattar, and Study West of Scotland Coronary Prevention. 2002. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland coronary prevention study. Diabetes 51 (5):1596–600.
  1254. Gantz, I., N. Erondu, M. Mallick, B. Musser, R. Krishna, W. K. Tanaka, K. Snyder et al., 2007. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92 (5):1754–7. doi:10.1210/jc.2006-1806.
  1255. Gardiner, J., and S. Bloom. 2008. Ghrelin gets its GOAT. Cell Metab 7 (3):193–4. doi:10.1016/j.cmet. 2008.02.009.
  1256. Ghilardi, N., and R. C. Skoda. 1997. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol 11 (4):393–9. doi:10.1210/mend.11.4.9907.
  1257. Gibbs, J., R. C. Young, and G. P. Smith. 1973. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84 (3):488–95.
  1258. Goldstone, A. P., U. A. Unmehopa, S. R. Bloom, and D. F. Swaab. 2002. Hypothalamic NPY and agoutirelated protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J Clin Endocrinol Metab 87 (2):927–37. doi:10.1210/jcem.87.2.8230.
  1259. Grandt, D., M. Schimiczek, C. Beglinger, P. Layer, H. Goebell, V. E. Eysselein, and J. R. Reeve, Jr. 1994. Two molecular forms of peptide YY (PYY) are abundant in human blood: Characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51 (2):151–9.
  1260. Gray, J., G. S. Yeo, J. J. Cox, J. Morton, A. L. Adlam, J. M. Keogh, J. A. Yanovski et al., 2006. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes 55 (12):3366–71. doi:10.2337/db06-0550.
  1261. Grill, H. J., and M. R. Hayes. 2012. Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab 16 (3):296–309. doi:10.1016/j.cmet.2012.06.015.
  1262. Grill, H. J., and G. P. Smith. 1988. Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 254 (6 Pt 2):R853–6.
  1263. Grimble, R. F. 2002. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 5 (5):551–9.
  1264. Gros, L., B. Thorens, D. Bataille, and A. Kervran. 1993. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 133 (2):631–8. doi:10.1210/endo.133.2.8102095.
  1265. Halaas, J. L., K. S. Gajiwala, M. Maffei, S. L. Cohen, B. T. Chait, D. Rabinowitz, R. L. Lallone, S. K. Burley, and J. M. Friedman. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (5223):543–6.
  1266. Hallschmid, M., R. Smolnik, G. McGregor, J. Born, and H. L. Fehm. 2006. Overweight humans are resistant to the weight-reducing effects of melanocortin4-10. J Clin Endocrinol Metab 91 (2):522–5. doi:10.1210/ jc.2005-0906.
  1267. Hamilton, B. S., D. Paglia, A. Y. Kwan, and M. Deitel. 1995. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1 (9):953–6.
  1268. Havel, P. J., S. J. Parry, D. L. Curry, J. S. Stern, J. O. Akpan, and R. L. Gingerich. 1992. Autonomic nervous system mediation of the pancreatic polypeptide response to insulin-induced hypoglycemia in conscious rats. Endocrinology 130 (4):2225–9. doi:10.1210/endo.130.4.1347741.
  1269. Haynes, W. G., D. A. Morgan, S. A. Walsh, A. L. Mark, and W. I. Sivitz. 1997. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100 (2):270–8. doi:10.1172/JCI119532.
  1270. Heisler, L. K., E. E. Jobst, G. M. Sutton, L. Zhou, E. Borok, Z. Thornton-Jones, H. Y. Liu et al., 2006. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51 (2):239–49. doi:10.1016/j.neuron.2006.06.004.
  1271. Henry, M., L. Ghibaudi, J. Gao, and J. J. Hwa. 2005. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res 13 (1):36–47. doi:10.1038/oby.2005.6.
  1272. Heymsfield, S. B., A. S. Greenberg, K. Fujioka, R. M. Dixon, R. Kushner, T. Hunt, J. A. Lubina et al., 1999. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 282 (16):1568–75.
  1273. Holst, J. J. 1983. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—current status. Gastroenterology 84 (6):1602–13.
  1274. Holst, J. J. 1997. Enteroglucagon. Annu Rev Physiol 59:257–71. doi:10.1146/annurev.physiol.59.1.257.
  1275. Hotamisligil, G. S., A. Budavari, D. Murray, and B. M. Spiegelman. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94 (4):1543–9. doi:10.1172/JCI117495.
  1276. Hotamisligil, G. S., P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (5249):665–8.
  1277. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. Adipose expression of tumor necrosis factoralpha: Direct role in obesity-linked insulin resistance. Science 259 (5091):87–91.
  1278. Hotta, K., M. Nakamura, T. Nakamura, T. Matsuo, Y. Nakata, S. Kamohara, N. Miyatake et al., 2009. Association between obesity and polymorphisms in SEC16B, TMEM18, GNPDA2, BDNF, FAIM2 and MC4R in a Japanese population. J Hum Genet 54 (12):727–31. doi:10.1038/jhg.2009.106.
  1279. Huszar, D., C. A. Lynch, V. Fairchild-Huntress, J. H. Dunmore, Q. Fang, L. R. Berkemeier, W. Gu et al., 1997. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1):131–41.
  1280. Jesudason, D. R., M. P. Monteiro, B. M. McGowan, N. M. Neary, A. J. Park, E. Philippou, C. J. Small, G. S. Frost, M. A. Ghatei, and S. R. Bloom. 2007. Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 97 (3):426–9. doi:10.1017/S0007114507336799.
  1281. Kalra, S. P., M. G. Dube, S. Pu, B. Xu, T. L. Horvath, and P. S. Kalra. 1999. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20 (1):68–100. doi:10.1210/ edrv.20.1.0357.
  1282. Kamohara, S., R. Burcelin, J. L. Halaas, J. M. Friedman, and M. J. Charron. 1997. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389 (6649):374–77. doi:10.1038/38717.
  1283. Kennedy, G. C. 1953. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond B Biol Sci 140 (901):578–96.
  1284. Kern, P. A., M. Saghizadeh, J. M. Ong, R. J. Bosch, R. Deem, and R. B. Simsolo. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95 (5):2111–9. doi:10.1172/JCI117899.
  1285. Kieffer, T. J., R. S. Heller, and J. F. Habener. 1996. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 224 (2):522–7. doi:10.1006/bbrc.1996.1059.
  1286. Kojima, M., H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa. 1999. Ghrelin is a growthhormone-releasing acylated peptide from stomach. Nature 402 (6762):656–60. doi:10.1038/45230.
  1287. Kolterman, O. G., J. B. Buse, M. S. Fineman, E. Gaines, S. Heintz, T. A. Bicsak, K. Taylor et al., 2003. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (7):3082–9. doi:10.1210/jc.2002-021545.
  1288. Korner, J., R. Conroy, G. Febres, D. J. McMahon, I. Conwell, W. Karmally, and L. J. Aronne. 2013. Randomized double-blind placebo-controlled study of leptin administration after gastric bypass. Obesity (Silver Spring) 21 (5):951–6. doi:10.1002/oby.20433.
  1289. Krempler, F., D. Breban, H. Oberkofler, H. Esterbauer, E. Hell, B. Paulweber, and W. Patsch. 2000. Leptin, peroxisome proliferator-activated receptor-gamma, and CCAAT/enhancer binding protein-alpha mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20 (2):443–9.
  1290. Kreymann, B., G. Williams, M. A. Ghatei, and S. R. Bloom. 1987. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 2 (8571):1300–4.
  1291. Krishna, R., B. Gumbiner, C. Stevens, B. Musser, M. Mallick, S. Suryawanshi, L. Maganti et al., 2009. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 86 (6):659–66. doi:10.1038/clpt.2009.167.
  1292. Laaksonen, D. E., T. A. Lakka, H. M. Lakka, K. Nyyssonen, T. Rissanen, L. K. Niskanen, and J. T. Salonen. 2002. Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabet Med 19 (6):456–64.
  1293. Lapchak, P. A., and F. Hefti. 1992. BDNF and NGF treatment in lesioned rats: Effects on cholinergic function and weight gain. Neuroreport 3 (5):405–8.
  1294. Larhammar, D. 1996. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65 (3):165–74.
  1295. Le Roux, C. W., C. M. Borg, K. G. Murphy, R. P. Vincent, M. A. Ghatei, and S. R. Bloom. 2008. Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 45 (Pt 1):93–5. doi:10.1258/acb.2007.007068.
  1296. Lee, G. H., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee, and J. M. Friedman. 1996. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379 (6566):632–5. doi:10.1038/379632a0.
  1297. Licinio, J., S. Caglayan, M. Ozata, B. O. Yildiz, P. B. de Miranda, F. O’Kirwan, R. Whitby et al., 2004. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101 (13):4531–6. doi:10.1073/pnas.0308767101.
  1298. Lin, L., J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P. J. de Jong, S. Nishino, and E. Mignot. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 (3):365–76.
  1299. Liu, J., H. Askari, and S. Dagogo-Jack. 1999. Basal and stimulated plasma leptin in diabetic subjects. Obes Res 7 (6):537–44.
  1300. Lonnqvist, F., P. Arner, L. Nordfors, and M. Schalling. 1995. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1 (9):950–3.
  1301. Lou, P. H., G. Yang, L. Huang, Y. Cui, T. Pourbahrami, G. K. Radda, C. Li, and W. Han. 2010. Reduced body weight and increased energy expenditure in transgenic mice over-expressing soluble leptin receptor. PLoS One 5 (7):e11669. doi:10.1371/journal.pone.0011669.
  1302. Lyons, W. E., L. A. Mamounas, G. A. Ricaurte, V. Coppola, S. W. Reid, S. H. Bora, C. Wihler, V. E. Koliatsos, and L. Tessarollo. 1999. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 96 (26):15239–44.
  1303. Macdonald, I. A. 1998. Energy expenditure in humans: The influence of activity, diet and sympathetic nervous system. In Clinical Obesity, edited by PG. and Stock Kopelman, MJ., 112–128. Oxford, UK: Blackwell Science.
  1304. Maffei, M., M. Stoffel, M. Barone, B. Moon, M. Dammerman, E. Ravussin, C. Bogardus, D. S. Ludwig, J. S. Flier, M. Talley et al., 1996. Absence of mutations in the human OB gene in obese/diabetic subjects. Diabetes 45 (5):679–682.
  1305. Masuzaki, H., Y. Ogawa, N. Sagawa, K. Hosoda, T. Matsumoto, H. Mise, H. Nishimura et al., 1997. Nonadipose tissue production of leptin: Leptin as a novel placenta-derived hormone in humans. Nat Med 3 (9):1029–33.
  1306. Matarese, G. 2000. Leptin and the immune system: How nutritional status influences the immune response. Eur Cytokine Netw 11 (1):7–14.
  1307. Matson, C. A., M. F. Wiater, J. L. Kuijper, and D. S. Weigle. 1997. Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 18 (8):1275–8.
  1308. McLaughlin, C. L. 1982. Role of peptides from gastrointestinal cells in food intake regulation. J Anim Sci 55 (6):1515–27.
  1309. Moller, D. E. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11 (6):212–7.
  1310. Montague, C. T., I. S. Farooqi, J. P. Whitehead, M. A. Soos, H. Rau, N. J. Wareham, C. P. Sewter et al., 1997. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 (6636):903–8. doi:10.1038/43185.
  1311. Moon, H. S., G. Matarese, A. M. Brennan, J. P. Chamberland, X. Liu, C. G. Fiorenza, G. H. Mylvaganam et al., 2011. Efficacy of metreleptin in obese patients with type 2 diabetes: Cellular and molecular pathways underlying leptin tolerance. Diabetes 60 (6):1647–56. doi:10.2337/db10-1791.
  1312. Moran, T. H. 2000. Cholecystokinin and satiety: Current perspectives. Nutrition 16 (10):858–65.
  1313. Muller, T. D., L. M. Sullivan, K. Habegger, C. X. Yi, D. Kabra, E. Grant, N. Ottaway et al., 2012. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18 (6):383–93. doi:10.1002/psc.2408.
  1314. Myers, M. G., Jr., S. B. Heymsfield, C. Haft, B. B. Kahn, M. Laughlin, R. L. Leibel, M. H. Tschop, and
  1315. J. A. Yanovski. 2012. Challenges and opportunities of defining clinical leptin resistance. Cell Metab 15 (2):150–6. doi:10.1016/j.cmet.2012.01.002.
  1316. Nakazato, M., N. Murakami, Y. Date, M. Kojima, H. Matsuo, K. Kangawa, and S. Matsukura. 2001. A role for ghrelin in the central regulation of feeding. Nature 409 (6817):194–8. doi:10.1038/35051587.
  1317. Neary, N. M., A. P. Goldstone, and S. R. Bloom. 2004. Appetite regulation: From the gut to the hypothalamus. Clin Endocrinol (Oxf) 60 (2):153–60.
  1318. Nishino, S. 2003. The hypocretin/orexin system in health and disease. Biol Psychiatry 54 (2):87–95.
  1319. Nishino, S., B. Ripley, S. Overeem, S. Nevsimalova, G. J. Lammers, J. Vankova, M. Okun, W. Rogers, S. Brooks, and E. Mignot. 2001. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50 (3):381–388.
  1320. Norman, R. A., C. Bogardus, and E. Ravussin. 1995. Linkage between obesity and a marker near the tumor necrosis factor-alpha locus in Pima Indians. J Clin Invest 96 (1):158–162. doi:10.1172/JCI118016.
  1321. Oral, E. A., V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A. J. Wagner et al., 2002. Leptinreplacement therapy for lipodystrophy. N Engl J Med 346 (8):570–578. doi:10.1056/NEJMoa012437.
  1322. Ozcan, L., A. S. Ergin, A. Lu, J. Chung, S. Sarkar, D. Nie, M. G. Myers, Jr., and U. Ozcan. 2009. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9 (1):35–51. doi:10.1016/j.cmet.2008.12.004.
  1323. Page-Wilson, G., K. T. Nguyen, D. Atalayer, K. Meece, H. A. Bainbridge, J. Korner, R. J. Gordon et al., 2017. Evaluation of CSF and plasma biomarkers of brain melanocortin activity in response to caloric restriction in humans. Am J Physiol Endocrinol Metab 312 (1):E19–E26. doi:10.1152/ajpendo.00330.2016.
  1324. Paolisso, G., M. R. Tagliamonte, M. R. Rizzo, P. Gualdiero, F. Saccomanno, A. Gambardella, D. Giugliano, F. D’Onofrio, and B. V. Howard. 1998. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 41 (10):1127–1132. doi:10.1007/ s001250051041.
  1325. Pelleymounter, M. A., M. J. Cullen, M. B. Baker, R. Hecht, D. Winters, T. Boone, and F. Collins. 1995. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (5223):540–543.
  1326. Phillips, M. S., Q. Liu, H. A. Hammond, V. Dugan, P. J. Hey, C. J. Caskey, and J. F. Hess. 1996. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13 (1):18–19. doi:10.1038/ng0596-18.
  1327. Pi-Sunyer, X., A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, D. C. Lau et al., 2015. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373 (1):11–22. doi:10.1056/NEJMoa1411892.
  1328. Pocai, A. 2014. Action and therapeutic potential of oxyntomodulin. Mol Metab 3 (3):241–251. doi:10.1016/j. molmet.2013.12.001.
  1329. Randle, P. J., A. L. Kerbey, and J. Espinal. 1988. Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones. Diabetes Metab Rev 4 (7):623–638.
  1330. Reichardt, L. F. 2006. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361 (1473):1545–1564. doi:10.1098/rstb.2006.1894.
  1331. Robertson, S. A., G. M. Leinninger, and M. G. Myers, Jr. 2008. Molecular and neural mediators of leptin action. Physiol Behav 94 (5):637–642. doi:10.1016/j.physbeh.2008.04.005.
  1332. Rosmond, R., Y. C. Chagnon, G. Holm, M. Chagnon, L. Perusse, K. Lindell, B. Carlsson, C. Bouchard, and P. Bjorntorp. 2000. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res 8 (3):211–218. doi:10.1038/ oby.2000.24.
  1333. Rossi, M., M. S. Kim, D. G. Morgan, C. J. Small, C. M. Edwards, D. Sunter, S. Abusnana et al., 1998. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139 (10):4428–4431. doi:10.1210/ endo.139.10.6332.
  1334. Rothman, R. B., N. Vu, X. Wang, and H. Xu. 2003. Endogenous CART peptide regulates mu opioid and serotonin 5-HT(2A) receptors. Peptides 24 (3):413–417.
  1335. Sakurai, T., A. Amemiya, M. Ishii, I. Matsuzaki, R. M. Chemelli, H. Tanaka, S. C. Williams et al., 1998. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 (4):573–585.
  1336. Sanchez-Garrido, M. A., S. J. Brandt, C. Clemmensen, T. D. Muller, R. D. DiMarchi, and M. H. Tschop. 2017. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. doi:10.1007/ s00125-017-4354-8.
  1337. Savontaus, E., I. M. Conwell, and S. L. Wardlaw. 2002. Effects of adrenalectomy on AGRP, POMC, NPY and CART gene expression in the basal hypothalamus of fed and fasted rats. Brain Res 958 (1):130–138.
  1338. Schjoldager, B. T., F. G. Baldissera, P. E. Mortensen, J. J. Holst, and J. Christiansen. 1988. Oxyntomodulin: A potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18 (5):499–503.
  1339. Schwartz, M. W., E. Peskind, M. Raskind, E. J. Boyko, and D. Porte, Jr. 1996. Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans. Nat Med 2 (5):589–593.
  1340. Schwartz, M. W., S. C. Woods, D. Porte, Jr., R. J. Seeley, and D. G. Baskin. 2000. Central nervous system control of food intake. Nature 404 (6778):661–671. doi:10.1038/35007534.
  1341. Secher, A., J. Jelsing, A. F. Baquero, J. Hecksher-Sorensen, M. A. Cowley, L. S. Dalboge, G. Hansen et al., 2014. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124 (10):4473–4488. doi:10.1172/JCI75276.
  1342. Shankar, S. S., R. R. Shankar, L. Mixson, B. S. Pramanik, A. Stoch, and H. Steinberg. Oxyntomodulin has significant acute glucoregulatory effects comparable to liraglutide in subjecs with type 2 diabetes. Diabetes 62:A48.
  1343. Shimabukuro, M., K. Koyama, G. Chen, M. Y. Wang, F. Trieu, Y. Lee, C. B. Newgard, and R. H. Unger. 1997. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 94 (9):4637–4641.
  1344. Shyangdan, D. S., P. Royle, C. Clar, P. Sharma, N. Waugh, and A. Snaith. 2011. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev (10):CD006423. doi:10.1002/14651858. CD006423.pub2.
  1345. Sinha, M. K., J. P. Ohannesian, M. L. Heiman, A. Kriauciunas, T. W. Stephens, S. Magosin, C. Marco, and
  1346. J. F. Caro. 1996. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 97 (5):1344–1347. doi:10.1172/JCI118551.
  1347. Sloth, B., J. J. Holst, A. Flint, N. T. Gregersen, and A. Astrup. 2007. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292 (4):E1062–E1068. doi:10.1152/ajpendo.00450.2006.
  1348. Small, C. J., M. S. Kim, S. A. Stanley, J. R. Mitchell, K. Murphy, D. G. Morgan, M. A. Ghatei, and S. R. Bloom. 2001. Effects of chronic central nervous system administration of agouti-related protein in pairfed animals. Diabetes 50 (2):248–254.
  1349. Stefan, N., B. Vozarova, T. Funahashi, Y. Matsuzawa, C. Weyer, R. S. Lindsay, J. F. Youngren et al., 2002. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51 (6):1884–1888.
  1350. Strobel, A., T. Issad, L. Camoin, M. Ozata, and A. D. Strosberg. 1998. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18 (3):213–215. doi:10.1038/ng0398-213.
  1351. Taheri, S., J. M. Zeitzer, and E. Mignot. 2002. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 25:283–313. doi:10.1146/annurev.neuro.25.112701.142826.
  1352. Takaya, K., Y. Ogawa, N. Isse, T. Okazaki, N. Satoh, H. Masuzaki, K. Mori, N. Tamura, K. Hosoda, and K. Nakao. 1996. Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225 (1):75–83. doi:10.1006/bbrc.1996.1133.
  1353. Tartaglia, L. A., M. Dembski, X. Weng, N. Deng, J. Culpepper, R. Devos, G. J. Richards et al., 1995. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (7):1263–1271.
  1354. Tecott, L. H., L. M. Sun, S. F. Akana, A. M. Strack, D. H. Lowenstein, M. F. Dallman, and D. Julius. 1995. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374 (6522):542–546. doi:10.1038/374542a0.
  1355. Thorleifsson, G., G. B. Walters, D. F. Gudbjartsson, V. Steinthorsdottir, P. Sulem, A. Helgadottir, U. Styrkarsdottir et al., 2009. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 41 (1):18–24. doi:10.1038/ng.274.
  1356. Tschop, M., C. Weyer, P. A. Tataranni, V. Devanarayan, E. Ravussin, and M. L. Heiman. 2001. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (4):707–709.
  1357. Turton, M. D., D. O’Shea, I. Gunn, S. A. Beak, C. M. Edwards, K. Meeran, S. J. Choi et al., 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (6560):69–72. doi:10.1038/379069a0.
  1358. Unger, R. H. 1995. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44 (8):863–70.
  1359. Unger, T. J., G. A. Calderon, L. C. Bradley, M. Sena-Esteves, and M. Rios. 2007. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 27 (52):14265–74. doi:10.1523/JNEUROSCI.3308-07.2007.
  1360. Vaisse, C., J. L. Halaas, C. M. Horvath, J. E. Darnell, Jr., M. Stoffel, and J. M. Friedman. 1996. Leptin activation of State in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 14 (1):95–7. doi:10.1038/ng0996-95.
  1361. Valentino, M. A., A. Terzic, and S. A. Waldman. 2010. Sizing up pharmacotherapy for obesity. Clin Transl Sci 3 (3):123–5. doi:10.1111/j.1752-8062.2010.00191.x.
  1362. Verdich, C., A. Flint, J. P. Gutzwiller, E. Naslund, C. Beglinger, P. M. Hellstrom, S. J. Long, L. M. Morgan, J. J. Holst, and A. Astrup. 2001. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 (9):4382–9. doi:10.1210/jcem.86.9.7877.
  1363. Wang, Y., K. K. Kuropatwinski, D. W. White, T. S. Hawley, R. G. Hawley, L. A. Tartaglia, and H. Baumann. 1997. Leptin receptor action in hepatic cells. J Biol Chem 272 (26):16216–23.
  1364. Weigle, D. S., T. R. Bukowski, D. C. Foster, S. Holderman, J. M. Kramer, G. Lasser, C. E. Lofton-Day, D. E. Prunkard, C. Raymond, and J. L. Kuijper. 1995. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 96 (4):2065–70. doi:10.1172/JCI118254.
  1365. West, D. B., M. R. Greenwood, K. A. Marshall, and S. C. Woods. 1987. Lithium chloride, cholecystokinin and meal patterns: Evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite 8 (3):221–7.
  1366. Williams, G., C. Bing, X. J. Cai, J. A. Harrold, P. J. King, and X. H. Liu. 2001. The hypothalamus and the control of energy homeostasis: Different circuits, different purposes. Physiol Behav 74 (4–5):683–701.
  1367. Willie, J. T., R. M. Chemelli, C. M. Sinton, and M. Yanagisawa. 2001. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 24:429–58. doi:10.1146/annurev.neuro.24.1.429. Wren, A. M., L. J. Seal, M. A. Cohen, A. E. Brynes, G. S. Frost, K. G. Murphy, W. S. Dhillo, M. A. Ghatei, and S. R. Bloom. 2001. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 (12):5992. doi:10.1210/jcem.86.12.8111.
  1368. Wren, A. M., C. J. Small, H. L. Ward, K. G. Murphy, C. L. Dakin, S. Taheri, A. R. Kennedy et al., 2000. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141 (11):4325–8. doi:10.1210/endo.141.11.7873.
  1369. Wynne, K., A. J. Park, C. J. Small, K. Meeran, M. A. Ghatei, G. S. Frost, and S. R. Bloom. 2006. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial. Int J Obes (Lond) 30 (12):1729–36. doi:10.1038/sj.ijo.0803344.
  1370. Wynne, K., A. J. Park, C. J. Small, M. Patterson, S. M. Ellis, K. G. Murphy, A. M. Wren et al., 2005. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: A double-blind, randomized, controlled trial. Diabetes 54 (8):2390–5.
  1371. Wynne, K., S. Stanley, and S. Bloom. 2004. The gut and regulation of body weight. J Clin Endocrinol Metab 89 (6):2576–82. doi:10.1210/jc.2004-0189.
  1372. Xu, B., E. H. Goulding, K. Zang, D. Cepoi, R. D. Cone, K. R. Jones, L. H. Tecott, and L. F. Reichardt. 2003. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6 (7):736–742. doi:10.1038/nn1073.
  1373. Xu, Y., J. E. Jones, D. Kohno, K. W. Williams, C. E. Lee, M. J. Choi, J. G. Anderson et al., 2008. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60 (4):582–589. doi:10.1016/j.neuron.2008.09.033.
  1374. Yang, J., M. S. Brown, G. Liang, N. V. Grishin, and J. L. Goldstein. 2008. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132 (3):387–396. doi:10.1016/j.cell.2008.01.017.
  1375. Yeo, G. S., C. C. Connie Hung, J. Rochford, J. Keogh, J. Gray, S. Sivaramakrishnan, S. O’Rahilly, and I. S.
  1376. Farooqi. 2004. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 7 (11):1187–1189. doi:10.1038/nn1336.
  1377. Zelissen, P. M., K. Stenlof, M. E. Lean, J. Fogteloo, E. T. Keulen, J. Wilding, N. Finer et al., 2005. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: A randomized, placebo-controlled trial. Diabetes Obes Metab 7 (6):755–761. doi:10.1111/j.1463-1326.2005.00468.x.
  1378. Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (6505):425–432. doi:10.1038/372425a0.
  1379. Ahima RS, Antwi DA: Brain regulation of appetite and satiety, Endocrinol Metab Clin North Am 37:811–823, 2008.
  1380. American Heart Association: Dietary recommendations for children and adolescents: a guide for practitioners, Pediatrics 117:544–559, 2006.
  1381. Anzman-Frasca S, Stifter CA, Birch LL: Temperament and childhood obesity risk: a review of the literature, J Dev Behav Pediatr 33(9):732–745, 2012.
  1382. August GP, Caprios S, Fennoy I, et al: Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline based on expert opinion, J Clin Endocrinol Metab 93:4576–4599, 2008.
  1383. Block JP, Condon SK, Kleinman K, et al: Consumers’ estimation of calorie content at fast food restaurants: cross sectional observational study, BMJ 346:14, 2013.
  1384. Bocca G, Corpeleijn E, Stolk RP, et al: Results of a multidisciplinary treatment program in 3-year-old to 5-year-old overweight or obese children, Arch Pediatr Adolesc Med 166:1109–1115, 2012.
  1385. Bochukova EG, Huang N, Keogh J, et al: Large, rare chromosomal deletions associated with severe early-onset obesity, Nature 463:666–670, 2010.
  1386. Bond DS, Vithiananthan S, Nash JM, et al: Improvement of migraine headaches in severely obese patients after bariatric surgery, Neurology 76:1135–1138, 2011.
  1387. Boutelle KN, Norman GJ, Rock CL, et al: Guided self-help for the treatment of pediatric obesity, Pediatrics 131(5):e1435–e1442, 2013.
  1388. Boutelle KN, Cafri G, Crow SJ: Parent predictors of child weight change in family based behavioral obesity treatment, Obesity (Silver Spring) 20(7):1539–1543, 2012.
  1389. Brara SM, Koebnick C, Porter AH, et al: Pediatric idiopathic intracranial hypertension and extreme childhood obesity, J Pediatr 161:602–607, 2012.
  1390. Bray GA, Fr?hbeck G, Ryan DH, Wilding JPH: Management of obesity, Lancet 387: 1947–1965, 2016.
  1391. Carlsson LMS, Peltonen M, Ahlin S, et al: Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects, N Engl J Med 367:695–704, 2012.
  1392. Casazza K, Fontaine KR, Astrup A, et al: Myths, presumptions, and facts about obesity, N Engl J Med 368:446–454, 2013.
  1393. Cecchini M, Sassi F, Lauer JA, et al: Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness, Lancet 376:1775–1784, 2010.
  1394. Centers for Disease Control and Prevention: Recommended community strategies and measurements to prevent obesity in the United States, MMWR Recomm Rep 58:1–29, 2009.
  1395. Centers for Disease Control and Prevention: Differences in prevalence of obesity among black, white, and Hispanic adults—United States, 2006–2008, MMWR Morb Mortal Wkly Rep 58:740–744, 2009.
  1396. Centers for Disease Control and Prevention: Effect of switching from whole to low-fat/fat-free milk in public schools—New York City, 2004–2009, MMWR Morb Mortal Wkly Rep 59:70–73, 2010.
  1397. Centers for Disease Control and Prevention: CDC grand rounds: childhood obesity in the United States, MMWR Morb Mortal Wkly Rep 60:42–46, 2011.
  1398. Centers for Disease Control and Prevention: Obesity prevalence among low-income, preschool-aged children—New York City and Los Angeles County, 2003–2011, MMWR Morb Mortal Wkly Rep 62:17–22, 2013.
  1399. Claussnitzer M, Dankel SN, Kim KH, et al: FTO obesity variant circuitry and adipocyte browning in humans, N Engl J Med 373(10):895–906, 2015.
  1400. Courcoulas AP, Christian NJ, Belle SH, et al: Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity, JAMA 310:2416–2424, 2013.
  1401. De Ruyter JC, Olthof MR, Seidell JC, et al: A trial of sugar-free or sugar-sweetened beverages and body weight in children, N Engl J Med 367:1397–1406, 2012.
  1402. Dunn W, Schwimmer JB: The obesity epidemic and nonalcoholic fatty liver disease in children, Curr Gastroenterol Rep 10:67–72, 2008.
  1403. Ebbeling CB, Feldman HA, Chomitz VR, et al: A randomized trial of sugar-sweetened beverages and adolescent body weight, N Engl J Med 367:1407–1416, 2012.
  1404. Farley TA: The role of government in preventing excess calorie consumption, JAMA 308:1093–1094, 2012.
  1405. Flegal KM, Kit BK, Orpana H, et al: Association of all-cause mortality with overweight and obesity using standard body mass index categories, JAMA 309:71–80, 2013.
  1406. Ford AL, Bergh C, S?dersten P, et al: Treatment of childhood obesity by retraining eating behaviour: randomized controlled trial, BMJ 340:b5388, 2010.
  1407. Fothergill E, Guo J, Howlard L, et al: Persistent metabolic adaptation 6 years after “the biggest loser” competition, Obesity (Silver Spring) 24(8):1612–1619, 2016.
  1408. Franks PW, Hanson RL, Knowler WC, et al: Childhood obesity, other cardiovascular risk factors, and premature death, N Engl J Med 362:485–492, 2010.
  1409. Gahagan S, Uauy R, Roseboom TJ: Developmental origins of pediatric obesity, Int J Pediatr 309863:2012.
  1410. Glaser Pediatric Research Network Obesity Study Group: Metformin extended-release treatment of adolescent obesity, Arch Pediatr Adolesc Med 164:116–123, 2010.
  1411. Global Burden of Disease 2015 Obesity Collaborators: Health effects of overweight and obesity in 195 countries over 25 years, N Engl J Med 377:13–24, 2017.
  1412. Golden NH, Schneider M, Wood C: Preventing onesity and eating disorders in adolescents, Pediatrics 138(3):e10161649, 2016.
  1413. Gortmaker SL, Swinburn BA, Levy D, et al: Changing the future of obesity: science, policy, and action, Lancet 378:838–846, 2011.
  1414. Gulati AK, Kaplan DW, Daniels SR: Clinical tracking of severely obese children: a new growth chart, Pediatrics 130:1136–1140, 2012.
  1415. Heymsfield SB, Wadden TA: Mechanisms, pathophysiology, and management of obesity, N Engl J Med 376(3):254–266, 2017.
  1416. Ho M, Garnett SP, Baur L, et al: Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis, Pediatrics 130:e1647–e1671, 2012.
  1417. Ibaaez L, Lopez-Bermejo A, Diaz M, et al: Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity, J Pediatr 156:98–102, 2010.
  1418. Inge TH, Jenkins TM, Xanthakos SA, et al: Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis, Lancet 5(3):165–173, 2017.
  1419. Jacquemont S, Reymond A, Zufferey F, et al: Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus, Nature 478:97–102, 2011.
  1420. Johnson BS, Kanters S, Bandayrel K, et al: Comparison of weight loss among named diet programs in overweight and obese adults—a meta analysis, JAMA 312:923–932, 2014.
  1421. Kaisari P, Yannakoulia M, Panagiotakos DB: Eating frequency and overweight and obesity in children and adolescents: a meta-analysis, Pediatrics 131:958–967, 2013.
  1422. Karra E, O’Daly OG, Choudhury AI, et al: A link between FTO, ghrelin, and impaired brain food-cue responsivity, J Clin Invest 123(8):3539–3551, 2013.
  1423. Kelly AS: The harsh reality of severe obesity, J Pediatr 163:6–8, 2013.
  1424. Khera R, Murad MH, Chandar AK, et al: Association of pharmacological treatments for obesity with weight loss and adverse events, JAMA 315(22):2424–2434, 2016.
  1425. Komaroff AL: The microbiome and risk for obesity and diabetes, JAMA 317(4):355–356, 2017.
  1426. Kuhnen P, Cl?ment K, Wiengand S, et al: Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist, N Engl J Med 375(3):240–246, 2016.
  1427. Larder R, O’Rahilly S: Guts over glory—why diets fail, Nat Med 18:666–668, 2012.
  1428. Lee IM, Djouss? L, Sesso HD, et al: PA and weight gain prevention, JAMA 303: 1173–1179, 2010.
  1429. Leung CW, Blumenthal SJ, Hoffnagle EE, et al: Associations of food stamp participation with dietary quality and obesity in children, Pediatrics 131:463–472, 2013.
  1430. Ludwig J, Sanbonmatsu L, Gennetian L, et al: Neighborhoods, obesity, and diabetes—a randomized social experiment, N Engl J Med 365:1509–1518, 2011.
  1431. Maggard-Gibbons M, Maglione M, Livhits M, et al: Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes, JAMA 309: 2250–2260, 2013.
  1432. Manco M, Dallapiccola B: Genetics of pediatric obesity, Pediatrics 130:123–133, 2012.
  1433. Marcus CL, Brooks LJ, Draper KA, et al: Diagnosis and management of childhood obstructive sleep apnea syndrome, Pediatrics 130(3):e714–e755, 2012.
  1434. Markwald RR, Melanson EL, Smith MR, et al: Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain, Proc Natl Acad Sci USA 110:5695–5700, 2013.
  1435. Martin RM, Patel R, Kramer MS, et al: Effects of promoting longer-term and exclusive breastfeeding on adiposity and insulin-like growth factor-1 at age 11.5 years, JAMA 309:1005–1012, 2013.
  1436. Mead E, Atkinson G, Richter B, et al: Drug interventions for the treatment of obesity in children and adolescents (review), Cochrane Database Syst Rev (11):CD012436, 2016.
  1437. The Medical Letter: Two new drugs for weight loss, Med Lett Drugs Ther 54:69–72, 2012.
  1438. The Medical Letter: Diet, drugs, and surgery for weight loss, Med Lett 57:21–28, 2015.
  1439. Murray R, Battista M: Managing the risk of childhood overweight and obesity in primary care practice, Curr Probl Pediatr Adolesc Health Care 39:145–166, 2009.
  1440. Nader P, Huang TK, Gahagan S, et al: Next steps in obesity prevention: altering early life systems to support healthy parents, infants and toddlers, Child Obes 8(3):195–204, 2012.
  1441. Nadler EP, Brotman LM, Miyoshi T, et al: Morbidity in obese adolescents who meet the adult National Institutes of Health criteria for bariatric surgery, J Pediatr Surg 44:1869–1876, 2009.
  1442. O’Brien PE, Sawyer SM, Laurie C, et al: Laparoscopic adjustable gastric banding in severely obese adolescents, JAMA 303:519–526, 2010.
  1443. Ogden CL, Carroll MD, Kit BK, et al: Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010, JAMA 307:483–490, 2012.
  1444. Page KA, Chan O, Arora J, et al: Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways, JAMA 309:63–70, 2013.
  1445. Pal A, Barber TM, van de Bunt M, et al: PTEN mutations as a cause of constitutive insulin sensitivity and obesity, N Engl J Med 367:1002–1010, 2012.
  1446. Pan L, Freedman DS, Sharma AJ, et al: Trends in obesity among participants aged 2-4 years in the Special Supplemental Nutrition Program for Women, Infants, and Children—United States, 2000–2014, MMWR 65(45):1256–1260, 2016.
  1447. Patwari PP, Rand CM, Berry-Kravis EM, et al: Monozygotic twins discordant for ROHHAD phenotype, Pediatrics 128:e711–e715, 2011.
  1448. Paz-Priel I, Cooke DW, Chen AR: Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome, J Pediatr 158(2):337–339, 2011.
  1449. Perkins E, Murphy SK, Murtha AP, et al: Insulin-like growth factor 2/H19 methylation at birth and risk of overweight and obesity in children, J Pediatr 161:31–39, 2012.
  1450. Puzziferri N, Roshek TB III, Mayo HG, et al: Long-term follow-up after bariatric surgery—a systematic review, JAMA 312:934–942, 2014.
  1451. Rand CM, Patwari PP, Rodikova EA, et al: Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation: analysis of hypothalamic and autonomic candidate genes, Pediatr Res 70:375–378, 2011.
  1452. Reinehr T: Predicting weight loss of obese adolescents in lifestyle interventions by genetic screening: a promising approach for researchers and clinicians?, J Pediatr 161:382–384, 2012.
  1453. Runn T, Volkov P, Daveg?rdh C, et al: A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue, PLoS Genet 9:e1003572, 2013.
  1454. Sacher PM, Kolotourou M, Chadwick PM, et al: Randomized controlled trial of the MEND program: a family-based community intervention for childhood obesity, Obesity (Silver Spring) 18:S62–S68, 2010.
  1455. Sacks FM, Bray GA, Carey VJ, et al: Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates, N Engl J Med 360:859–872, 2009.
  1456. Savoye M, Nowicka P, Shaw M, et al: Long-term results of an obesity program in an ethnically diverse pediatric population, Pediatrics 127(3):402–410, 2011.
  1457. Scharf RJ, Demmer RT, DeBoer MD: Longitudinal evaluation of milk type consumed and weight status in preschoolers, Arch Dis Child 98:335–340, 2013.
  1458. Schauer PR, Kashyap SR, Wolski K, et al: Bariatric surgery versus intensive medical therapy in obese patients with diabetes, N Engl J Med 366:1567–1576, 2012.
  1459. Spyropoulos C, Kehagias I, Panagiotopoulos S, et al: Revisional bariatric surgery, Arch Surg 145:173–177, 2010.
  1460. Styne DM, Arslanian SA, Connor EL, et al: Pediatric obesity—assessment, treatment, and prevention: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab 102(3):1–49, 2017.
  1461. Swinburn B, Sacks G, Ravussin E: Increased food energy supply is more than sufficient to explain the US epidemic of obesity, Am J Clin Nutr 90:1453–1456, 2009.
  1462. Taveras EM, Rifas-Shiman SL, Belfort MB, et al: Weight status in the first 6 months of life and obesity at 3 years of age, Pediatrics 123:1177–1183, 2009.
  1463. US Department of Agriculture: Dietary guidelines for Americans, 2005. www.health.gov/dietaryguidelines/dga2005/document/html/chapter2.htm.
  1464. US Preventive Services Task Force: Recommendation statement: Screening for obesity in children and adolescents, JAMA 317(23):2417–2426, 2017.
  1465. Van Cauter E, Knutson K: Sleep and the epidemic of obesity in children and adults, Eur J Endocrinol 159:S59–S66, 2008.
  1466. Van Cleave J, Gortmaker SL, Perrin JM: Dynamics of obesity and chronic health conditions among children and youth, JAMA 303:623–630, 2010.
  1467. Vandanmagsar B, Youm YH, Ravussin A, et al: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance, Nat Med 17(2):179–188, 2011.
  1468. Vanselow MS, Pereira MA, Neumark-Sztainer D, et al: Adolescent beverage habits and changes in weight over time: finding from Project EAT, Am J Clin Nutr 90: 1489–1495, 2009.
  1469. Wabitsch M, Funcke JB, Lennerz B, et al: Biologically inactive leptin and early-onset extreme obesity, N Engl J Med 372(1):48–54, 2015.
  1470. Waters E, de-Silva-Sanigorski A, Hall BJ, et al: Interventions for preventing obesity in children, Cochrane Database Syst Rev (12):CD001871, 2011.
  1471. Weiss R, Kaufman F: Metabolic complications of childhood obesity: identifying and mitigating the risk, Diabetes Care 31:S310–S316, 2008.
  1472. Weng SF, Redsell SA, Swift JA, et al: Systematic review and meta-analyses of risk factors for childhood overweight identifiable during infancy, Arch Dis Child 97(12): 1019–1026, 2012.
  1473. Wilfley DE, Stein RI, Saelens BE, et al: Efficacy of maintenance treatment approaches for childhood overweight: a randomized controlled trial, JAMA 298:1661–1673, 2007.
  1474. Willett WC, Ludwig DS: Science souring on sugar, BMJ 346:7, 2013.
  1475. Wojcicki JM: Peptide YY in children: a review, J Pediatr Endocrinol Metab 25:227–232, 2012.
  1476. Yang J, Loos RJF, Powell JE, et al: FTO genotype is associated with phenotypic variability of body mass index, Nature 490:267–272, 2012.
  1477. Yanovski SZ: Naltrexone extended-release plus bupropion extended-release for treatment of obesity, JAMA 313(12):1213–1214, 2015.
  1478. Yanovski SZ, Yanovski JA: Long-term drug treatment for obesity—a systematic and clinical review, JAMA 311:74–84, 2014.

- Âåðíóòüñÿ â ðàçäåë "Ïðîôèëàêòèêà çàáîëåâàíèé"

Ðåäàêòîð: Èñêàíäåð Ìèëåâñêè. Äàòà îáíîâëåíèÿ ïóáëèêàöèè: 21.11.2026

Ìåäóíèâåð Ïîèñê ïî ñàéòó è åãî ðàçäåëû Ìû â Telegram Ìû â MAX Ìû â YouTube Êîíòàêòû, ðåêëàìà
Èíôîðìàöèÿ íà ñàéòå ïîäëåæèò êîíñóëüòàöèè ëå÷àùèì âðà÷îì è íå çàìåíÿåò î÷íîé êîíñóëüòàöèè ñ íèì.
Ñì. ïîäðîáíåå â ïîëüçîâàòåëüñêîì ñîãëàøåíèè.